Cover Page for Protocol 
Sponsor name:  Novo Nordisk A/S 
NCT number [STUDY_ID_REMOVED] 
Sponsor trial ID: NN1535-4592 
Official title of study: A 52-week study co mparing the efficacy and safety of once 
weekly IcoSema and once weekly semaglutide, both treatment 
arms with or without oral anti -diabetic drugs, in participants 
with type 2 diabetes inadequa tely controlled with a GLP-1 
receptor agonist. COMBINE 2 
Document date: 23 March 2023 
Protocol 
CONFIDENTIAL Date: 23 March 2023 Novo Nordisk 
Study ID: NN1535-4592 Version: 8.0 
      Status: Final 
      Page: 1 of 113 
 
 Protocol 
 
Protocol Title:  
A 52 -week study comparing the efficacy and safety of once weekly IcoSema and  once weekly 
semaglutide, both treatment arms with or without oral an ti-diabetic drugs, in participants with type 
2 diabetes inadequately controlled with a GLP -1 receptor agonist. COMBINE 2 
 
Substance:  IcoSema (insulin icodec and semaglutide) 
Universal Trial Number: U1111-1260-8268  
EudraCT Number:  2020-005308-21  
IND Number : 145811 
 
Study phase:  3a 
 
6<0-.7447?16/!7>7!7:,1;3%)6,1<;)..141)<-;?144*-; <)<-,);G!7>7!7:,1;3H  
 
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed without prior written approval from Novo Nordisk. Access to this document must  be restricted to relevant 
parties. CONFIDENTIAL
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed without prior written approval from Novo Nordisk. Access to this document must be restricted to relevant 
parties.
VV-CLIN-219731 1 .0 .
Protocol 
CONFIDENTIAL Date: 23 March 2023 Novo Nordisk 
Study ID: NN1535-4592 Version: 8.0 
      Status: Final 
      Page: 2 of 113 
 
 
 
  
DOCUMENT HISTORY  
Document version Date Applicable in country(-ies) and/or site(s)  
Protocol version 8.0 23-Mar-2023 All countries 
Protocol version 7.0 10-May-2022 All countries 
Protocol version 6.0 12-Jan-2022 Slovakia only 
Protocol version 5.0 22-Nov-2021 Japan only 
Protocol version 4.0 10-Aug-2021 All countries  
Protocol version 3.0 13-Jul-2021 Brazil only  
Protocol version 2.0 01-Jul-2021 All countries except Brazil 
Original protocol version 1.0 21-Jun-2021 Not submitted 
 
Protocol version 8.0 (23-Mar-2023) 
This amendment is considered to be non-substantial based on the criteria set forth in Article 10(a) of 
Directive 2001/20/EC of the European Parliament and the Council of the European Union,1 because 
it neither significantly impacts the safety nor physical/mental integrity of participants nor the scientific value of the study.  
Overall rationale for preparing protocol, version 8.0: 
The protocol has been amended to correct below errors detected, in addition to further changes 
shown below:  
Section # and name Description of change Brief rationale 
Section 2 
Introduction Detailed information about the insulin icodec 
molecule has been deleted. Alignment with phase 3b protocol. The 
information is not relevant for trial conduct 
Section 2.3 Benefit-
rsik assessment  Text crossed out was deleted as follows:  
The risks of IcoSema presented in this section 
are a combination of important and non
-important risks for IcoSema and for the 
mono -components insulin icodec and 
semaglutide.  All risks for mono- components 
that have not been identified for IcoSema 
directly, are classified as potential risks for 
IcoSema, although these may be classified as 
identified risks for the mono-components.  New risks from the mono-components are now 
evaluated using clinical data for IcoSema  
Section 2.3.1 Risk 
assessment  The IcoSema IB is added as reference for 
benefits and risks of insulin icodec and 
semaglutide instead of the IBs of the mono-
components.    Alignment with updated IBs 
Section 4.3 
Justification for dose Text in italics  was added, and text crossed out 
was deleted as follows:  
The maximum dose and the ratio of IcoSema 
is based on the clinical findings [reference to 
IcoSema IB ] from the mono-components 
insulin icodec4 and semaglutide s.c.6 Alignment with updated IBs CONFIDENTIAL
VV-CLIN-219731 1 .0 .
Protocol 
CONFIDENTIAL Date: 23 March 2023 Novo Nordisk 
Study ID: NN1535-4592 Version: 8.0 
      Status: Final 
      Page: 3 of 113 
 
 Section # and name Description of change Brief rationale 
Section 8.2.1. Dose; 
Appendix 8: Titration guideline In the description of collection of injection 
site G)6, semaglutideH1;),,-,)6,G;07=4,H
0);*--6+0)6/-,<7G5=;<H .  
 
 
 
    eCRF correctly collects injection site area 
collected in both arms, while protocol erroneously only described it for IcoSema. Injection site area in both arms is required for originally planned 
population PK analysis to 
assess a potential differential effect of injection 
region between IcoSema and the mono -
component  
Section 8.2.4. Eye 
examination  Text in italics  was added, and text crossed out 
was deleted as follows: For participants who 
discontinue randomised treatment, eye 
examination can be performed up to 2 weeks after the visit at week 52 visit 54A .  Clarification of visit number to 54A 
Appendix 2: Clinical 
laboratory tests  Text and footnotes in  italics  were added to 
table 10.2:  
Hypersensitivity data will not be shared with 
investigators until a fter CSR finalisation.  
c Samples collected from Chinese participants 
will be analysed by a central lab in China. 
Samples collected from participants in the 
rest of the  world will be analysed by Novo 
Nordisk MÃ¥lÃ¸v, Denmark  
d Samples will be analysed by Novo Nordisk 
MÃ¥lÃ¸v, Denmark for all countries except 
China, where these tests will not be done (see 
Appendix 11, Section 10.11. 
e Samples collected from Chinese participants 
will be analysed in a special lab in China. Samples collected from participants in the rest of the world will be analysed by a special lab designated by Novo Nordisk.  To clarify which hypersensitivity tests will be 
performed by which laboratories  
Appendix 11: 
Country/Region specific requirements - China
 Added text in italics :  
The following hypersensitivity analytes are 
not possible to be tested in China, see 
Appendix 2 (Section 10.2), and will not be 
included in the hypersensitivity case 
assessment:  
 Anti-human insulin IgE 
 Anti-insulin icodec IgE 
 Anti-semaglutide IgE 
The following hypers ensitivity analytes will 
be tested by the Central lab in China:  
 Tryptase 
 Total IgE antibodies 
The following hypersensitivity analytes will 
be tested by special lab in China:  
 Anti-insulin icodec binding antibodies  
 Anti-semaglutide binding antibodies  To clearly reflect which hypersensitivity tests 
will be conducted in China due to local unavailability of some test and the impossibility of export
ing samples outside China 
Section 11 
References Version numbers of the IB for Ozempic and 
for IcoSema are updated.  Newer versions of IBs have become available. 
 CONFIDENTIAL
VV-CLIN-219731 1 .0 .
Protocol 
CONFIDENTIAL Date: 23 March 2023 Novo Nordisk 
Study ID: NN1535-4592 Version: 8.0 
      Status: Final 
      Page: 4 of 113 
 
 Section # and name Description of change Brief rationale 
The insulin icodec IB is deleted as reference.   The relevant information from the insulin 
icodec IB is included in the updated IcoSema IB 
 CONFIDENTIAL
VV-CLIN-219731 1 .0 .
Protocol 
CONFIDENTIAL Date: 23 March 2023 Novo Nordisk 
Study ID: NN1535-4592 Version: 8.0 
      Status: Final 
      Page: 5 of 113 
 
 
  
 Page 
 Protocol ..................................................................................................................... ....................................... 1  
Protocol amendment summary of changes table ................................................................................... ........ 2  
Table of Contents.............................................................................................................. ................................ 5  
1 Protocol summary .............................................................................................................. ......................... 9  
1.1 Synopsis ...................................................................................................................... ........................ 9  
1.2 Flowchart ..................................................................................................................... ..................... 12  
1.3 Flowchart F phone contacts .............................................................................................................. 14 
2 Introduction .................................................................................................................. ............................. 15  
2.1 Study rationale ............................................................................................................... ................... 15  
2.2 Background .................................................................................................................... ................... 16  
2.3 Benefit-risk assessment ....................................................................................................... .............. 17  
2.3.1  Risk assessment ............................................................................................................... .. 18 
2.3.2  Benefit assessment ............................................................................................................ . 23 
2.3.3  Overall benefit-risk conclusion ......................................................................................... 24  
3 Objectives, endpoints and estimands ........................................................................................... ............ 25  
3.1 Objectives .................................................................................................................... ..................... 25  
3.1.1  Primary objective ............................................................................................................. .. 25 
3.1.2  Secondary objectives ......................................................................................................... 25 
3.2 Endpoints ..................................................................................................................... ..................... 25  
3.2.1  Primary endpoint .............................................................................................................. . 25 
3.2.2  Secondary endpoints .......................................................................................................... 25 
3.2.2.1  Supportive secondary endpoints .................................................................... 25  
3.2.3  Exploratory endpoints........................................................................................................ 2 6 
3.3 Primary estimand .............................................................................................................. ................ 26  
4 Study design .................................................................................................................. ............................. 27  
4.1 Overall design ................................................................................................................ ................... 27  
4.2 Scientific rationale for study design .................................................................................................. 28  
4.3 Justification for dose ........................................................................................................ ................. 29  
4.4 End of study definition ....................................................................................................... ............... 30  
5 Study population .............................................................................................................. ......................... 31  
5.1 Inclusion criteria ............................................................................................................ ................... 31  
5.2 Exclusion criteria ............................................................................................................ .................. 31  
5.3 Lifestyle considerations ...................................................................................................... .............. 33  
5.3.1  Meals and dietary restrictions ............................................................................................ 33  
5.3.2  Caffeine, alcohol and tobacco ........................................................................................... 33  
5.4 Screen failures ............................................................................................................... .................... 33  
5.5 Run-in criteria, randomisation criter ia and dosing day criteria ......................................................... 33  
6 Study interventions and concomitant therapy ................................................................................... ..... 34  
6.1 Study interventions administered .............................................................................................. ........ 34  
6.2 Preparation, handling, storage and accountability ............................................................................ 36 
6.3 Measures to minimise bias: Ra ndomisation and blinding................................................................. 37  
6.4 Drug treatment compliance ..................................................................................................... .......... 37  
6.5 Dose modification ............................................................................................................. ................ 38  
6.6 Continued access to randomised tr eatment after end of study .......................................................... 38  
6.7 Treatment of overdose ......................................................................................................... ............. 38  
6.8 Concomitant therapy ........................................................................................................... .............. 39  
6.8.1  Rescue medicine ............................................................................................................... . 39 CONFIDENTIAL
VV-CLIN-219731 1 .0 .
Protocol 
CONFIDENTIAL Date: 23 March 2023 Novo Nordisk 
Study ID: NN1535-4592 Version: 8.0 
      Status: Final 
      Page: 6 of 113 
 
 7 Discontinuation of study intervention  and participant withdrawal ..................................................... 40  
7.1 Discontinuation of study intervention ......................................................................................... ...... 40  
7.1.1  Discontinuation of randomised treatment .......................................................................... 40  
7.1.2  Temporary discontinuation of randomised treatment ........................................................ 41  
7.1.3  Rescue criteria ............................................................................................................... .... 41  
7.2 Participant withdrawal  from the study ......................................................................................... ..... 42  
7.2.1  Replacement of participants .............................................................................................. 42  
7.3 Lost to follow-up.............................................................................................................. ................. 42  
8 Study assessments and procedures .............................................................................................. ............ 44  
8.1 Efficacy assessments .......................................................................................................... ............... 45  
8.1.1  Self-measured glucose ....................................................................................................... 4 5 
8.1.2  Clinical efficacy ............................................................................................................. .... 45  
8.2 Safety assessments ............................................................................................................ ................ 45  
8.2.1  Dose .......................................................................................................................... ......... 46  
8.2.2  Physical examinations ....................................................................................................... 4 6 
8.2.3  Vital signs ................................................................................................................... ....... 47  
8.2.4  Eye examination ............................................................................................................... . 48 
8.2.5  Electrocardiograms ............................................................................................................  48 
8.2.6  Clinical safety laboratory assessments .............................................................................. 49  
8.2.7  Pregnancy testing ............................................................................................................. .. 49 
8.3 Adverse events and other safety reporting ..................................................................................... ... 49  
8.3.1  Time period and frequency for collecti ng adverse event information ............................... 50  
8.3.2  Method of detecting adverse events .................................................................................. 51  
8.3.3  Follow-up of adverse events .............................................................................................. 51  
8.3.4  Regulatory reporting requirements for serious adverse events .......................................... 51  
8.3.5  Pregnancy ..................................................................................................................... ..... 51  
8.3.6  Technical complaints ......................................................................................................... 51 
8.4 Pharmacokinetics .............................................................................................................. ................ 52  
8.5 Genetics ...................................................................................................................... ...................... 52  
8.6 Biomarkers .................................................................................................................... .................... 52  
8.7 Immunogenicity assessments .................................................................................................... ........ 52  
8.7.1  Anti-drug antibodies ..........................................................................................................  52 
8.7.2  Hypersensitivity .............................................................................................................. ... 53  
9 Statistical considerations .................................................................................................... ...................... 55  
9.1 Statistical hypotheses ........................................................................................................ ................ 55  
9.2 Analysis sets.................................................................................................................. .................... 55  
9.3 Statistical analyses .......................................................................................................... .................. 56  
9.3.1  General considerations ...................................................................................................... 5 6 
9.3.2  Primary estimand analysis ................................................................................................. 56  
9.3.2.1  Sensitivity analysis ......................................................................................... 57  
9.3.3  Secondary estimand analyses ............................................................................................ 57  
9.3.3.1  Supportive secondary estimands .................................................................... 57  
9.3.4  Exploratory estimand analysis ........................................................................................... 58  
9.3.5  Other safety analyses .........................................................................................................  58 
9.3.6  Other analyses ................................................................................................................ ... 58  
9.3.6.1  Pharmacokinetic modelling ............................................................................ 58  
9.4 Interim analysis .............................................................................................................. ................... 58  
9.5 Sample size determination ..................................................................................................... ........... 58  
9.6 Partial database lock ......................................................................................................... ................ 60  
10 Supporting documentation and operational considerations.................................................................. 61  
10.1  Appendix 1: Regulatory, ethical, and study oversight considerations .............................................. 61  
10.1.1  Regulatory and ethical considerations ............................................................................... 61  
10.1.2  Financial disclosure .......................................................................................................... . 61 CONFIDENTIAL
VV-CLIN-219731 1 .0 .
Protocol 
CONFIDENTIAL Date: 23 March 2023 Novo Nordisk 
Study ID: NN1535-4592 Version: 8.0 
      Status: Final 
      Page: 7 of 113 
 
 10.1.3  Informed consent process .................................................................................................. 62  
10.1.4  Information to participants during the study ..................................................................... 62  
10.1.5  Data protection ............................................................................................................... ... 62  
10.1.6  Committees structure ......................................................................................................... 63 
10.1.6.1  Novo Nordisk safety committee..................................................................... 63  
10.1.6.2  Event adjudication committee ........................................................................ 63  
10.1.7  Dissemination of clinical study data .................................................................................. 63  
10.1.8  Data quality assurance ....................................................................................................... 64 
10.1.8.1  Case report forms ........................................................................................... 64  
10.1.8.2  Monitoring ..................................................................................................... 64  
10.1.8.3  Protocol compliance ....................................................................................... 65  
10.1.9  Source documents ..............................................................................................................  65 
10.1.10  Retention of clinical study documentation ........................................................................ 66  
10.1.11  Study and site closure ........................................................................................................  66 
10.1.12  Responsibilities .............................................................................................................. .... 67  
10.1.13  Indemnity statement .......................................................................................................... 67 
10.1.14  Publication policy ............................................................................................................ .. 68 
10.1.14.1  Communication of results .............................................................................. 68  
10.1.14.2  Authorship ...................................................................................................... 68  
10.1.14.3  Site-specific publication(s) by investigator(s)................................................ 69  
10.1.14.4  Investigator access to data and review of results ........................................... 69  
10.2  Appendix 2: Clinical laboratory tests.......................................................................................... ...... 70  
10.3  Appendix 3: Adverse Events and Serious Adverse Events: Definitions and procedures for 
recording, evaluating, follow-up, and reporting ...............................................................................  72 
10.3.1  Definition of adverse event ................................................................................................ 72  
10.3.2  Definition of a serious adverse event................................................................................. 72  
10.3.3  Description of adverse events requiring additional data collection and other events 
requiring collection of additional information ................................................................... 74  
10.3.4  Recording and follow-up of adverse event and/or serious adverse event .......................... 75  
10.3.4.1  Adverse event and serious adverse event recording....................................... 75  
10.3.4.2  Assessment of severity ................................................................................... 76  
10.3.4.3  Assessment of causality ................................................................................. 76  
10.3.4.4  Final outcome ................................................................................................. 77  
10.3.4.5  Follow-up of adverse event and serious adverse event .................................. 77  
10.3.5  Reporting of serious adverse events .................................................................................. 77  
10.3.6  Reporting of adverse events for non -Novo Nordisk medical devices ............................... 79  
10.4  Appendix 4: Contraceptive guidance and co llection of pregnanc y information ............................... 80  
10.4.1  Definitions ................................................................................................................... ...... 80  
10.4.2  Contraceptive guidance ..................................................................................................... 80  
10.4.3  Collection of pregnancy information ................................................................................. 81  
10.5  Appendix 5: Technical complaints: Definition and procedures for recording, evaluation, 
follow-up and reporting ....................................................................................................... ............. 83  
10.5.1  Definition of technical complaint ...................................................................................... 83  
10.5.2  Recording and follow-up of technical comp laints ............................................................. 83  
10.5.3  Reporting of technical complaints for products not included in the technical 
complaint form ................................................................................................................ .. 84 
10.6  Appendix 6: Retention of human biosamples ................................................................................... 8 5 
10.7  Appendix 7: Hypoglycaemic episodes ............................................................................................ .. 86 
10.8  Appendix 8: Titration guideline ............................................................................................... ......... 88  
10.9  Appendix 9:  Events requiring adjudication .................................................................................... . 92 
10.10  Appendix 10: Mitigations to ensure participant safety and data integrity during an emergency 
situation ..................................................................................................................... ........................ 94  
10.10.1  Definition and scope of appendix ...................................................................................... 94  
10.10.2  Visits ........................................................................................................................ .......... 94  
10.10.3  Assessments ................................................................................................................... .... 95  CONFIDENTIAL
VV-CLIN-219731 1 .0 .
Protocol 
CONFIDENTIAL Date: 23 March 2023 Novo Nordisk 
Study ID: NN1535-4592 Version: 8.0 
      Status: Final 
      Page: 8 of 113 
 
 10.10.4  Study intervention ............................................................................................................ . 95 
10.11  Appendix 11: Country/Region-specific requirements .................................................................... 101  
10.12  Appendix 12: Abbreviations .................................................................................................... ....... 106  
10.13  Appendix 13: Protocol amendment history .................................................................................... 10 8 
11 References .................................................................................................................... ............................ 111  
 
Protocol Attachment I  Global list of key staff and relevant departments and suppliers 
Protocol Attachment II  Country list of key staff and relevant departments 
 CONFIDENTIAL
VV-CLIN-219731 1 .0 .
Protocol 
CONFIDENTIAL Date: 23 March 2023 Novo Nordisk 
Study ID: NN1535-4592 Version: 8.0 
      Status: Final 
      Page: 9 of 113 
 
 1 
  
1.1 Synopsis 
This is an interventional, multi-national, mult i-centre, randomised, 52-week, open label, parallel 
group, treat-to-target/dose escalation, confi rmatory study with two treatment arms.  
Rationale 
This study is designed to investigate the efficacy and safety of once weekly IcoSema, which is a 
combination product of insulin icodec and semaglutid e. IcoSema will be compared to once weekly 
1 mg semaglutide s.c., both treatment arms with or  without oral anti-diabetic drugs, in participants 
with type 2 diabetes inadequatel y controlled with a GLP-1 receptor agonist. The purpose is to show 
that there is an added benefit of the combination product compared to the once weekly semaglutide 
mono-component according to regulatory guidelines on clinical development of fixed combination 
products. 
Overall, the results of the present study will be important for evaluating the efficacy and safety of 
IcoSema in GLP-1 receptor agonist experienced participants with type 2 diabetes when 
intensification is needed. Furthermore, once we ekly IcoSema is developed to provide a simple 
treatment regimen. 
Objectives, endpoints and estimand 
Primary objective 
To confirm superiority of once weekly IcoSema compared with once weekly semaglutide, both 
treatment arms with or without oral anti-diabetic d rugs, in terms of glycaemic control measured by 
change in HbA 1c from baseline after 52 weeks in participants with type 2 diabetes inadequately 
controlled with a GLP-1 receptor agonist.  
Primary endpoint 
Endpoint title Time frame Unit 
Change in HbA 1c From baseline week 0 (V2) to week 52 (V54) %-point  
Estimand 
The primary estimand is described by the following 5 attributes: 
 Treatment condition: The effect of randomised treatment (titration of once weekly IcoSema 
versus fixed dose escalation of once weekly semaglutide 1 mg) with or without oral anti-diabetic drugs,  regardless of initiation of non-randomised insulin treatment or additional 
anti-diabetic treatments for more than 2 weeks and adherence to randomised treatment 
 Population: type 2 diabetes inadequately controlled with a GLP-1 receptor agonist 
 Endpoint: Change in HbA
1c from baseline to week 52 
 Remaining ICEs: None. The two intercurrent ev ents are captured under treatment condition and 
handled as follows:  CONFIDENTIAL
VV-CLIN-219731 1 .0 .
Protocol 
CONFIDENTIAL Date: 23 March 2023 Novo Nordisk 
Study ID: NN1535-4592 Version: 8.0 
      Status: Final 
      Page: 10 of 113 
 
 o Initiation of non-randomised insulin treatmen t or additional anti-diabetic treatments 
for more than 2 weeks by the treatment policy strategy 
o Discontinuation of randomised treatment for  any reason by the treatment policy 
strategy 
 Population-level summary: Difference in mean changes from baseline 
Overall design 
The study duration is approximately 59 weeks and consists of: 
 an up to 2 weeks screening period 
 a 52-week treatment period 
 a 5-week follow-up period 
Treatment arms and duration 
680 participants will be randomised (1:1) to  receive once weekly IcoSema or once weekly 
semaglutide, both treatment arms with or without oral anti-diabetic drugs. 
When discontinuing randomised treatment, the participant will be transferred to a suitable marketed 
product at the discretion of the investigator. 
Investigational medicinal products 
 IcoSema 700 units/mL + 2 mg/mL, subcutaneous, solution for injection, 1.5 mL pre-filled 
PDS290 pen injector 
 Semaglutide 1.34 mg/mL, subcutaneous, soluti on for injection, 1.5 mL pre-filled PDS290 
pen-injector  
Participant characteristics 
The participants will be male or female diagnosed  with type 2 diabetes, inadequately controlled 
with a GLP-1 receptor agonist, and aged above 18 ye ars at inclusion. They will meet the following 
key inclusion criteria and none of the following key exclusion criteria: 
Key inclusion criteria  
1. Male or female and age above or equal to 18 ye ars at the time of signing informed consent. 
2. 1)/67;-,?1<0<A8-
,1)*-<-;5-441<=;E	,)A;*-.7:-;+:-- 616/  
3. HbA 1c of 7.0-10.0% (53.0-85.8 mmol/mol) (both inclusive) as assessed by central laboratory on 
the day of screening. 
4. Insulin naÃ¯ve. The following exceptions are permitted: short term insulin treatment for a 
maximum of 14 days before screening and/or prior insulin treatment for gestational diabetes. 
5. Treated with stable doses of daily or weekly GLP-1 receptor agonist (excluding once weekly 
semaglutide with doses higher than 1.0 mg) according to local label for the treatment of diabetes 
E 90 days before screening. The treatment can be with or without any of the following 
anti-diabetic drugs with stable doses E 90 days before screening:  
Âƒ Metformin 
Âƒ Sulfonylureasa 
Âƒ Meglitinides (glinides)a CONFIDENTIAL
VV-CLIN-219731 1 .0 .
Protocol 
CONFIDENTIAL Date: 23 March 2023 Novo Nordisk 
Study ID: NN1535-4592 Version: 8.0 
      Status: Final 
      Page: 11 of 113 
 
 Âƒ DPP-4 inhibitorsa 
Âƒ Sodium-glucose co-transporter 2 inhibitors 
Âƒ Alpha-glucosidase-inhibitors 
Âƒ Thiazolidinediones 
Âƒ Marketed oral combination products only including the products listed above. 
6. 7,A5);;16,-@ D3/52. 
a Sulfonylureas, meglitinides (glinides) and DPP-4 in hibitors must be discontinued at randomisation. 
Key exclusion criteria    
1. Female who is pregnant, breast-feeding or intends to become pregnant or is of childbearing 
potential and not using a highly ef fective contraceptive method. 
2. Anticipated initiation or change in concomitant medication (for more than 14 consecutive days) 
known to affect weight or glucose metabolism (e.g. treatment with orlistat, thyroid hormones, or 
systemic corticosteroids).  
3. Treatment with any medication for the indication of diabetes or obesity other than stated in the 
inclusion criteria within 90 days before screening. 
4. Any episodesa of diabetic ketoacidosis within 90 days before screening. 
5. Presence or history of pancreatitis (acute or chronic) within 180 days before screening. 
6. Any of the following: Myocardial infarction, stroke, hospitalization for unstable angina pectoris 
or transient ischaemic attack within 180 days before screening. 
7. Chronic heart failure classified as being in New York Heart Association Class IV at screening. 
8. Uncontrolled and potentially unstable diabetic re tinopathy or maculopathy. Verified by a fundus 
examination performed within the past 90 days before screening or in the period between 
screening and randomisation. Pharmacological pu pil-dilation is a requirement unless using a 
digital fundus photography camera specified for non-dilated examination. 
a as declared by the participant or in the medical records.  
Data monitoring committee: No 
 CONFIDENTIAL
VV-CLIN-219731 1 .0 .
Protocol       Date: 23 March 2023 Status:  Final  Novo Nordisk 
Study ID: NN1535-4592       Version: 8.0 Page: 12 of 113 
 
 1.2 Flowchart 
 Protocol 
Sections Screening Randomisation Treatment period Follow up Discontinuation 
 Visit  V1 V2 V3 V4 V5 V6 V8 V10 V12 V16 V20 V24a V28 V30a V34a V38 V42a V46 V50 V54 V55 V56 V54A 
 Weekly Phone Contact 
number (P)        P7 P9 P11 P13 
P14 
P15 P17 
P18 
P19 P21 
P22 
P23 P25 
P26 
P27 P29 P31 
P32 
P33 P35 
P36 
P37 P39 
P40 
P41 P43 
P44 
P45 P47 
P48 
P49 P51 
P52 
P53     
 Timing of Visit 
(Weeks)   <-2W 0W 1W 2W 3W 4W 6W 8W 10W 14W 18W 22W 26W 28W 32W 36W 40W 44W 48W 52W 54W 57W  
 Visit Window (Days)    Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 +3 +3  
    Informed Consent 
and Demography  10.1.3  
(App 1)  X                       
    Eligibility Criteria 5.1, 5.2 X X                      
    Concomitant 
Medication  6.8 X X X X X X X X X X X X X X X X X X X X X X X 
    Medical 
History/Concomitant 
Illness  8.2 X X                      
    Tobacco Use 5.3.2 X                       
    Childbearing 
Potential  10.4 
(App 4)  X                       
    Pregnancy Test 8.3.5 , 
10.4 
(App 4)  X X                  X  X X 
    Body Measurements 8.2.2 X X       X  X  X   X  X  X   X 
Body Weight 8.2.2 X X       X  X  X   X  X  X   X 
    Vital Signs 8.2.3 X X       X  X  X   X  X  X   X 
    Physical 
Examination  8.2.2 X                   X   X 
    ECG 8.2.5 X                   X   X 
    Eye Examination 8.2.4 X                   X   X 
VV-CLIN-219731 1.0 .
Protocol       Date: 23 March 2023 Status:  Final  Novo Nordisk 
Study ID: NN1535-4592       Version: 8.0 Page: 13 of 113 
 
  Protocol 
Sections Screening Randomisation Treatment period Follow up Discontinuation 
 Visit  V1 V2 V3 V4 V5 V6 V8 V10 V12 V16 V20 V24a V28 V30a V34a V38 V42a V46 V50 V54 V55 V56 V54A 
 Weekly Phone Contact 
number (P)        P7 P9 P11 P13 
P14 
P15 P17 
P18 
P19 P21 
P22 
P23 P25 
P26 
P27 P29 P31 
P32 
P33 P35 
P36 
P37 P39 
P40 
P41 P43 
P44 
P45 P47 
P48 
P49 P51 
P52 
P53     
 Timing of Visit 
(Weeks)   <-2W 0W 1W 2W 3W 4W 6W 8W 10W 14W 18W 22W 26W 28W 32W 36W 40W 44W 48W 52W 54W 57W  
 Visit Window (Days)    Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 +3 +3  
    Self Measured 
Plasma Glucose  8.1.1  X X X X X X X X X X X X X X X X X X X X X X 
    Adverse Eventb 8.3, 
10.3 
(App 3)  
10.7 
(App 7)      Xb X X X X X X X X X X X X X X X X X X X X 
    Laboratory 
Assessments  10.2 
(App 2)  X X       X  X  X   X  X  X   X 
    HbA 1c  X X       X  X  X   X  X  X   X 
    Antibodies 8.7  X  X   X  X  X  X   X    X  X X 
    Pop-PK 8.4    X   X  X  X  X   X    X  X X 
    Drug Dispensing 6  X       X  X  X   X  X      
    Training in Trial 
Product, Pen -handling 6.1  X X   X  X X  X  X   X  X      
    Hand Out and 
Instruct in Devices 6  X                      
    Attend Visit Fasting 5.3.1  X       X  X  X   X  X  X   X 
Notes: 
a Visits V24, V30, V34 and V42 can be performed as either s ite visits, or phone/video contacts, at the discretion of the invest igator 
b All AEs and SAEs must be collected from first administration of randomised treatment 
VV-CLIN-219731 1.0 .
Protocol       Date: 23 March 2023 Status:  Final  Novo Nordisk 
Study ID: NN1535-4592       Version: 8.0 Page: 14 of 113 
 
 1.3 Flowchart ! phone contacts 
 
 Protocol 
Sections P7-P53 
 Visit Window (Days)  Â±3 
    Concomitant Medication 6.8 X 
    Self Measured Plasma Glucose 8.1.1 X 
    Adverse Eventa 8.3, 
10.3 
(App 3)  
10.7 
(App 7)    X 
a All AEs and SAEs must be collected from first administration of randomised treatment
VV-CLIN-219731 1.0 .
Protocol 
CONFIDENTIAL Date: 23 March 2023 Novo Nordisk 
Study ID: NN1535-4592 Version: 8.0 
      Status: Final 
      Page: 15 of 113 
 
 2 
  
Diabetes mellitus is a metabolic disorder character ised by the presence of hyperglycaemia due to 
defective insulin secretion, insulin action or both. Chronic hyperglycaemia of diabetes mellitus is 
associated with significant long-term complications , particularly tissues damage and dysfunction or 
organ failure - especially the kidney, eye, and nerves.2 Diabetes is generally classified according to 
aetiological factors, where type 1 diabetes and type 2 diabetes (T2D) constitutes the vast majority of cases. In the Internati 76)41)*-<-;-,-:)<176J;1) *-<-;<4);
	<0--;<15)<-, ?7:4,?1,-
diabetes prevalence was 463 million, with a prediction that by 2045, the number of people with 
diabetes will have increased to 700 million.
3 
T2D is a progressive disease, and the need for tr eatment intensification over time can be covered in 
a simple setting by a titratable fixed ratio combination product as IcoSema. IcoSema is a 
combination product of insulin icodec and the gluc agon-like peptide 1 (GLP-1) receptor agonist 
semaglutide, which is developed to provide an ef fective and convenient, once weekly treatment 
regimen for people with T2D.  
Insulin icodec is a novel long-acting insulin analog ue which is under development (global phase 3a 
programme initiated during the fourth quarter of  2020) to safely cover the basal insulin 
requirements for a full week with a single subcutaneous (s.c.) injection. Insulin icodec has a 
terminal half-life of approximately 196 hours. Insulin icodec is a recombinant protein produced 
using yeast.  
Semaglutide is a GLP-1 receptor agonist with a half-life of 149 to 164 hours, suitable for once 
weekly s.c. administration.4 The long half-life was obtained by applying the fatty acid acylation 
technology that provides specific high-affinity albumin binding. Furthermore, semaglutide has full stability against DPP-4 degradation. Semaglutide ex hibits GLP-1 receptor mediated effects, leading 
to lowering of glucose and decreased appetite through physiologically relevant mechanisms. As a 
result, semaglutide provides strong glycaemic control and weight loss. In addition, the 
cardiovascular safety of semaglutide has been c onfirmed. The mechanism of action of semaglutide 
was characterized in extensive non-clinical and clinical studies.
5, 6 Semaglutide (OzempicÂ®) is 
currently approved in more than 60 countries for the treatment of T2D. In addition, semaglutide is 
approved for use in combination with insulin.5 
IcoSema is expected to provide an effect on HbA 1c reduction through actions on both fasting and 
prandial glycaemic control. IcoSema is also expected  to reduce the risk of hypoglycaemic episodes 
and to provide weight loss compared to basal insuli n and basal-bolus insulin treatment, and to show 
a comparable or better gastrointes tinal adverse event (AE) profile as compared to semaglutide. 
2.1 Study rationale 
The present study is a 52-week, parallel study, with  two treatment arms designed to investigate the 
efficacy and safety of once weekly IcoSema in co mparison to once weekly 1 mg semaglutide s.c. 
(referred to as semaglutide in this document), bot h treatment arms with or without oral anti-diabetic 
drugs (OADs), in participants with T2D inadequa tely controlled with a GLP-1 receptor agonist. The 
purpose is to show that there is an added benefit of the combination product compared to the once 
weekly semaglutide mono-component according to regulatory guidelines on clinical development of 
fixed combination products.7 CONFIDENTIAL
VV-CLIN-219731 1 .0 .
Protocol 
CONFIDENTIAL Date: 23 March 2023 Novo Nordisk 
Study ID: NN1535-4592 Version: 8.0 
      Status: Final 
      Page: 16 of 113 
 
 Overall, the results of the present study will be important for evaluating the efficacy and safety of 
IcoSema in GLP-1 receptor agonist experienced participants with T2D when intensification is 
needed. Furthermore, once weekly IcoSema is de veloped to provide a simple treatment regimen.  
2.2 Background 
Diabetes mellitus  
T2D is characterised by insulin resistance, impa ired insulin secretion, increased hepatic glucose 
output due to glucagon dysregulation resulting in chronic hyperglycaemia.8 The pathogenesis is not 
fully understood but seems to be heterogeneous, i nvolving environmental, lifestyle, and genetic 
factors leading to chronic hyperglycaemia caused by  peripheral tissue insulin resistance, impaired 
insulin secretion due to abnormal beta-cell function and abnormal glucose metabolism in the liver.9 
Treatment of type 2 diabetes mellitus  
The current treatment cascade recommended by the American Diabetes Association and the 
European Association for the Study of Diabetes foll ows a stepwise approach comprising lifestyle 
changes in combination with pharmacological intervention.10 Metformin is recommended as initial 
therapy, followed by combination therapy with ot her OADs, GLP-1 receptor agonists and insulin as 
the disease progresses.10 
Despite the development of new treatments, a substantial proportion of people with T2D fail to 
achieve the recommended glycaemic targets. This clinical inertia prolongs the duration of people ;J
hyperglycaemia, which consequently puts them at  an increased risk of diabetes-associated 
complications and reduced life expectancy. Specifically, there is an unmet medical need for 
products with the potential to improve clinical outcomes through reduced treatment burden, i.e. 
fewer injections, and increased treatment adherence and persistence11 compared to other treatment 
regimens requiring daily or several weekly injections. 
For people with advanced T2D in need of im proved fasting and prandial glycaemic control, 
combined treatment with a GLP-1 receptor ag onist and a basal insulin can provide improved 
glycaemic outcomes.12 Experiences with fixed ratio combination products e.g. insulin 
degludec/liraglutide (XultophyÂ®) has shown improved treatment effect whilst reducing the side 
effects compared to the mono-components.13 However, market research has shown that people with 
diabetes would prefer fewer injections14 and increased flexibility15 than currently provided by once 
daily treatment. 
IcoSema  
IcoSema is a once weekly injectable fixed ratio combination product comprising the novel insulin 
icodec and the GLP-1 receptor agonist semaglutid e and is developed for late stage treatment 
intensification for people with advanced T2D. The development of IcoSema is based on learnings 
from other fixed ratio combination products e.g. insulin degludec/liraglutide (XultophyÂ®), showing 
that combination products benefit from the co mplementary actions of both mono-components on 
glycaemic control. Hence, IcoSema benefits from both insulin icodec and the potent GLP-1 receptor 
agonist semaglutide. IcoSema has been investigated in a clinical pharmacology study 
(NN1535-4359) in participants with T2D. Data from NN1535-4359 has contributed to development 
of the IcoSema titration guidelines included in  the phase 3a development programme. A CONFIDENTIAL
VV-CLIN-219731 1 .0 .
Protocol 
CONFIDENTIAL Date: 23 March 2023 Novo Nordisk 
Study ID: NN1535-4592 Version: 8.0 
      Status: Final 
      Page: 17 of 113 
 
 comprehensive review of the results from the clinical pharmacology study can be found in the 
+=::-6<16>-;<1/)<7:J;*:7+0=:-16 or any updates hereof. 
Semaglutide 
Semaglutide is a GLP-1 receptor agonist with a half-life of approximately 149 to 164 hours, suitable 
for once weekly s.c. administration.17 In the semaglutide s.c. clinical development programme, 
semaglutide 0.5 and 1.0 mg demonstrated a safety profile in line with the GLP-1 receptor agonist class, and clinically relevant and superior glycae mic control and weight loss versus placebo and 
active comparators, both as monotherapy, in drug-naÃ¯ve people with T2D, and in combination with 
other anti-hyperglycaemic agents, including basal insulin, in people with T2D with inadequate 
glycaemic control. For more information, please see the current semaglutide 16>-;<1/)<7:J;*:7+ hure 
or any updates hereof,
17 or the current EMA summary of produ ct characteristics for semaglutide 
(OzempicÂ®),5 the US prescribing information for semaglutide (OzempicÂ®),6 or any locally approved 
label. 
Study population 
The study population will consist of insulin naÃ¯ve participants with T2D inadequately controlled 
with GLP-1 receptor agonist. The study population is further described in Section 4.2. 
2.3 Benefit-risk assessment 
The main benefits and risks related to participation in  the study are described in the below sections.  
The risks of IcoSema presented in this section are a combination of important and non-important 
risks for IcoSema and for the mono-compone nts insulin icodec and semaglutide.   
More detailed information about the known and expected benefits and risks and reasonably 
expected adverse events (AEs) of IcoSema may be found in the current 16>-;<1/)<7:J;*:7+0=:-16 or 
any updates hereof.  CONFIDENTIAL
VV-CLIN-219731 1 .0 .
Protocol 
CONFIDENTIAL Date: 23 March 2023 Novo Nordisk 
Study ID: NN1535-4592 Version: 8.0 
      Status: Final 
      Page: 18 of 113 
 
 2.3.1 Risk assessment 
Table 2-1 Risk assessment 
Risk of clinical significance  Summary of data/rationale for 
risk Mitigation strategy 
IcoSema 
Identified risk  
Gastrointestinal  AEs (Nausea, 
vomiting and diarrhoea)  Gastrointestinal AEs is a class risk 
for all GLP -1 receptor agonist 
products. The precise mechanism 
remains unclear but involve s a 
GLP -1 receptor- mediated activation 
and it is therefore considered a class 
risk for all GLP -1 receptor agonist 
products. In general, these reactions 
are mild or moderate in severity, of short duration, and dose dependent.   In 
the phase 1 single dose study 
!!	

N
57:- participants  
experienced gastrointestinal AEs, 
predominantly nausea and vomiting, following administration of IcoSema compared to the 
mono- components. 
This was likely due to the relatively 
higher maximum concentration of 
semaglutide following IcoSema administration 
of 175 units / 0.5 mg 
compared to separate dose administration o
f 0.5 mg 
semaglutide.  
Gastrointestinal  AEs have also been 
observed in non -clinical studies as 
well as the clinical studies with 
semaglutide. The most frequently 
reported AEs across the semaglutide clinical programmes were 
gastrointestinal
 AEs (e.g., nausea, 
vomiting and diarrhoea).   
 To mitigate the risk of 
gastrointestinal AEs , once weekly 
IcoSema will be initiated at  a low 
starting dos e of 40 dose steps 
(equivalent to 40 units of insulin 
icodec and 0.114 mg of semaglutide, 
i.e. half the semaglutide starting dose 
of 0.25 mg ) and titrated with 
Â±10 dose steps (equivalent to 
10 units of insulin icodec and 
0.029  mg of semaglutide) to a 
maximum dose of 350 dose steps 
(equivalent to 350 units of insulin 
icodec and 1 mg of semaglutide). Participants
 who experience 
vomiting and /or diarrhoea will be 
instructed  to maintain adequate fluid 
intake  to compensate for the volume 
depletion.  
Identified risk  
Hypoglycaemia  
 Hypoglycaemia is an anticipated 
undesirable effect related to the  
pharmacolo gical mechanism of 
insulin.  
In the phase 1 single dose study 
!!	

N
0A87/4A+)-51+
episodes were reported in ~33% 
participants in the IcoSema arm and 32% of the participants in the insulin 
icodec arm. No severe 
hypoglycaemic episodes were reported. Mos
t hypoglycaemic 
episodes were asymptomatic .  
Hypoglycaemia has been observed 
in clinical studies with insulin 
icodec. There is a low risk of 
hypoglycaemic episodes when 
semaglutide is used as 
mono-therapy. Frequent blood glucose 
measurements are encouraged throughout drug exposure by means 
of a blood glucose 
(BG) meter. The 
participant will receive written information describing 
hypoglycaemic symptoms and how 
to manage low blood glucose levels. Prevention 
or worsening of 
hypoglycaemia will be sought by 
early detection and administration of carbohydrates and medical treatment, if needed. 
 
When adjusting IcoSema dose, 
recommended titration schemes 
should be followed.  
Potential risk:  
Hypersensitivity  As with all protein-based drugs, 
treatment with IcoSema may evoke allergic reactions, including severe As a precaution, participants with 
suspected hypersensitivity to  CONFIDENTIAL
VV-CLIN-219731 1 .0 .
Protocol 
CONFIDENTIAL Date: 23 March 2023 Novo Nordisk 
Study ID: NN1535-4592 Version: 8.0 
      Status: Final 
      Page: 19 of 113 
 
 Risk of clinical significance  Summary of data/rationale for 
risk Mitigation strategy 
systemic hypersensitivity reactions 
and angioedema.  
One non -serious type-1 
drug-induced hypersensitivity 
reaction was reported in the IcoSema 
phase 1  single dose study NN1535-
4359.  
No systemic hypersensitivity 
reactions have been observed in clinical studies with insulin icodec.  Hypersensitivity is an adverse reaction identified in phase 3a 
studies for semaglutide in 
participants with T2D. randomised treatment will not be 
enrolled in this study.  
Participants and investigators will be 
instructed about the signs and 
symptoms of allergic reactions and instructed to contact the site 
immediat
ely in case of signs of 
hypersensitivity.  
 
 
Potential risk:  
Serious allergic reactions  As with all protein-based drugs, 
treatment with IcoSema may evoke allergic reactions, including severe systemic hypersensitivity reactions 
and angioedema. 
 
No serious allergic reactions have 
been observed with IcoSema in the phase 1
 single dose study 
NN1535 -4359. 
No systemic hypersensitivity 
reactions have been observed in 
studies with insulin icodec.  
Events of allergic reactions 
(generally mild and non -serious) 
have been reported in participants with T2D treated with semaglutide. 
Few events of anaphylactic reaction 
were reported; however, none of these events were related to the treatment with semaglutide. Events of angioedema were also reported from post marketing sources. As a precaution, participants with 
suspected hypersensitivity to  
randomised treatment will not be 
enrolled in this study.  
Participants and investigators will be 
instructed about the signs and symptoms of allergic reactions and instructed 
to contact the site 
immediately in case of signs of 
hypersensitivity.  
 
 
Potential risk:  
Medication error due to potential 
mix-up  Despite the open-label study design, 
medication error is still a n applicable 
risk for participants treated with 
multiple insulins. Medication errors 
can have clinical consequences such as hypoglycaemia or 
hyperglycaemia. 
 
No information is available from 
completed clinical studies with IcoSema. Very few medication errors have been observed in the completed clinical studies with
 
insulin icodec, none associated with 
AEs. Participants will be instructed to 
visually verify the dialled units on 
the dose counter of the pen. In stud
ies involving different pens, 
participants must be instructed to 
always check the pen label before 
each injection to avoid  potential 
mix-ups.  
 
Potential risk:  
Injection site reactions  Injection site reactions may occur 
with all injectable peptide -based 
treatments.  
In the phase 1 single dose study 
NN1535 -4359 with IcoSema, one 
event of injection site haematoma 
was reported after administration of the mono-component semaglutide. Participants will be instructed to 
monitor for signs and symptoms of injection site reactions. Participants 
should be instructed to contact the 
site immediately in case of signs of 
worsening of injection site reactions 
for further action. 
 CONFIDENTIAL
VV-CLIN-219731 1 .0 .
Protocol 
CONFIDENTIAL Date: 23 March 2023 Novo Nordisk 
Study ID: NN1535-4592 Version: 8.0 
      Status: Final 
      Page: 20 of 113 
 
 Risk of clinical significance  Summary of data/rationale for 
risk Mitigation strategy 
Injection site reactions were 
observed in participants with T2D treated with insulin
 icodec.  
In the studies with semaglutide s.c. 
for T2D, injection site reactions 
were reported by a low 
(approximately 1%) proportion of 
participants with semaglutide and were not recurrent in those individuals.  Participants will be instructed on the 
most appropriate injection techniques. Recommendations on 
rotation of the site of injection are 
inc
luded in Table 6-1 . 
Potential risk 
Diabetic retinopathy complications  
 The risk of diabetic retinopathy 
complications has been observed in 
T2D treated with semaglutide in 
clinical studies.  
In a 2 -year clinical study with. 
semaglutide s.c (NN9535-3744) 
involving 3,297 participant s with 
T2D,  high cardio vascular risk, long 
duration of diabetes and poorly 
controlled blood glucose, EAC
-confirmed events of diabetic 
retinopathy complications occurred in more 
participants treated with 
semaglutide s.c  (3.0%) compared to 
placebo (1.8%). The absolute risk 
increase for diabetic retinopathy 
complications was larger among 
participants  with a history of diabetic 
retinopathy at baseline. In the participants
 who did not have a 
documented history of diabetic 
retinopathy the number of events w
as similar for semaglutide s.c and 
placebo. In the other clinical  stud ies 
up to 1 year involving 4,807 participants
 with T2D, AEs related 
to diabetic retinopathy were reported 
in similar proportions of participants treated with 
semaglutide s.c (1.7%) 
and comparators (2.0%). Rapid improvement in glucose 
control has been associated with a 
temporary worsening of diabetic 
retinopathy, but other mechanisms 
cannot be excluded. Lo ng-term 
glycaemic control decreases the risk 
of diabetic retinopathy. These participants should be monitored 
closely and treated according to 
clinical guidelines. 
 
Participants will have an eye 
examination performed at baseline and at 
week 52. Diagnostic artificial 
intelligence algorithms may possibly 
be used as screening tool. If 
diagnostic artificial intelligence 
algorithms are used and in case of 
changes indicated by the algorithm, 
an additional eye examination must be performed
, see section 8.2.4 . 
Uncontrolled and potentially 
unstable diabetic retinopathy or maculopathy is an exclusion criterion in 
this study.  
Potential risk:  
Acute pancreatitis  Acute pancreatitis has been observed 
with the use of GLP -1 receptor 
agonists. In the completed phase 3 
studies with semaglutide s.c. and 
oral semaglutide, both the event rate and the proportion of participants experiencing confirmed pancreatitis were similar with semaglutide and 
comparator. Few events were 
confirmed; the events occurred throughout the study periods and the overall rates were similar to the rates reported in background populations. Participants should be informed of 
the characteristic symptoms of acute 
pancreatitis and if pancreatitis is 
suspected, IcoSema or semaglutide 
should be discontinued. If confirmed, 
IcoSema or semaglutide 
should not be restarted.  
 CONFIDENTIAL
VV-CLIN-219731 1 .0 .
Protocol 
CONFIDENTIAL Date: 23 March 2023 Novo Nordisk 
Study ID: NN1535-4592 Version: 8.0 
      Status: Final 
      Page: 21 of 113 
 
 Risk of clinical significance  Summary of data/rationale for 
risk Mitigation strategy 
Potential risk:  
Neoplasms (malignant and non -
malignant)  Participants with T2D, as well as 
participants with overweight or obesity, have an increased risk of 
certain types of cancer. There is no 
evidence from clinical studies that GLP
-1-based therapies increase the 
risk of neoplasms. However, in the 
semaglutide s.c. as well as oral 
semaglutide phase 3a studies, the 
proportion of participants with neoplasms (malignant and non
-
malignant) were slightly higher with 
semaglutide than with comparator. 
The number of participants exposed to semaglutide s.c. or oral semaglutide for a longer period is considered insufficient for a thorough assessment of the risk of 
neoplasms.
 
 Participants with presence or history 
of malignant neoplasm within 5
 years prior to the day of screening 
will not be enrolled in this study. 
Basal and  squamous cell skin cancer 
and any carcinoma in -situ is allowed. 
 
 
Potential risk:  
Pancreatic cancer  Participants with T2D have an 
increased risk of certain types of cancer such as pancreatic cancer. There is currently no support from non
-clinical studie s, clinical studies 
or post -marketing data that GLP- 1 
based therapies increase the risk of 
pancreatic cancer. However, 
pancreatic cancer has been classified as a potential class risk for all marketed GLP
-1 receptor agonists 
by regulatory agencies. There is  no 
indication of an increased relative risk in the semaglutide treatment groups vs. comparator, including placebo. The rates of EAC
-
confirmed events of pancreatic 
cancer were consistently low across 
studies. Participants with history of 
malignant neoplasm  within 5 years 
prior to the day of screening will not be enrolled in this study.
 
 
Potential risk:  
Medullary thyroid cancer  Thyroid C-cell tumours were seen in 
mouse and rat carcinogenicity 
studies after daily exposure to 
semaglutide for 2 years. The rodent 
C-cell tumours are caused by a non-
genotoxic, specific GLP -1 receptor 
mediated mechanism to which rodents are particularly sensitive. No 
C
-cell tumours were observed in 
monkeys after 52 weeks exposure up 
to 52 -fold above the clinical plasma 
exposure at  14 mg/day. The GLP -1 
receptor is not expressed in the 
normal human thyroid, and therefore 
the clinical relevance of the findings is considered to be low. Exclusion criteria related to personal 
or first -degree relative(s) history of 
multiple endocrine neoplasia type 2 
or medullary thyroid carcinoma.  
 CONFIDENTIAL
VV-CLIN-219731 1 .0 .
Protocol 
CONFIDENTIAL Date: 23 March 2023 Novo Nordisk 
Study ID: NN1535-4592 Version: 8.0 
      Status: Final 
      Page: 22 of 113 
 
 Risk of clinical significance  Summary of data/rationale for 
risk Mitigation strategy 
Study procedures 
Risk of COVID-19 infection in  
relation to participation in study  Participants may be exposed to the 
risk of COVID -19 transmission and 
infection in relation to site visits if an outbreak is ongoing in the given country
.  
 
 The risk of COVID-19 transmission 
in relation to site visits is overall considered to be low, however this may 
vary between geographical 
areas.  
To minimize the risk as much as 
possible, the following measures 
have been taken:  
 Cautious participant 
recruitment planning ensures 
controlled participant 
enrolment in countries where 
the COVID- 19 pandemic is 
evaluated to b e sufficiently 
under control, and at sites 
where health care resources are 
evaluated to be adequate. 
 Study procedures including the 
number and frequency of study procedures and assessments have been critically evaluated 
to limit the number of on- site 
visits to the extent possible. 
Remot e visits can be performed 
either by phone or by video call 
depending on the preference of 
the participant and the 
investigator.  
 Guidance is provided to site 
staff to request that on-site 
visits are planned to be as short 
as possible. Physical contact 
between participants and site 
staff will be limited to the 
extent possible, and protective measures will be implemented (describe e.g. use of masks, 
sanitizers, no aerosol-
generating procedures 
etc.). 
 Please refer to App endix 10 
(Section 10.10 ) which lists the 
additional actions to be taken 
in case a site or country are 
locked down and it is not 
possible for participa nts to visit 
the site. 
Other 
Device medication error  If the pen-injector is damaged or used differently than described in the directions for use
, a risk of overdose 
or underdose of randomised 
treatment  exists. This may cause 
hypoglycaemia  due to overdose or 
hyperglycaemia due to underdose. Training in injections and use of devices
 and guidance materials for 
investigator, site staff and pa
rticipants will be provided. CONFIDENTIAL
VV-CLIN-219731 1 .0 .
Protocol 
CONFIDENTIAL Date: 23 March 2023 Novo Nordisk 
Study ID: NN1535-4592 Version: 8.0 
      Status: Final 
      Page: 23 of 113 
 
 Risk of clinical significance  Summary of data/rationale for 
risk Mitigation strategy 
For more information about the 
known and expected benefits and risks of i
nsulin icodec , please refer to 
the IcoSema 16>-;<1/)<7:J;
brochure .16   
For more information about the 
known and expected benefits and 
risks of semaglutide, please refer to 
the IcoSema 16>-;<1/)<7:J;
brochure ,16 the current EMA 
summary of product  characteristics 
for semaglutide ,5 the US prescribing 
information for se maglutide,6 or any 
locally approved label.    
Pregnancy and fertility. Studies with insulin icodec in rats 
have shown no effects on fertility, embryo
-foetal survival or on major 
and minor foetal abnormalities. In an 
embryo -foetal development study in 
rabbits, no effect on major and minor foetal visceral and skeletal
 
abnormalities at any dose levels was 
observed. Consequently, insulin 
1+7,-+1;+)<-/7:1;-,);I=6413-4A
risk of human 
teratogenicity/ fetotoxicity. 
Studies in  animals have shown 
reproductive toxicity in studies with 
semaglutide. There are limited data from the use of s
emaglutide in 
pregnant women. The randomised treatment should not 
be used during pregnancy. Women of childbearing potential are required to use highly effective contraceptive 
methods when participating in the 
study
, see Appendix 4 (Section 10.4, 
Table 10-3 ). If a participant wishes 
to become pregnant, or pregnancy 
occurs, the rando mised treatment 
should be discontinued , please refer 
to Section 8.3.5  for further 
guidance). The effect of IcoSema on 
fertility in humans is unknown.  
 
Risk assessment has been conducted for the PDS 290 pen-injector for IcoSema in accordance with 
ISO 14971:2019 when using the PDS290 pen-injector in people with T2D. All identified risks (i.e. 
injection site reactions, see Table 2-1 ) associated with using the PDS290 pen-injector for IcoSema 
according to the clinical procedures specified in this protocol have been reduced as far as possible 
and are acceptable, taking into account the cu rrent state of the art. The use of the PDS290 
pen-injector for IcoSema, in this study is therefore considered to be of non-significant risk. 
2.3.2 Benefit assessment 
Based on experience from the mono-components and on the learnings from insulin 
degludec/liraglutide as described in the in troduction, we expect at positive benefit of the 
combination product IcoSema. This benefit assess ment section is based on clinical data available 
for the mono-components insulin icodec and semaglutide in the T2D population. 
Insulin icodec is currently in development and has been shown to have a long and stable 
pharmacokinetic and pharmacodynamic profile supporting a once weekly treatment. Market 
research has shown that people with diabetes me llitus would prefer fewer injections and greater 
flexibility than those provided by the current once daily treatment regimen.14 Therefore, the 
compliance and quality of life are expected to in crease by introducing a once weekly basal insulin 
treatment.  CONFIDENTIAL
VV-CLIN-219731 1 .0 .
Protocol 
CONFIDENTIAL Date: 23 March 2023 Novo Nordisk 
Study ID: NN1535-4592 Version: 8.0 
Status: Final 
Page: 24 of 113 
Clinical data on once weekly semaglutide have dem onstrated superior glyc aemic control, superior 
reductions in body weight versus placebo and acti ve comparators, and reduced cardiovascular risk 
compared to placebo in participants with T2D. Further, once weekly dosing offers flexibility and 
fewer injections as opposed to current therapy.  
Based on these data, the combination of semaglutid e and insulin icodec in a once weekly fixed ratio 
combination product is expected to provide superior efficacy on HbA 1c lowering compared to the 
mono-components.   
IcoSema is also expected to show a comparable or better gastrointestinal AE profile as compared to 
semaglutide.  
For all participants, the anticipated benefits include improved glycaemic control. To ensure all participants receive adequate treatment, investigat ors are encouraged to optimise glycaemic control 
every week throughout the study in accordance with the titration guidelines, see Appendix 8 
(Section 10.8). Participants will receive intense medical care by means of weekly contact with the 
sites.  
2.3.3 Overall benefit-risk conclusion 
No new significant safety information that changes the current benefit-risk profile of IcoSema 
emerged from the completed phase 1 single dos e IcoSema study NN1535-4359 or safety profile 
generated from clinical and non-clinical development programme for the mono-components. 
Necessary precautions have been implemented in the design and planned conduct of the study in 
order to minimise the risks and inconveniences of participation in the study. 
IcoSema is expected to provide an effect on HbA 1c reduction through actions on both fasting and 
prandial glycaemic control. IcoSema is also expected  to reduce the risk of hypoglycaemic episodes 
and to provide weight loss compared to basal insuli n and basal-bolus insulin treatment, and to show 
a comparable or better gastrointestinal AE  profile as compared to semaglutide. 
Considering the measures taken to minimise risk to participants, the potential risks identified in 
association with IcoSema are justified by the anti cipated benefits that may be afforded to people 
with T2D. 
More detailed information about the known and exp ected benefits and risks of IcoSema can be 
found in the current i 6>-;<1/)<7:J; brochure16 or any updates hereof. CONFIDENTIAL
VV-CLIN-219731 1 .0 .
Protocol 
CONFIDENTIAL Date: 23 March 2023 Novo Nordisk 
Study ID: NN1535-4592 Version: 8.0 
      Status: Final 
      Page: 25 of 113 
 
 3 
  
3.1 Objectives 
3.1.1 Primary objective 
To confirm superiority of once weekly IcoSema compared with once weekly semaglutide, both 
treatment arms with or without OADs, in terms of  glycaemic control measured by change in HbA 1c 
from baseline after 52 weeks in participants wi th T2D inadequately controlled a GLP-1 receptor 
agonist.  
3.1.2 Secondary objectives 
To compare parameters of glycaemic control and safety of once weekly IcoSema with once weekly 
semaglutide, both treatment arms with or without OADs, in participants with T2D inadequately 
controlled with a GLP-1 receptor agonist. 
3.2 Endpoints 
3.2.1 Primary endpoint 
Endpoint title Time frame Unit 
Change in HbA 1c From baseline week 0 (V2) to week 52 (V54) %-point  
3.2.2 Secondary endpoints 
3.2.2.1  Supportive secondary endpoints 
Secondary efficacy endpoints 
Endpoint title Time frame Unit 
Change in fasting plasma glucose (FPG) From baseline week 0 (V2) to week 52 (V54) mmol/L  
Change in body weight From baseline week 0 (V2) to week 52 (V54) Kg  
Secondary safety endpoints 
Endpoint title Time frame Unit 
Number of clinically significant 
hypoglycaemic episodes (level  2) 
(<3.0  mmol/L (54 mg/dL), confirmed by 
BG meter) or severe hypoglycaemic 
episodes (level 3) From baseline week 0 (V2) to week 57 (V56) Number of episodes 
Number of clinically significant 
hypoglycaemic episodes (level  2) 
(<3.0  mmol/L (54 mg/dL), confirmed by 
BG meter)   From baseline week 0 (V2) to week 57 (V56) Number of episodes 
Number of severe hypoglycaemic 
episodes (level 3) From baseline week 0 (V2) to week 57 (V56) Number of episodes CONFIDENTIAL
VV-CLIN-219731 1 .0 .
Protocol 
CONFIDENTIAL Date: 23 March 2023 Novo Nordisk 
Study ID: NN1535-4592 Version: 8.0 
      Status: Final 
      Page: 26 of 113 
 
 3.2.3 Exploratory endpoints 
Not applicable for this study. 
3.3 Primary estimand 
The primary clinical question of interest 
What is the treatment effect between once weekly  IcoSema and once weekly semaglutide in change 
in HbA 1c from baseline to week 52 in participants with T2D inadequately controlled with a GLP-1 
receptor agonist regardless of discontinuation of randomised treatment for any reason and 
regardless of initiation of non-randomised insulin treatment or additional anti-diabetic treatments 
for more than 2 weeks?  
The primary estimand is described by the following 5 attributes: 
 Treatment condition: The effect of randomised treatment (titration of once weekly IcoSema 
versus fixed dose escalation of once weekly semaglutide 1 mg) with or without OAD(s),  
regardless of initiation of non-randomised in sulin treatment or additional anti-diabetic 
treatments for more than 2 weeks a nd adherence to randomised treatment 
 Population: T2D inadequately controlled with a GLP-1 receptor agonist 
 Endpoint: Change in HbA 1c from baseline to week 52 
 Remaining ICEs: None. The two intercurrent ev ents are captured under treatment condition and 
handled as follows:  
o Initiation of non-randomised insulin treatmen t or additional anti-diabetic treatments 
for more than 2 weeks by the treatment policy strategy 
o Discontinuation of randomised treatment for  any reason by the treatment policy 
strategy 
 Population-level summary: Difference in mean changes from baseline 
The rationale for the primary estimand is that this estimand captures both the efficacy and safety of 
the randomised treatment with and without additional anti-diabetic/glucose-lowering medication 
and thus aim at reflecting clinical practice. CONFIDENTIAL
VV-CLIN-219731 1 .0 .
Protocol
CONFIDENTIALDate: 23 March 2023 Novo Nordisk
Study ID: NN1535-4592 Version: 8.0
     Status: Final
     Page: 27 of 113
4	 
4.1 Overall design
This is an interventional, multi-national, mult i-centre, randomised, 52-week, open label, parallel 
group, treat-to-target/dose escalation, confirmato ry study with two treatment arms. The study 
investigates the efficacy and safety of treatmen t with once weekly IcoSema compared to once 
weekly semaglutide, both treatment arms with  or without OADs, in participants with T2D 
inadequately controlled with a GLP-1 receptor agonist. 
The study duration is approximately 59 weeks and consists of:
an up to 2 weeks screening period
a 52-week treatment period
a 5-week follow-up period
The study includes a screening visit (V1) to assess participant J;-41/1*141<A.<-:;+:--616/)44
eligible participants will be randomised (1:1) at  visit 2 (V2). The overall study design and visit 
schedule are outlined in Figure 4-1 and the study flowchart (Section 1.2), respectively.
Figure 4-1 Study design
680 participants will be randomised (1:1) to  receive once weekly IcoSema or once weekly 
semaglutide. With the exception of oral GLP-1 receptor agonists, sulfonylureas, glinides and DPP-4 
inhibitors that must be discontinued at random isation (V2), the dose and dosing frequency of any 
pre-study OADs should not be changed during the study, unless due to safety concerns. 
During the study, participants will measure daily self-measured plasma glucose (SMPG). The 
SMPG measurements will be evaluated by the investigator at the weekly contact either as site visits, 
by phone or video call. At the weekly contacts, the dosing will be adjusted in accordance with the 
parti+18)6<J;6--,;)6,;).-<A , see also titration guidelines Appendix 8 (Section 10.8). However, it 
1;)4?)A;=8<7<0-,1;+:-<1767.<0-16>-;<1/)<7:<7);;-;;8) :<1+18)6<J;16,1>1,=)46--,;)6,;).-<A
in accordance with local standard of care.
After the 52 weeks of treatment, participants will come in for visit V54, where data for the primary 
endpoint will be collected. The visit at week 52 (V54)  will be one week after the last dose of once 
weekly IcoSema or once weekly semaglutide. After the 52 weeks of treatment participants will be 
transferred to a suitable marketed product at the di scretion of the investig ator. See also titration 
guideline, Appendix 8 (Section 10.8). 
CONFIDENTIAL
VV-CLIN-219731 1 .0 .
Protocol 
CONFIDENTIAL Date: 23 March 2023 Novo Nordisk 
Study ID: NN1535-4592 Version: 8.0 
      Status: Final 
      Page: 28 of 113 
 
 The treatment period is followed by a 5-week fol low-up period to ensure safety data collection. 
During the follow-up period, two follow-up visits (V55 and V56) will be performed, 2 and 5 weeks 
after the visit at week 52 (V54), re spectively. Hence, the last follo w-up visit (V56) will take place 
6 weeks after the last dose of once weekly IcoSema or once weekly semaglutide. The last follow-up 
visit (V56) is scheduled to allow for appropriate  wash-out of randomised treatment, following at 
least 5 half-lives of once weekly IcoSema or once weekly semaglutide. 
In case of persistent and unacceptable hyperglycaemia as judged by the investigator based on the 
daily SMPGs, and in accordance with local standa rd of care, treatment with non-randomised insulin 
(basal or bolus) limited to up to 14 consecutive da ys can be considered to be added to the 
randomised treatment at the discretion of the inve stigator to safeguard the participants. Initiation of 
new anti-diabetic medication and any changes he reto must be recorded on the concomitant 
medication form in the eCRF. 
Event adjudication will be performed for acute coronary syndrome events (acute myocardial 
infarction and unstable angina pectoris requiring hospitalisation), cerebrovascular events (stroke 
and transient ischemic attack), heart failure (requi ring hospitalisation and urgent heart failure visit) 
and all-cause death. All AEs will be collected  from visit 2 and recorded from visit 3. 
Overall, the measures taken to ensure participant Js safety, includes weekly contacts with site staff, a 
5-week follow-up period, training of investigators and other site staff, safety surveillance including 
event adjudication and titration surveillance. In  addition, in accordance with GCP, it is the 
investigators responsibility to assess participant' s safety and at their discretion act accordingly. 
4.2 Scientific rationale for study design 
The study is designed in alignment with the estimand (Section 3) to investigate the efficacy and 
safety of once weekly IcoSema compared to once weekly semaglutide during 52 weeks. 
In order to confirm the superiority of the fixed ratio combination of IcoSema to its GLP-1 receptor 
agonist mono-component, once weekly semaglutide is the comparator. The treatment arms will be 
open label in order to avoid the risk of pen-mix-up in a double-blind, double dummy study. 
Furthermore, the open label design has also been chosen due to the different titration/escalation of 
the two different regimens; treat- to-target for the IcoSema arm with a max allowed weekly dose of 
IcoSema of 350 dose steps (equivalent to 350 units insulin icodec and 1 mg semaglutide), and fixed 
dose/dose escalation treatment of semaglutide with  a maximal recommended weekly dose of 1 mg, 
see also Appendix 8 (Section 10.8). Blinding of the study would increase the treatment complexity 
and hence increase the burden on the participants.  
The treatment duration of 52 weeks is evaluated to  be adequate for assessing efficacy on glycaemic 
control as well as safety. This duration will also  ensure sufficient time to reach the maintenance 
dose of IcoSema for the broad study population and allow adequate time in maintenance phase. The 
treat-to-target approach has been chosen to en sure optimal titration of the IcoSema arm based on 
SMPG values with the aim of improving HbA 1c in the treatment period. The dose escalation of the 
fixed dose treatment of semaglutide to obtain a max imal recommended weekly dose of 1 mg is in 
accordance with the current EMA summary of product characteristics for semaglutide (OzempicÂ®),5 
the US prescribing information for semaglutide (OzempicÂ®),6 or any locally approved label.  CONFIDENTIAL
VV-CLIN-219731 1 .0 .
Protocol 
CONFIDENTIAL Date: 23 March 2023 Novo Nordisk 
Study ID: NN1535-4592 Version: 8.0 
      Status: Final 
      Page: 29 of 113 
 
 Participants entering the study will be insulin na Ã¯ve and inadequately controlled with a daily or 
weekly GLP-1 receptor agonist with or without OADs ensuring a study population representative of 
a broad and advanced T2D population.  
Risk of hypoglycaemia increases when insulin secr etagogues like sulfonylureas and glinides are 
used in association with insulin and combin ation injectable anti diabetic therapy.10, 18 Hence, to 
minimise the risk, sulfonylureas and glinides are discontinued at randomisation (V2). DPP-4 
inhibitors must likewise be discontinued since the combined use of a GLP-1 receptor agonist 
(semaglutide component of IcoSema) and a DPP-4 inhibitor is not currently recommended.19 
To safeguard participants, the inclusion and exclus ion criteria defined in this study will limit the 
study population to participants not suffering from advanced underlying diseases other than T2D 
and related diseases. This is to avoid compromising the safety of the participants, and to strengthen 
the conclusions regarding the efficacy and safety of IcoSema. 
For more information on the study population, see the inclusion and exclusion criteria, Sections 5.1 
and 5.2, respectively. 
4.3 Justification for dose 
The IcoSema pen is developed with one ratio and one titration algorithm for the phase 3a 
programme in order to simplify the treatment regiments for patients and physicians.  
Once weekly IcoSema will be switched from the pre-study daily or weekly GLP-1 receptor 
agonists. IcoSema will be initiated at 40 dose s teps (equivalent to 40 units of insulin icodec and 
0.114 mg of semaglutide), and titrated to target acc ording to the principles outlined in the titration 
guideline in Appendix 8 (Section 10.8).  
The starting dose of 40 dose steps (equivalent to 40 units of insulin icodec and 0.114 mg of 
semaglutide) is selected base d on pharmacokinetics (PK) fi ndings from the development 
programme of IcoSema. The combination of the s tarting dose and the titration algorithm of Â±10 
dose step increments (equivalent to 10 units of insulin icodec and 0.029 mg of semaglutide) is 
considered to be safe, due to the combined acti on of the two mono-components on both fasting and 
prandial glycaemic control. Furthermore, the sele cted starting dose and titration algorithm are 
expected to ensure a comparable or better gastroi ntestinal adverse event (A E) profile as compared 
to semaglutide s.c.  
The maximum dose of 350 dose steps is equivalent to 350 units insulin icodec and 1 mg 
semaglutide, which is the currently approved maximum dose for semaglutide s.c. in treatment of 
T2D  (as of 21 June 2021).5,6 The maximum dose and the ratio of IcoSema is based on the clinical 
findings16 and learnings from the once daily fixed ratio combination product, insulin 
degludec/liraglutide (XultophyÂ®).13The ratio is selected with the focus on balancing the benefits 
from semaglutide and the expected durability of treatment with the insulin component. Providing 
350 units of insulin icodec to 1 mg of semaglutide, is expected to meet the clinical needs for the 
majority of the target population, while their safety is also ensured.  
Once weekly semaglutide will be switched from  the pre-study daily or weekly GLP-1 receptor 
agonist. Semaglutide will be initiated at a dose of 0.25 mg and follow a fixed dose escalation CONFIDENTIAL
VV-CLIN-219731 1 .0 .
Protocol 
CONFIDENTIAL Date: 23 March 2023 Novo Nordisk 
Study ID: NN1535-4592 Version: 8.0 
      Status: Final 
      Page: 30 of 113 
 
 regimen. After 4 weeks of treatment with 0.25 mg , the dose should be increased to 0.5 mg once 
weekly. After at least 4 more weeks the dose should be increased to 1 mg once weekly. See the 
titration guideline in Appendix 8 (Section 10.8). 
After randomisation, participants should start once we ekly injections of IcoSema or semaglutide on 
the same day as randomisation. Due to the long half-life of the IcoSema and semaglutide, the last 
once weekly injections must be taken 51 weeks after randomisation. 
Further details on dose adjustment can be found in  the titration guideline in Appendix 8 (Section 
10.8).  
Guidance on missed doses can be found in the titration guideline in Appendix 8 (Section 10.8).  
4.4 End of study definition 
The end of the study is defined as the date of the last visit of the last participant in the study 
globally. 
A participant is considered to have completed th e study if he/she has completed all periods of the 
study including the visit at week 52 (V54) and the last follow-up visit (V56). 
The primary endpoint is evaluated at the visit at week 52 (V54). The primary completion date is 
defined as the date of visit at week 52 (V54) on which the last participant in the clinical study has an assessment for the primary endpoint. If the last participant is withdrawn early from the study, the 
primary completion date is considered the date when the second-to-last participant completes the 
visit at week 52 (visit 54).  CONFIDENTIAL
VV-CLIN-219731 1 .0 .
Protocol 
CONFIDENTIAL Date: 23 March 2023 Novo Nordisk 
Study ID: NN1535-4592 Version: 8.0 
      Status: Final 
      Page: 31 of 113 
 
 5 	   
Prospective approval of protocol deviations to recruitment and enrolment criteria, also known as 
protocol waivers or exemptions, is not permitted. 
Pre-screening is defined as review of the patien t medical records, including handing out participant 
information, as well as database review. Any pre-scr eening activities must be documented on site 
by the investigator. 
For country-specific requirements to the inclusion and exclusion criteria, please refer to Appendix 
11 (Section 10.11 ) for further information.  
5.1 Inclusion criteria 
Participants are eligible to be included in th e study only if all the following criteria apply: 
1. Informed consent obtained before any study-relate d activities. Study-related activities are any 
procedures that are carried out as part of the stud y, including activities to determine suitability 
for the study. 
2. Male or female. 
3. Age above or equal to 18 years at the time of signing informed consent. 
4. 1)/67;-,?1<0<A8-
,1)*-<-;5-441<=;E	,)A; before screening. 
5. HbA 1c of 7.0-10.0% (53.0-85.8 mmol/mol) (both inclusive) as assessed by central laboratory on 
the day of screening. 
6. Insulin naÃ¯ve. The following exceptions are permitted: short term insulin treatment for a 
maximum of 14 days before screening and/or prior insulin treatment for gestational diabetes. 
7. Treated with stable doses of daily or weekly  GLP-1 receptor agonist (excluding once weekly 
semaglutide with doses higher than 1.0 mg) accord ing to local label for the treatment of diabetes 
E 90 days before screening.  The treatment can be with or without any of the following 
anti-diabetic drugs with stable doses E 90 days before screening:  
Âƒ Metformin 
Âƒ Sulfonylureasa 
Âƒ Meglitinides (glinides)a 
Âƒ DPP-4 inhibitorsa 
Âƒ Sodium-glucose co-transporter 2 inhibitors 
Âƒ Alpha-glucosidase-inhibitors 
Âƒ Thiazolidinediones 
Âƒ Marketed oral combination products only including the products listed above. 
8. 7,A5);;16,-@ D3/52. 
9. Not currently using real time continuous or flash glucose monitoring. 
a Sulfonylureas, meglitinides (glinides) and DPP-4 inhibitors must be discontinued at randomisation. 
5.2 Exclusion criteria  
Participants are excluded from the study if any of the following criteria apply: 
1. Known or suspected hypersensitivity to randomised treatment or related products. 
2. Previous participation in this study. Particip ation is defined as signed informed consent. CONFIDENTIAL
VV-CLIN-219731 1 .0 .
Protocol 
CONFIDENTIAL Date: 23 March 2023 Novo Nordisk 
Study ID: NN1535-4592 Version: 8.0 
      Status: Final 
      Page: 32 of 113 
 
 3. Female who is pregnant, breast-feeding or intends to become pregnant or is of childbearing 
potential and not using a highly effective contraceptive method, as defined in Appendix 4 
(Section 10.4). 
4. Participation (i.e., signed informed consent) in any interventional, clinical study within 90 days 
before screening. 
Note:  Simultaneous participation in a study with the primary objective of evaluating an 
approved or non-approved investigational me dicinal product for prevention or treatment of 
COVID-19 disease or postinfectious conditions is allowed if the last dose of the investigational 
medicinal product has been received more than 30 days before screening in the current study 
and if simultaneous participation is allowed by local authorities.  
5. Any disorder, except for conditions associated with T2D ?01+016<0-16>-;<1/)<7:J;7816176
51/0<2-78):,1;-8):<1+18)6<J ;;).-<A7:+75841)6+-?1<0< he protocol. 
6. Anticipated initiation or change in concomitant medication (for more than 14 consecutive days) 
known to affect weight or glucose metabolism (e.g. treatment with orlistat, thyroid hormones, or 
systemic corticosteroids).  
7. Treatment with any medication for the indication of diabetes or obesity other than stated in the 
inclusion criteria within 90 days before screening. 
8. Any episodesa of diabetic ketoacidosis within 90 days before screening. 
9. Personal or first-degree relative(s) history of mult iple endocrine neoplasia  type 2 or medullary 
thyroid carcinoma. 
10. Presence or history of pancreatitis (acute or chronic) within 180 days before screening. 
11. Any of the following: Myocardial infarction, stroke, hospitalization for unstable angina pectoris 
or transient ischaemic attack within 180 days before screening. 
12. Chronic heart failure classified as being in New York Heart Association Class IV at screening. 
13. Planned coronary, carotid or peripheral artery revascularisation. 
14. Renal impairment measured as estimated glomerular filtration rate value of 
< 30 ml/min/1.73 m2 at screening as defined by KDIGO 2012.20 
15. 58)1:-,41>-:.=6+<176,-.16-,) ;)4)616-)5167<:)6;.-:);-E 

<15-;7:*141:=*16  1.5 times 
upper normal limit at screening. 
16. Inadequately treated blood pressure defined as s A;<741+E	55/7:,1);<741+E		55/  
at screening. 
17. Uncontrolled and potentially unstable diabetic re tinopathy or maculopathy. Verified by a fundus 
examination performed within the past 90 days before screening or in the period between 
screening and randomisation. Pharmacological pupil-dilation is a requirement unless using a 
digital fundus photography camera specified for non-dilated examination, see 8.2.4 . 
18. Presence or history of malignant neoplasm (other than basal or squamous cell skin cancer, 
in-situ carcinomas of the cervix, or in situ pros tate cancer) within 5 years before screening. 
a as declared by the participant or in the medical records.  
A participant, who does not fulfil the eligibility (inclusion/exclusion) criteria, must not be 
randomised. Randomisation in violation of any of the eligibility criteria is good clinical practice 
(GCP) non-compliance and must be reported to the sponsor without delay. This will be handled as 
an important protocol deviation, and the independen t ethics committee/institutional review board 
(IEC/IRB) and regulatory authorities must be notified according to local requirements. 
 CONFIDENTIAL
VV-CLIN-219731 1 .0 .
Protocol 
CONFIDENTIAL Date: 23 March 2023 Novo Nordisk 
Study ID: NN1535-4592 Version: 8.0 
      Status: Final 
      Page: 33 of 113 
 
 5.3 Lifestyle considerations 
5.3.1 Meals and dietary restrictions 
The participants should be fasting when attending some of the visits, see flowchart (Section 1.2). 
Fasting is defined as at least eight hours without food and drink intake, except for water and other 
prescribed medication. Randomised treatment and othe r glucose lowering agents should be withheld 
on the day of the fasting visit until blood sampling has been performed. Any other prescribed 
medication should be taken as usual. If the participant attends a fasting visit in a non-fasting state, 
the blood sampling procedures and weight measurements should be re-scheduled.  
5.3.2 Caffeine, alcohol and tobacco 
Tobacco use is defined as smoking at least one cigarette or equivalent daily. 
5.4 Screen failures 
A screen failure occurs when a participant who cons ents to participate in the clinical study is not 
subsequently eligible for participation according to the inclusion/exclusion criteria. A minimal set 
of screen failure information is required to ensure transparent reporting of screen failure participants 
to meet requirements from regulatory authorities. Minimal information includes informed consent 
date, demography, screen failure details, eligibility criteria. 
A screen failure session must be made in the Randomisation and Trial Supply Management system 
(RTSM). 
Individuals who do not meet the criteria for participation in this study may not be rescreened.  If the 
participant has failed one of the inclusion criteria or fulfilled one of the exclusion criteria related to 
laboratory parameters, re-sampling is not allowed. However, in case of technical issues (e.g., 
haemolysed or lost sample), re-sampling is allowed for the affected parameter(s). 
5.5 Run-in criteria, randomisation criteria and dosing day criteria 
Not applicable for this study. CONFIDENTIAL
VV-CLIN-219731 1 .0 .
Protocol 
CONFIDENTIAL Date: 23 March 2023 Novo Nordisk 
Study ID: NN1535-4592 Version: 8.0 
      Status: Final 
      Page: 34 of 113 
 
 6 	 

  
Study intervention is defined as any investigationa l intervention(s), marketed product(s), placebo, or 
medical device(s) intended to be administered to a study participant according to the study protocol. 
Study interventions comprise IcoSema, semaglutide and OADs. BG meter is not considered study 
interventions. 
Trial products comprise invest igational medicinal products (IMPs), including placebo and 
comparators, non-investigational medicinal produ cts (NIMPs) and/or investigational medical 
devices. 
Trial products consist of IcoSema and semaglutide. OADs are NIMPs but not considered trial 
products in this protocol. 
Randomised treatment consists of IcoSema and se maglutide, hence randomised treatment and IMPs 
are covering the same. 
Trial products and randomised tr eatment consist of IcoSema and semaglutide. Randomised 
treatment will be used throughout the protocol wh ile trial products is used when addressing product 
accountability. 
6.1 Study interventions administered 
Training in the pen-injectors is the responsibilit y of the investigator or a delegate and must be 
repeated during the study at regular intervals, as specified in the flowchart (see Section 1.2.) in 
order to ensure correct use of the pen-injector. The following documents must be provided to the 
participants: 
IcoSema: directions for use 
Semaglutide: directions for use  
Investigational medicinal products (IMP) 
All IMPs are listed in Table 6-1.  CONFIDENTIAL
VV-CLIN-219731 1 .0 .
Protocol 
CONFIDENTIAL Date: 23 March 2023 Novo Nordisk 
Study ID: NN1535-4592 Version: 8.0 
      Status: Final 
      Page: 35 of 113 
 
 Table 6-1 Investigationa l medicinal products 
Intervention IcoSema treatment arm Comparator treatment arm 
Intervention name  IcoSema  Semaglutide  
Intervention type IMP, test product IMP, reference therapy 
Pharmaceutical form  Solution for injection Solution for injection 
Route of administration  s.c. (into the thigh, upper arm or 
abdomen)  s.c. (into the thigh, upper arm or 
abdomen)  
IMP strength 700 units/mL + 2 mg/mL 1.34 mg/mL 
Dose and dose frequency Administer IcoSema once weekly, 
on the same day each week, at any 
time of the day. For more information, please refer to 
Appendix 
8 (Section 10.8) Semaglutide should be administered 
once weekly, at any time of the day 
irrespective of meals,  
but on  the same day each week . For 
more information, please refer to 
Appendix 8 (Section 10.8) 
Dosing instructions and 
administration  The day of weekly administration 
can be changed if necessary, by up to 
3 days. A minimum of 4 days 
between injections should always be ensured.
 
Rotation of injection site within the 
same area  is recommended. For 
more information, please refer to 
Appendix 8 (Section 10.8) The day of weekly administration 
can be changed if necessary , as long 
as the time between two doses is at 
least 3 days.  Rotation of injection 
site within the same area is 
recommended.   
For more information, please refer to 
Appendix 8 (Section  10.8) 
Transfer from other therapy Please refer to Appendix 8 
(Section 10.8) Please refer to Appendix 8 
(Section 10.8) 
Sourcing Manufactured and supplied by Novo 
Nordisk A/S  Manufactured and supplied by Novo 
Nordisk A/S  
Packaging and labelling  1.5 mL pre-filled PDS290 
pen-injector. 1.5 mL pre-filled PDS290 
pen-injector.  
 
 At randomisation visit (V2) participants should administer IcoSema or semaglutide at site. 
 The first dose of IcoSema or semaglutide should be administered at least 5 days after the last 
dose of pre-trial weekly GLP-1 receptor agonist. The first dose of IcoSema or semaglutide 
can be administered the following day after the last dose of pre-trial daily GLP-1 receptor 
agonist 
 Instructions on missed doses can be found in the titration guideline in Appendix 8 
(Section 10.8). 
 It is not allowed to split a dose between two pens. 
 Information about the PDS290 pre-filled pen-inject or can be found in the directions for use 
provided in the eDiary.  
 The actual in-use time of the IcoSema pen should be captured by the participant, which will 
be used to support the clinical qualification of in-use time for IcoSema. The in-use time of IcoSema is specified in the Trial Materials Manual.  
Non-investigational med icinal products (NIMP) 
After randomisation participants s hould continue their pre-study OADs (see list of allowed OADs 
in Section 5.1) throughout the entire study except for treatment with oral GLP-1 receptor agonists, 
sulfonylureas, glinides and DPP 4 inhibitors that  must be discontinued at randomisation. The OADs 
should be maintained at the stable, pre-study dose and at the same frequency during the entire CONFIDENTIAL
VV-CLIN-219731 1 .0 .
Protocol 
CONFIDENTIAL Date: 23 March 2023 Novo Nordisk 
Study ID: NN1535-4592 Version: 8.0 
      Status: Final 
      Page: 36 of 113 
 
 treatment period unless due to safety concerns, wh ich will be assessed at the discretion of the 
investigator. Combination products containing either sulfonylureas, glinides or DPP-4 inhibitors 
must also be discontinued, while the residual anti-diabetic mono-component of the combination 
product should in general be maintained at the pre-study dose throughout the study similar to other 
OADs. If the pre-study dose of the residual anti-diabetic medication is not available, the participant 
should increase the dose to the next available dose. 
In addition, the OADs: 
 are considered to be NIMP 
 will not be supplied or reimbursed by Novo Nord isk unless required by lo cal law and should be 
purchased or otherwise delivered to participants  in accordance with local health plans  
 should be used in accordance with standard of care or local label in the individual country. 
Auxiliary supplies including medica l device(s) not under investigation 
Auxiliary supplies comprise supplies other than trial products. Auxiliary supplies will be provided 
in accordance with the Trial Mater ials manual, please also see Table 6-2 . 
Table 6-2 Auxiliary supplies  
Auxiliary  Model  Details  Manufacturer  
Needles  NovoFineÂ® needles 
or similar according 
to local requirements  Only needles with a max length of 6 mm 
provided and approved by Novo Nordisk 
must be used for administration  
of randomised treatment. 
Needle must be discarded after each 
injection and the pen -injector should be 
stored without a needle attached.  Novo Nordisk 
Blood glucose (BG) 
meter (including auxiliaries)
 Roche Accu-ChekÂ® 
Guide / Instant  At randomisation (V2) participants must 
be instructed in how to use the BG meter and the BG meter should be linked to the eDiary as described in the eDiary site guide.
 
Please  :-.-:<7<0-$7+0-5)6=.)+<=:-:J;
guide. Roche Diabetes Care 
Inc. 
eDiary Electronic Patient 
Interaction Device 
(ePID)  Participant Mobile App in Study Phone, 
HCP web p ortal in Trial tablet, & Cloud 
Service.  
Please refer to the eDiary site guide.  Novo Nordisk 
6.2 Preparation, handling, storage and accountability 
Only participants enrolled in the study may use randomised treatment and only delegated site staff 
may supply randomised treatment. Each site will be supplied with sufficient randomised treatment 
for the study on an ongoing basis according to recruitment and randomisation. 
The investigator or designee must confirm that  appropriate temperature conditions have been 
maintained during transit for all trial products receiv ed, and that any discrepancies are reported and 
resolved before use of the trial products. CONFIDENTIAL
VV-CLIN-219731 1 .0 .
Protocol 
CONFIDENTIAL Date: 23 March 2023 Novo Nordisk 
Study ID: NN1535-4592 Version: 8.0 
      Status: Final 
      Page: 37 of 113 
 
 All trial products must be stored in  a secure, controlled, and monit ored (manual or automated) area 
in accordance with the labelled storage conditions with access limited to the investigator and 
delegated site staff. 
The investigator must inform Novo Nordisk immediately if any trial product has been stored outside 
specified conditions. The trial product must not be di spensed to any participant before it has been 
evaluated and approved for further use by Novo Nordisk. Additional details regarding handling of 
temperature deviations can be found in the Trial Materials Manual. 
The investigator or designee is responsible for trial product accountability and record maintenance 
(i.e., receipt, accountability and final disposition records). Drug accountability should be performed 
in the RTSM. 
The investigator or designee must instruct the participant to return all IMPs (both used and not 
used) at the next dispensing visit. 
The investigator or designee must instruct the part icipant on how to manage and record the in-use 
time of the dispensed products. The in-use time can be found in the Trial Materials Manual. 
 
Destruction of trial products can be performed on an  ongoing basis and will be done according to 
local procedures after accountability is finalised by the site and reconciled by the monitor. 
All returned (used or un-used), expired or damage d trial products (for technical complaint samples, 
see Appendix 5 [Section 10.5]) must be stored separately from non-allocated trial products. No 
temperature monitoring is required. 
Non-allocated trial products, including expired or damaged products, must be accounted as unused, 
at the latest at closure of the site. 
Acceptable temperature ranges and conditions for storage and handling of each trial product when 
not in use and when in use are described in th e Trial Materials Manual  and trial product label. 
Each single pen should be accounted for. 
6.3 Measures to minimise bias: Randomisation and blinding 
All participants will be screened and centrally ra ndomised using an RTSM and assigned to the next 
available treatment according to the randomisation schedule. Trial product will be allocated by the 
RTSM and dispensed by the investigator at the study visits summarised in the flowchart 
(Section 1.2). 
This is an open-label study; however, the specific trial products for a participant will be assigned 
using an RTSM. The site will access the RTSM be fore the start of trial product administration for 
each participant. Potential bias will be reduc ed by central randomisation and adjudication. 
6.4 Drug treatment compliance 
Throughout the study, the investigator will remind the participants to follow the study procedures 
and requirements to encourage participant compliance. CONFIDENTIAL
VV-CLIN-219731 1 .0 .
Protocol 
CONFIDENTIAL Date: 23 March 2023 Novo Nordisk 
Study ID: NN1535-4592 Version: 8.0 
      Status: Final 
      Page: 38 of 113 
 
 When participants self-administer trial pr oduct at home, compliance with trial product 
administration will be assessed, and the assessmen t documented in source documents at each visit 
where information is available. If any suspicion of  non-compliance arises, the site must enter into a 
dialogue with the participant, re-emphasizing th e importance of compliance and uncover barriers to 
compliance. This dialogue must be documented. Comp liance will be assessed by cross checking the 
following sources and comparing these to the expected use:  
 Drug accountability information  
 Review of eDiaries including SMPG prof iles, dosing and hypoglycaemia reporting 
 Evaluating glycaemic control and adherence to the visit schedule 
6.5 Dose modification 
IcoSema doses are adjusted according to blood/pl asma glucose values as described in Appendix 8 
(Section 10.8)  
6.6 Continued access to randomised treatment after end of study 
Randomised treatment will not be accessible after end of study. When discontinuing randomised 
treatment, the participant should be transferred to a suitable marketed product at the discretion of 
the investigator, please see the titration guideline in Appendix 8 (Section 10.8). The medication 
should be recorded in the concomitant med ication form, as described in Section 6.8.  
6.7 Treatment of overdose 
Accidental overdose must be reported as a medication error. Intentional overdose must be reported 
as misuse and abuse, please refer to Section 8.3 and Appendix 3 (Section 10.3) for further details. 
In the event of an overdose, the investigator shoul d closely monitor the participant for overdose-
related AEs/serious adverse events (SAEs). 
A specific overdose for IcoSema cannot be defi ned; however, hypoglycaemia may develop over 
sequential stages if the doses administered are too high relative to the participant J;:-9=1:-5-6<;  
Mild hypoglycaemia  can be treated by oral administration of glucose or sugary products.  
Severe hypoglycaemia  where the participant is not able to treat him/herself, can be treated by 
glucagon (0.5 to 1 mg) given intramuscularly or subcutaneously by a trained person, by other drugs 
for the indication of treatment hypoglycaemia in accordance with local guidelines or by glucose 
given intravenously by a medical professional. Gluc ose must also be given intravenously, if the 
participant does not respond to glucagon within 10-15 minutes. If the participant has been 
unconscious, administration of oral carbohydrates is recommended for the participant upon 
regaining consciousness, in order to prevent a relapse. 
Decisions regarding dose interruptions or modifications will be made by the investigator based on 
the clinical evaluation of the participant and in accordance with local standard of care. 
For more information on overdose, also consult the current version of the IcoSema16 and 
semaglutide17 16>-;<1/)<7:J;*:7+0=:- s. CONFIDENTIAL
VV-CLIN-219731 1 .0 .
Protocol 
CONFIDENTIAL Date: 23 March 2023 Novo Nordisk 
Study ID: NN1535-4592 Version: 8.0 
      Status: Final 
      Page: 39 of 113 
 
 6.8 Concomitant therapy 
Any medication that the participant is receiving at sc reening visit (V1) or receives until the visit at 
week 52 (V54) must be recorded. From week 52 (V 54) and until the last follow-up visit (V56) only 
anti-diabetic medication and medication related to SAEs must be recorded. The medication must be 
recorded along with: 
 Select predefined medication. If not listed, enter trade name or generic name 
 Primary indication  
 Dates of administration including start and stop dates 
 Relevant for participants in COVID-19 stud ies: Type of study and type of drug   
Changes in concomitant therapy must be recorded. If  a change is due to an AE, then this must be 
reported according to Section 8.3.  
For information regarding restrictions to anti-diabetic medication other than the randomised 
treatment, please see Section 6.1. 
For information regarding concomitant medicatio n collection for participants who discontinue 
randomised treatment, see Section 7.1.1 . 
6.8.1 Rescue medicine 
Not applicable for this study. In case of lack of efficacy, please refer to section 7.1.1 .  CONFIDENTIAL
VV-CLIN-219731 1 .0 .
Protocol 
CONFIDENTIAL Date: 23 March 2023 Novo Nordisk 
Study ID: NN1535-4592 Version: 8.0 
      Status: Final 
      Page: 40 of 113 
 
 7 
 
  
Discontinuation of specific sites or of the st udy as a whole is detailed in Appendix 1 
(Section 10.1.11 ). 
7.1 Discontinuation of study intervention 
Study intervention may be discontinued at any time during the study at the discretion of the 
participant or at the discretion of the invest igator for safety, behavioural, compliance or 
administrative reasons. 
7.1.1 Discontinuation of randomised treatment 
Discontinuation of randomised treatment corr esponds to discontinuation of IcoSema or 
semaglutide. 
If a participant discontinues randomised treatment,  the participant should as soon as possible attend 
the discontinuation visit (V54A).  
The investigator should change participant status in the healthcare professional (HCP) web portal to 
'follow-up' at the discontinuation visit (V54A) to ensure that the participant should no longer report 
randomised treatment dose. 
The participant should also complete the two follow-up visits (V55 and V56).   
Hypoglycaemic episodes will not be collected after the last follow-up visit (V56). 
Efforts must be made to have the participants who discontinue randomised treatment attend the visit 
at week 52 (V54) to collect: 
 Data for primary endpoint (HbA 1c). 
 Data for secondary endpoint for body weight. 
AEs, medication related to SAEs, and anti-diabetic  medication should be collected and recorded in 
the eCRF until the visit at week 52 (V54). No other concomitant medication than medication related 
to SAEs and anti-diabetic medication will be coll ected and reported in the eCRF for participants 
who discontinue randomised treatment.  
Please, refer to Section 6.6 for treatment after discontinuation of randomised treatment. 
The site should stay in contact with the partic ipants who discontinue randomised treatment by 
phone, video call and/or site visits to motivate th e participants to attend the follow-up visits (V55 
and V56) and the visit at week 52 (V54). Site contacts should be doc umented in the medical record. 
In case of any uncertainty regarding the schedulin g of the visits after discontinuation of randomised 
treatment or questions to said visits, the inve stigator should consult Novo Nordisk for further 
guidance CONFIDENTIAL
VV-CLIN-219731 1 .0 .
Protocol 
CONFIDENTIAL Date: 23 March 2023 Novo Nordisk 
Study ID: NN1535-4592 Version: 8.0 
      Status: Final 
      Page: 41 of 113 
 
 Only participants who withdraw consent will be considered as withdrawn from the study. 
Participants must be informed about the continued scientific importance of their data, even if they 
discontinue randomised treatment. 
The randomised treatment must be discontinued, if an y of the following applies for the participant: 
1. Safety concern related to randomised tr eatment or unacceptable intolerability 
2. Pregnancy 
3. Intention of becoming pregnant 
4. Simultaneous use of an approved or non-approved  investigational medicinal product in another 
clinical study 
Note:  Simultaneous participation in a study with the primary objective of evaluating an 
approved or non-approved investigational me dicinal product for prevention or treatment of 
COVID-19 disease or post-infectious conditions is allowed at the investigator J;,1;+:-<176
without discontinuation of randomised treatment if simultaneous participation is allowed by 
local authorities.  
5. Lack of efficacy, defined as fulfilment of ALL criteria (a, b and c) below after week 8 and 
onwards: 
a. Mean of pre-breakfast SMPG values (on the two days before and on the day of visit) 
of 3 consecutive weeks after week 8 are above 15 mmol/L (270 mg/dL), AND  
b. no treatable intercurrent cause for the hyperglycaemia (e.g. non-compliance) has 
been identified.  
c. In such case, the participant must be called for a confirmatory fasting plasma glucose 
(FPG) measurement as soon as possible. A confirmatory FPG must be obtained and 
analysed by the central laboratory. If this FPG exceeds 15 mmol/L (270 mg/dL), 
participant fulfils the lack of efficacy criteria. 
To allow time for up-titration of the randomised tr eatment and to observe the expected effect of 
randomised treatment on glycaemic pa rameters, lack of efficacy criteri a will be applied on week 8 
and onwards. 
The primary reason for discontinuation of randomised  treatment must be specified in the CRF, and 
final trial product accountability mu st be performed. A discontinuati on session must be made in the 
RTSM.  
7.1.2 Temporary discontinuation of randomised treatment 
The participant should adhere to the randomised tr eatment to the extent possible, with the exception 
of any AEs such as hospitalisation or safety concerns , at the discretion of the investigator. If a 
participant due to an AE or safety concern tem porarily has discontinued randomised treatment, 
she/he is allowed to restart randomised treatm ent, unless any of the discontinuation criteria 
specified in Section 7.1 applies. 
7.1.3 Rescue criteria 
Not applicable for this study . CONFIDENTIAL
VV-CLIN-219731 1 .0 .
Protocol 
CONFIDENTIAL Date: 23 March 2023 Novo Nordisk 
Study ID: NN1535-4592 Version: 8.0 
      Status: Final 
      Page: 42 of 113 
 
 7.2 Participant withdrawal from the study 
A participant may withdraw consent at any time at his/her own request. 
If a participant withdraws consent prior to randomisation, he/she will not be asked to have any 
follow-up assessments performed. The following da ta must be collected: Demography, completed 
-41/1*141<A+:1<-:1),)<-7.16.7:5-,+76;-6<,)<-7.;+:--61 6/)6,<0-,)<-?0-68):<1+18)6<J;
participation ended. The end of study form must be completed. 
If a participant withdraws consent after randomisat ion, the investigator must ask the participant if 
he/she is willing, as soon as possible, to ha ve assessments performed according to discontinuation 
visit V54A. The investigator should also ask the par ticipant if he/she is willing to attend the two 
follow-up visits V55 and V56 (see Section 7.1 regarding the scheduling of the follow-up visits). See 
the flowchart for data to be collected. 
Final trial product accountability must be performed ev en if the participant is not able to come to 
the site. A discontinuation session must be made in the RTSM. 
If the participant withdraws consent, Novo Nord isk may retain and continue to use any data 
collected before such a withdrawal of consent for the purpose of the study or scientific research. 
If a participant withdraws from the study, he/she  may request destruction of any samples taken and 
not tested, and the investigator must document this in the medical record. 
Although a participant is not obliged to give his/her reason(s) for withdrawing, the investigator 
5=;<5)3-):-);76)*4--..7:<<7);+-:<)16<0-:-);76;?014- .=44A:-;8-+<16/<0-8):<1+18)6<J;
rights. Where the reasons are obtained, the primary reason for withdrawal must be specified in the 
CRF. 
7.2.1 Replacement of participants 
If a participant discontinues randomised treatmen t, withdraws consent or is withdrawn from the 
study by the investigator, he/she will not be replaced. 
7.3 Lost to follow-up 
A participant will be considered lost to follow-up if he/she repeatedly fail s to return for scheduled 
visits and is unable to be contacted by the site. 
The following actions must be taken if a participan t fails to return to the site for a required visit: 
 The site must attempt to contact the participant and reschedule the missed visit as soon as 
possible and counsel the participant on the importance of maintaining the assigned visit 
schedule and ascertain whether the participant wishes to and/or should continue in the study. 
 Before a participant is deemed lost to follow-up, the investigator or designee must make every 
effort to regain contact with the participant  (w here possible, at least three telephone calls and, if 
necessary, a certified letter to the par <1+18)6<J;4);<367?65)1416/),,:-;;7:47+)4-9=1>)4-6<
5-<07,;&0-;-+76<)+<)<<-58< ;;07=4,*-,7+=5-6<-,16<0-8) :<1+18)6<J;;7=:+-,7+=5-6<  CONFIDENTIAL
VV-CLIN-219731 1 .0 .
Protocol 
CONFIDENTIAL Date: 23 March 2023 Novo Nordisk 
Study ID: NN1535-4592 Version: 8.0 
      Status: Final 
      Page: 43 of 113 
 
  Should the participant continue to be unreachable, he/she will be considered to have withdrawn 
from the st=,A?1<0)8:15):A:-);767.I47;<<7.7447? -=8J  CONFIDENTIAL
VV-CLIN-219731 1 .0 .
Protocol 
CONFIDENTIAL Date: 23 March 2023 Novo Nordisk 
Study ID: NN1535-4592 Version: 8.0 
      Status: Final 
      Page: 44 of 113 
 
 8 	 
  
The following sections describe the assessments and procedures, while their timing is summarised 
in the flowchart (Section 1.2). 
Informed consent must be obtained before any study-related activity, see Appendix 1 
(Section 10.1.3 ). 
All screening evaluations must be completed and reviewed to confirm that potential participants 
meet all inclusion criteria and none of the exclusion criteria. 
The investigator will maintain a screening log to record details of all participants screened and to 
confirm eligibility or record reason for screen failure, as applicable. 
At screening, participants will be provided with a card stating that they are participating in a study 
and giving contact details of relevant site staff th at can be contacted in case of emergency.  
Adherence to the study design requirements, including those specified in the flowchart 
(Section 1.2), is essential and required for study conduct. 
;;-;;5-6<;;07=4,*-+)::1-,7=<) ++7:,16/<7<0-+4161+J;;<) 6,):,7.8:)+<1+-=64-;;;8-+1.1-,16
the current section. Efforts should be made to limit the bias between the assessments. The suggested 
order of the assessments at randomisation visit (V2) is as follows: 
 Blood sample collection 
 Other assessments to confirm eligibility 
 Randomisation in RTSM 
 The investigator should create a participant prof ile and record administrative information (e.g. 
subject ID, year of birth and gender) and treatment arm in the HCP web portal  
 Participants should be provided with an eDiary and instructed in how to use it  
 The BG meter should be connected with the eDiary  
 A fasting SMPG should be measured using the BG meter 
 Dispensing and dosing of randomised treatment. 
For information regarding the eDiary and HCP web portal please refer to the site guide.  
Please refer to Section 6.4 for drug treatment compliance. 
All data entered in the eDiary is considered sourc e data. The investigator should review all the data 
for the participants through the HCP web portal, before or during each visit/phone contact. 
Review of eDiaries, ECG, laboratory reports, eye- and physical examinations must be documented 
16<0-;7=:+-,7+=5-6<;7:<0-8):<1+18)6<J;5-,1+)4:-+7:,. +4):1.1+)<1767.-6<:1-;7:
discrepancies in the eDiary is needed, the partic ipant must be questioned, and a conclusion made in 
<0-8):<1+18)6<J;;7=:+-,7+=5-6<;):-5=;<*-<)3-667<<7* 1);<0-8):<1+18)6<  
Source data of clinical assessments performed and rec orded in the eCRF must be available and will 
usually be 16<0-8):<1+18)6<J;5-,1+)4:-+7:,;  CONFIDENTIAL
VV-CLIN-219731 1 .0 .
Protocol 
CONFIDENTIAL Date: 23 March 2023 Novo Nordisk 
Study ID: NN1535-4592 Version: 8.0 
      Status: Final 
      Page: 45 of 113 
 
 Repeat samples may be taken for technical issues  and unscheduled samples or assessments may be 
taken for safety reasons. Please refer to Appendix 2 (Section 10.2) for further details on laboratory 
samples. 
8.1 Efficacy assessments  
Planned time points for all efficacy assessments are provided in the flowchart (Section 1.2) and in 
appendix 2 ( 10.2). 
8.1.1 Self-measured glucose  
Participants will be provided with a blood glucos e meter (BG meter) including auxiliaries. The BG 
meters use test strips calibrated to plasma values. Therefore, all measurements performed with 
capillary blood are automatically calibrated to plasma equivalent glucose values, which will be 
shown on the display. 
The BG meter provided by Novo Nordisk should be used for the measurements required in the 
protocol. 
Participants must be instructed in how to transfer the results of the SMPG values daily into the 
eDiary.  
A baseline SMPG value, in fasting condition, s hould be collected using the BG meter at V2. 
Pre-breakfast daily self-measured plasma glucose  
Participants should be instructed to measure their pre-breakfast SMPG daily from week 0 (V2) to 
last follow-up visit (V56) and to transfer the measured SMPG values into the eDiary.  
Selected titration data (e.g. certain SMPGs and dose data) from the eDiary will be used during the 
study for central titration surveillance, to ensure compliance with the titration guideline in 
Appendix 8 (Section 10.8). All data will be stored by Novo Nordisk, see Appendix 1 (Section 10.1). 
8.1.2 Clinical efficacy 
All protocol-required laboratory assessments, as defined in Appendix 2 (Section 10.2), must be 
conducted in accordance with the flowchart (Section 1.2) and the laboratory manual. 
8.2 Safety assessments  
Planned time points for all safety assessments are provided in the flowchart (Section 1.2) and in 
appendix 2 ( 10.2).  
Medical history is a medical event that the participant experienced prior to the time point from 
which AEs are collected. All relevant medical history as judged by the investigator will be recorded 
in the eCRF. CONFIDENTIAL
VV-CLIN-219731 1 .0 .
Protocol 
CONFIDENTIAL Date: 23 March 2023 Novo Nordisk 
Study ID: NN1535-4592 Version: 8.0 
      Status: Final 
      Page: 46 of 113 
 
 As part of the medical history, information on the following will be collected: 
 History of diabetes 
 History of cardiovascular disorder and procedure  
 History of (non-alcoholic fatty liver disease) NAFLD 
 COVID-19 vaccines 
A concomitant illness  is any illness that is already present at the time point from which AEs are 
collected or found as a result of a screening p rocedure or other study procedures performed before 
exposure to study intervention under clinical investigation. 
In case of an abnormal and clinically significant finding fulfilling the definition of medical history 
or concomitant illness, the investigator must reco rd the finding on the medical history/concomitant 
illness form. 
8.2.1 Dose  
The prescribed IcoSema and semaglutide doses will be determined by the investigator in 
accordance with the titration guideline, see Appendix 8 (Section 10.8). 
The investigator must record the first and last date of trial product in the eCRF.  
During the study, starting at randomisation (V2), participants must be instructed to report date, 
actual dose applied and time of once weekly IcoS ema or once weekly semaglutide in the eDiary. 
The injection site area of IcoSema and semaglutide must be reported in the eCRF.  
Please refer to Appendix 8 (Section 10.8) for more information. 
8.2.2 Physical examinations 
A physical examination will include assessments of: 
 Head, ears, eyes, nose, throat, neck 
 Respiratory system 
 Cardiovascular system 
 Gastrointestinal system including mouth 
 Musculoskeletal system 
 Central and Peripheral Nervous System 
 Skin 
Investigators should pay special attention to clinical  signs related to previous serious illnesses. 
Abnormal, clinically significant findings at screening should be recorded as concomitant illness in 
the eCRF. At the following visits, any new abnormal, clinically significant findings or clinically 
significant deteriorations after randomisation should be reported as an AE, see Appendix 3 
(Section 10.3). 
Body measurements will be measured and recorded in the eCRF. Height will be measured and 
recorded at screening visit V1. Body weight will be measured and recorded accordingly to the CONFIDENTIAL
VV-CLIN-219731 1 .0 .
Protocol 
CONFIDENTIAL Date: 23 March 2023 Novo Nordisk 
Study ID: NN1535-4592 Version: 8.0 
      Status: Final 
      Page: 47 of 113 
 
 flowchart (Section 1.2). Waist circumference will be measured and recorded at visits V2, V28, V54 
and V54A (if applicable). 
 Fasting body weight should be measured in kilogram (kg) or pounds (lb) without coat and shoes 
wearing only light clothing. Body weight will be recorded to one decimal.  
 Body weight should be assessed with the same equipment throughout the study, if possible. 
 Height should be measured in centimetres (cm) or inches (in) without shoes. Height will be 
recorded to the nearest whole number. 
 The waist circumference is defined as the mi nimal abdominal circumference located midway 
between the lower rib margin and the iliac crest and will be measured using a non-stretchable 
measuring tape. The measurement of waist circum ference should be performed and recorded in 
the eCRF to the nearest Â½ cm or Â¼ in using the same measuring tape throughout the study. The 
waist circumference should be measured in a standing position with an empty bladder and 
wearing light clothing with accessible waist. The participant should be standing with arms down 
their side and feet together. The tape should t ouch the skin but not compress soft tissue. The 
participant should be asked to breathe normally, and the measurement should be taken when the 
subject is breathing out gently. 
From the body weight and height measured at V1, the body mass index (BMI) should be calculated 
to evaluate inclusion criteria no. 8 and recorded in the participant J;5-,1+)4:-+7:,; . 
8.2.3 Vital signs 
Pulse rate as well as systolic and dias tolic blood pressure will be assessed. 
Blood pressure and pulse rate measurements should be preceded by at least 5 minutes of rest for the 
participant in a quiet setting without distra ctions (e.g., no use of television, cell phones). 
Blood pressure and pulse rate measurements will be  assessed sitting with a completely automated 
device. Manual techniques must be used only if an automated device is not available. 
Blood pressure and pulse rate are collected at screening (V1), randomisation (V2), V12, V20, V28, 
V38, V46, V54, and V54A. 
Blood pressure will consist of 3 systolic and dias tolic blood pressure measurements with intervals 
of at least 1-2 minutes. An additional fourth blood pressure measurement must be performed if the 
first two readings on systolic or diastolic blood pre ssure differ by >10 mmHg. No more than four 
measurements should be performed. 
 
 The last 2 systolic and last 2 diastolic blood pressure measurements should be recorded in the 
CRF. 
 
Pulse rate will be measured in connection to the blood pressure measurements. 
 
 The pulse rate for the last 2 measurements should be recorded in the CRF.  CONFIDENTIAL
VV-CLIN-219731 1 .0 .
Protocol 
CONFIDENTIAL Date: 23 March 2023 Novo Nordisk 
Study ID: NN1535-4592 Version: 8.0 
      Status: Final 
      Page: 48 of 113 
 
 8.2.4 Eye examination 
Participants with uncontrolled and potentially unsta ble diabetic retinopathy or maculopathy are not 
eligible as this indicates retinopathy that has recen tly progressed to a level that requires intervention 
or is approaching intervention but has yet to be brought under control. 
Results of an eye examination performed by an opht halmologist or another suitably qualified health 
care provider (e.g., optometrist) possibly aided by diagnostic artificial intelligence algorithms 
approved by FDA and/or CE-marked must be availa ble and evaluated by the investigator before 
randomisation to assess eligibility. The eye examination should be performed as a fundus 
photography (e.g., 2-field 60 degree or better, colour or red-free) or by slit-lamp biomicroscopy 
examination (e.g., using a pre-corneal or corneal contact lens examination). Pharmacological pupil-
dilation is a requirement unless using a digital fun dus photography camera specified for non-dilated 
examination. If diagnostic artificial intelligence al gorithms are used an additional eye examination 
may be necessary if indicated so by the algorithm. 
If the participant had such an eye examination performed within 90 days prior to screening, the 
investigator may base his/her evaluation upon the re sults of that examination. The examination must 
be repeated before randomisation if the particip ant has experienced worsening of visual function 
since the last examination. If the applicable eye examination was performed before the participant 
signed the informed consent form, it must be documented that the reason for performing the 
examination was not related to this study. 
It is recommended that high risk T2D patients (individuals with T2D d =:)<1767.E	A-):;)
baseline HbA1c >8% and confirmed diabetic retinopa thy at baseline) will have an additional eye 
examination in accordance with local standard of  care , i.e. every 6-month performed by an 
ophthalmologist or another suitably qualified health care provider (e.g., optometrist) possibly aided 
by diagnostic artificial intelligence algorithms approved by FDA and/or CE-marked. 
Eye examinations required at the visit at week 52 (V54) can be performed within 2 weeks before 
the visit, if results are available for evaluati on at the visit. For participants who discontinue 
randomised treatment, eye examination can be pe rformed up to 2 weeks after the visit V54A. The 
investigator should examine the outcome of each eye examination. Relevant findings before 
randomisation must be recorded as concomitant il lness/medical history. While relevant findings 
occurring after randomisation should be reported as an AE, please refer to Section 8.3 and 
Appendix 3 (Section 10.3).  
8.2.5 Electrocardiograms 
The ECG should be preceded by at least 5 minutes of rest for the participant in a supine/sitting 
position in a quiet setting without distra ctions (e.g. no use of television, cell phones). 
The ECG must be interpreted, signed and dated by the investigator to verify that the data has been 
reviewed. 
The ECG required at screening can be obtained within two weeks before randomisation (V2) but at 
the latest at randomisation (V2). The results must be interpreted by the investigator before 
randomisation in order to determine th e eligibility of the participant. CONFIDENTIAL
VV-CLIN-219731 1 .0 .
Protocol 
CONFIDENTIAL Date: 23 March 2023 Novo Nordisk 
Study ID: NN1535-4592 Version: 8.0 
      Status: Final 
      Page: 49 of 113 
 
 The ECG required at the visit at week 52 (V54) can be obtained within two weeks before the visit. 
The results must be available for evaluation at the visit. 
Abnormal, clinically significant findings at screening should be recorded as concomitant illness in 
the eCRF. At the following visits, any new abnormal, clinically significant findings or clinically 
significant deteriorations after randomisation should be reported as an AE, see Appendix 3 
(Section 10.3). 
8.2.6 Clinical safety laboratory assessments 
All protocol-required laboratory assessments, as defined in Appendix 2 (Section 10.2), must be 
conducted in accordance with the protocol flowchart (Section 1.2) and the laboratory manual. 
8.2.7 Pregnancy testing  
Woman of childbearing potential (WOCBP) should only be included after a negative, highly 
sensitive urine pregnancy test (refer to Appendix 2 (Section 10.2)). 
Pregnancy testing should be performed whenever a menstruation is missed or when pregnancy is 
otherwise suspected. 
Additional pregnancy testing should be performed during the treatment period, if required locally, 
refer to Appendix 11 (Section 10.11 ). 
8.3 Adverse events and other safety reporting 
The investigator is responsible for detecting, doc umenting, recording and following up on events 
that meet the definition of an AE or SAE. 
 
The definition of AEs and SAEs can be found in Appendix 3 (Section 10.3), along with a 
description of AEs requiring additional data collec tion. The definition and description of events for 
adjudication can be found in Appendix 9 (Section 10.9). 
Some AEs require additional data collection on a specific event form. The relevant event(s) are 
listed below in Table 8-1 , together with event(s) for adjudication and other events requiring 
collection of additional information. 
Events for adjudication require completion of an  adjudication form, please refer to Appendix 9 
(Section 10.9). CONFIDENTIAL
VV-CLIN-219731 1 .0 .
Protocol 
CONFIDENTIAL Date: 23 March 2023 Novo Nordisk 
Study ID: NN1535-4592 Version: 8.0 
      Status: Final 
      Page: 50 of 113 
 
 Table 8-1 AEs requiring additional data collect ion, events for adjudication and other 
events requiring collection of additional information 
Event type  AE requiring 
additional data 
collection Event for adjudication 
 Other events requiring 
collection of additional 
information 
Medication error  X   
Misuse and abuse X   
Hypersensitivity X   
Injection site reactions X   
Acute gallbladder diseases X   
Malignant neoplasms X   
Hypoglycaemic episodes    X 
Death  X  
Acute coronary syndrome 
(including acute myocardial 
infarction and u nstable angina 
pectoris requiring hospitalisation)  X  
Cerebrovascular event 
(including stroke and transient ischemic attack)
a  X  
Heart failure (including 
requiring hospitalisation and 
urgent heart failure visit)  X  
a. All cerebrovascular events are to be reported and sent for adjudication, however the EAC will only confirm strokes 
 
Definitions and reporting timelines for the events mentioned in the above table can be found in Appendix 3 (Section 10.3) and Appendix 7 (Section 10.7) for hypoglycaemic episodes and 
Appendix 9 (Section 10.9) for events requiring adjudication.  
8.3.1 Time period and frequency for coll ecting adverse event information 
All AEs and SAEs must be collected from first administration of randomised treatment and until the 
last follow-up visit in accordance with the flowchart (Section 1.2) or whenever, within the above 
time period, the site becomes aware of an AE or SAE.  
 
Conditions present prior to the timepoint from which AEs are collected and anticipated day-to-day 
fluctuations of these conditions, including those identified during screening or during other study-
related procedures performed before exposure to random ised treatment, will be recorded as medical 
history/concomitant illness. 
AE and SAE reporting timelines can be found in Appendix 3 (Section  10.3). All SAEs must be 
recorded and reported to Novo Nordisk within 24 hours, and the investigator must submit any 
updated SAE data to Novo Nordisk within 24 hours of it being available. 
Investigators are not obligated to actively seek for AE or SAE in former study participants. 
However, if the investigator learns of any SAE, in cluding a death, at any time after a participant has 
been discontinued from/completed the study, and the investigator considers the event to be related CONFIDENTIAL
VV-CLIN-219731 1 .0 .
Protocol 
CONFIDENTIAL Date: 23 March 2023 Novo Nordisk 
Study ID: NN1535-4592 Version: 8.0 
      Status: Final 
      Page: 51 of 113 
 
 to the randomised treatment or related to study participation, the investigator must promptly notify 
Novo Nordisk. 
8.3.2 Method of detecting adverse events  
The method of recording, evaluating, and assessing causality of AE and SAE and the procedures for 
completing and transmitting SAE reports are provided in Appendix 3 (Section 10.3). 
Care should be taken not to introduce bias when  detecting AEs and/or SAEs. Open-ended and non-
leading verbal questioning of the participant is the preferred method to inquire about events. 
8.3.3 Follow-up of adverse events  
After the initial AE/SAE report, the investigator is required to proactively follow each participant at 
subsequent visits/contacts. All SAEs should be fo llowed until final outcome of the event or until the 
participant is lost to follow-up as described in Section 7.3. Further information on follow-up and 
final outcome of events is given in Appendix 3 (Section 10.3). 
8.3.4 Regulatory reporting requirement s for serious adverse events 
Prompt notification by the investigator to Novo Nordisk of an SAE is essential so that legal 
obligations and ethical responsibilities towards the safety of participants and the safety of a study 
intervention under clinical investigation are met. 
Novo Nordisk has a legal responsibility to notify both the local regulatory authority and other 
regulatory agencies about the safety of a study intervention under clinical investigation. Novo 
Nordisk will comply with country-specific regulatory requirements relating to safety reporting to 
the regulatory authority, IRB/IEC, and investigators. This also includes suspected unexpected 
serious adverse reactions (SUSARs). 
An investigator who receives an investigator safe ty report describing an SAE or other specific 
safety information (e.g., summary or listing of SAEs) from Novo Nordisk will review and then file 
it )476/?1<0<0-16>-;<1/)<7:J;*:7+0=:-)6,?14467<1.A<0-$ 1.)88:78:1)<-)++7:,16/<7
local requirements. 
8.3.5 Pregnancy  
Details of pregnancies in female participants will be collected after first exposure to IMP and until 
the new-born infant is one month of age. For deta ils regarding collection and reporting of pregnancy 
information, please refer to Appendix 4 (Section 10.4). 
8.3.6 Technical complaints  
Technical complaints will be collected for all products listed on the technical complaint form. 
Instructions for reporting technical complaints can be found in Appendix 5 (Section 10.5). 
In order for Novo Nordisk to perform a complete investigation of reported SAEs, Novo Nordisk 
might ask the investigator to complete a technical complaint form. CONFIDENTIAL
VV-CLIN-219731 1 .0 .
Protocol 
CONFIDENTIAL Date: 23 March 2023 Novo Nordisk 
Study ID: NN1535-4592 Version: 8.0 
      Status: Final 
      Page: 52 of 113 
 
 8.4 Pharmacokinetics 
Samples will be used to evalu ate the PK of insulin icodec and semaglutide. For participants 
randomised to IcoSema, PK samples of insulin ic odec and semaglutide will be collected, and for 
participants randomised to semaglutide, PK sample s of semaglutide will be collected. PK samples 
will be collected at the visits outlined in the flowchart (Section 1.2). The investigator must record 
the exact date and time for blood sampling in the laboratory requisition form.  
Procedures for sampling, handling, storage, label ling and shipments of the specimens must be 
performed in accordance with the laboratory manual.  A randomisation list will be provided to the 
special laboratory.  
Bioanalysis of insulin icodec samples will be pe rformed at a special laboratory using a validated 
luminescent oxygen channelling immunoassay. The ex act method will be outlined in a bioanalytical 
report. Bioanalysis of semaglutide samples will be performed at a special laboratory using a 
validated Liquid Chromatography Mass Spectometry as say. The exact methods will be outlined in a 
bioanalytical report. 
Genetic analyses will not be performed on these plasma/serum/whole blood samples. Participant 
confidentiality will be maintained. 
For retention of metabolism sample s (PK samples), please refe r to Appendix 6 (Section 10.6). 
 
Participants should be instructed to report dos ing information in the eDiary as per Section 8.2.1 . 
 
The investigator will not be able to review the PK  analysis report during the study, as the results 
?144764A*-)>)14)*4-).<-:<0-4);<8):<1+18)6<J;4);<>1;1<  Results from the PK analyses measured 
according to the flowchart (Section 1.2) will be available to Investig ators after the completion of the 
study.  
8.5 Genetics 
Not applicable for this study.  
8.6 Biomarkers 
Not applicable for this study.  
8.7 Immunogenicity assessments 
8.7.1 Anti-drug antibodies 
For participants randomised to IcoSema, anti-ins ulin icodec antibody samples will be collected 
according to the flowchart (Section 1.2). For participants randomised to semaglutide, no anti-drug 
antibody samples will be collected.  
All samples must be drawn before administration of randomised treatment if randomised treatment 
administration is planned on the sampling day. As sessment of anti-drug antibodies in serum will be 
performed at a Novo Nordisk appointed laboratory. For details on blood sampling, serum 
preparation and storage, please refer to the laboratory manual.  CONFIDENTIAL
VV-CLIN-219731 1 .0 .
Protocol 
CONFIDENTIAL Date: 23 March 2023 Novo Nordisk 
Study ID: NN1535-4592 Version: 8.0 
      Status: Final 
      Page: 53 of 113 
 
 Analysis for anti-drug antibodies will be done as listed in flowchart (Section 1.2) with a binding 
anti-drug antibody assay. Positive samples to insuli n icodec will be further characterised for titre, 
and cross-reactivity to human insulin. 
Detailed description of the assay methods will be included in an analytical report. Antibody assays 
were validated according to interna tional guidelines and recommendations. 
 
At the end of the study, the following data will be transferred to the Novo Nordisk database:  
 Anti-insulin icodec binding an tibodies (positive/negative) 
 Titre of anti-insulin icodec antibody positive samples 
 Anti-insulin icodec binding antibodies cros s-reacting with human insulin status 
(positive/negative).  
The investigator will not be able to review the results of antibody measurements in relation to AEs 
as the results will only be available after the 4);<8):<1+18)6<J;4);<>1;1<  Results from the binding 
anti-drug antibody analyses measured according to the flowchart (Section 1.2) will be available to 
Investigators after the completion of the study.  
For retention of antibody samples, please refer to Appendix 6 (Section 10.6).  
8.7.2 Hypersensitivity 
Participants randomised to IcoSema and investig ators will be instructed to detect signs and 
symptoms of systemic hypersensitivity. 
In the event of a systemic hypersensitivity reaction (not locally at the injection site), the participant 
should be called in as soon as possible to have additional blood samples taken (Section 10.2). 
The blood sampling should be repeated 2-4 weeks following onset of the systemic hypersensitivity 
reaction. If possible, the tests should also be performed on samples drawn before first 
administration of IcoSema. 
For details related to blood sampling, plasma preparation and storage, please refer to the laboratory 
manual. 
Analysis will be performed by Novo Nordisk or a Novo Nordisk appointed special laboratory 
(please refer to Attachment I ). The results will be reported in a se parate report and attached to the 
clinical study report. 
For retention of residual hypersensitivity samp les, please refer to Appendix 6 (Section 10.6). 
For participants randomised to semaglutide no additional blood samples will be taken 
Digital pictures 
For participants randomised to IcoSema the investig ator or the participant must take digital pictures 
of the affected area at time of identification, usin g any device available (mobile phone, camera etc.) 
and thereafter as often as judged necessary by the investigator. The pictures should include subject CONFIDENTIAL
VV-CLIN-219731 1 .0 .
Protocol 
CONFIDENTIAL Date: 23 March 2023 Novo Nordisk 
Study ID: NN1535-4592 Version: 8.0 
      Status: Final 
      Page: 54 of 113 
 
 ID, date and time, time after dosing and a ruler for sc aling. All pictures must be stored as part of 
source documentation at site.  CONFIDENTIAL
VV-CLIN-219731 1 .0 .
Protocol 
CONFIDENTIAL Date: 23 March 2023 Novo Nordisk 
Study ID: NN1535-4592 Version: 8.0 
      Status: Final 
      Page: 55 of 113 
 
 9 	

  
The statistical analysis plan (SAP) will be finalised prior to first participant first visit and it will 
include a more technical and detailed description of th e statistical analyses described in this section. 
This section is a summary of the planned stat istical analyses of the most important endpoints 
including the primary endpoint. 
9.1 Statistical hypotheses 
The primary objective is to show that IcoSema is superior to semaglutide in terms of change in 
HbA 1c (%) from baseline week 0 (V2) to week 52 (V54). 
7:5)44A4-<*-<0-5-)6<:-)<5-6<,1..-:-6+-I+7%-5)J516= ;I;-5)/4=<1,-J7.<0-  change in 
HbA 1c (%) from baseline week 0 (V2) to week 52 (V54). The null-hypothesis of IcoSema not being 
superior will be tested against the alternati ve hypothesis of superiority as given by  
H0E)/)16;< A: D < 0% 
Superiority will be considered confirmed if the upper bound of the two-sided 95% confidence 
interval for D is strictly below 0 %. 
9.2 Analysis sets 
The following populations are defined: 
Participant analysis set Description 
Full analysis set  All randomised participants. Participants will be included in the analyses 
according to the planned randomised treatment. 
Safety  analysis set All randomised participants who are exposed to random ised treatment. 
Participants will be included in the analyses  according to the randomised 
treatment they actually received. 
 
The following data points sets are defined: 
Data points sets Description 
In-study All data from randomisation until the last date of any of the following: 
 The last direct participant-site contact 
 Withdrawal for participants who withdraw their informed consent 
 The last participant- investigator contact as defined by the investigator 
for participants who are lost to follow- up (i.e. possibly an unscheduled 
phone visit) 
 Death for participants who di e before any of the above 
On-treatment All data from the date of first dose of ra ndomised treatment as recorded on the 
eCRF until the first date of any of the following: 
 The last follow-up visit (V56) 
 The last date on randomised treatment +6 weeks (corresponding to 5 
weeks after the end of the dosing interval for both treatment arms) 
 The end-date for the in-study data points sets  
 CONFIDENTIAL
VV-CLIN-219731 1 .0 .
Protocol 
CONFIDENTIAL Date: 23 March 2023 Novo Nordisk 
Study ID: NN1535-4592 Version: 8.0 
      Status: Final 
      Page: 56 of 113 
 
 The on-treatment data points set represent data collected in the period in which a participant is 
considered exposed to randomised treatment. 
Baseline assessments are always included in th e in-study and on-treatment data points sets. 
The full analysis set and the in-study data points se t will be used to estimate the primary estimand. 
9.3 Statistical analyses 
9.3.1 General considerations 
Baseline is defined as information collected at week 0 (V2). In case a measurement is not available 
at week 0 (V2) the most recent measurement prior to week 0 (V2) will be used as baseline. 
Presentation of results from a statistical analys is will include the estimated mean treatment 
difference (or ratio) presented together with the two-sided 95% confidence interval and the 
corresponding two-sided p-value. 
In the statistical models, explanatory factors will be coded as follows:  
 Randomised treatment: Once weekly IcoSema, Once weekly semaglutide  
 Region: Asia, Europe, North America, Other 
The regions will be defined as follows: 
 Asia: Japan, China, Taiwan 
 Europe: France, Greece, Slovakia, Switzerland, Sweden, Hungary 
 North America: United States, Canada 
 Other: Russia, Israel, Brazil 
9.3.2 Primary estimand analysis 
The primary endpoint is change in HbA 1c from baseline week 0 (V2) to week 52 (V54). 
The estimand (see Section 3), will be estimated based on the full analysis set using the in-study data 
points set which includes all HbA 1c measurements obtained at week 52 (V54) especially 
measurements from participants experiencing intercurrent events. The imputation approach for the 
primary estimand is a multiple imputation similar to the one described by McEvoy.21 
 Missing HbA 1c measurements at week 52 (V54) for par ticipants experiencing intercurrent 
events will be imputed from participants experiencing intercurrent events and have a 
measurement at week 52 (V54) in each treatment arm. 
 Missing HbA 1c measurements at week 52 (V54) for participants not experiencing intercurrent 
events are imputed from available measuremen ts at week 52 (V54) from participants not 
experiencing intercurrent events in each treatment arm.  CONFIDENTIAL
VV-CLIN-219731 1 .0 .
Protocol 
CONFIDENTIAL Date: 23 March 2023 Novo Nordisk 
Study ID: NN1535-4592 Version: 8.0 
      Status: Final 
      Page: 57 of 113 
 
 The multiple imputation approach will be done the following way:  
 Imputation: An ANCOVA model for change in HbA 1c from baseline week 0 (V2) to week 52 
(V54) for participants experiencing intercurren t events and have a measurement at week 52 
(V54) with randomised treatment as fixed factor, last available planned on-treatment HbA 1c 
observation without initiation of non-randomised insulin treatment or additional anti-diabetic 
treatments for more than 2 weeks, the time point (study day) of last available planned on-
treatment HbA 1c observation without initiation of non- randomised insulin treatment or 
additional anti-diabetic treatments for more than 2 weeks and baseline HbA 1c as covariate. If 
participants not experiencing intercurrent events are missing measurements at week 52 (V54) an 
ANCOVA model will be defined in a similar wa y using available data from participants not 
experiencing intercurrent events. The estimate d parameters, and their variances, from the 
imputation models will be used to impute missing HbA 1c measurements at week 52 (V54). This 
will be done 1000 times and results in 1000 complete datasets.  
 For each of the complete data sets, the primary endpoint will be analysed using an ANCOVA 
model with region and randomised treatmen t as fixed factors, and baseline HbA 1c as covariate. 
The estimates and standard deviations for the 1000 data sets will be pooled to one estimate and 
);;7+1)<-,;<)6,):,,->1)<176=;16/$=*16J;:=4-22 
 From the pooled estimate and standard deviation the 95% confidence interval for the treatment 
difference will be calculated. The corresponding two-sided p-value will also be calculated. 
This analysis has the underlying assumption that par ticipants with missing data behave similarly as 
comparable participants within the same treatm ent arm i.e. that participants experiencing 
intercurrent events with missing data at week 52 (V54) behave like participants experiencing 
intercurrent events with data at week 52 (V54) within the same treatment arm and similar for 
participants not experiencing intercurrent events. 
9.3.2.1  Sensitivity analysis 
The following sensitivity analysis will evaluate  the robustness of the results towards the missing 
data assumption. 
For the primary endpoint, a two-dimensional tipping point analysis will be performed where 
participants having imputed HbA 1c measurement at week 52 (V54) are assumed to have a worse 
outcome in the IcoSema arm and a better outcome in the semaglutide arm compared to what was 
imputed in the primary analysis. This is done by addi 6/7:;=*<:)+<16/>)4=-;M i to the imputed 
HbA 1c >)4=-;*-.7:-)6)4A;16/<0-,)<)&0->)4=-7.M i will be varied independently in the two 
<:-)<5-6<):5;&0-84)=;1*141<A7.<0->)4=-;7.M i where the conclusion of the primary analysis 
change will be evaluated to assess the robu stness of the primary analysis results. 
9.3.3 Secondary estimand analyses 
9.3.3.1  Supportive secondary estimands 
Details on analysis of secondary estimands rela ted to supportive secondary endpoints will be 
included in a SAP.  CONFIDENTIAL
VV-CLIN-219731 1 .0 .
Protocol 
CONFIDENTIAL Date: 23 March 2023 Novo Nordisk 
Study ID: NN1535-4592 Version: 8.0 
      Status: Final 
      Page: 58 of 113 
 
 9.3.4 Exploratory estimand analysis 
Not applicable for this study. 
9.3.5 Other safety analyses 
The standard safety assessments (AEs, safety laboratory parameters, vital signs, etc.) will be 
reported descriptively; including any notable changes of clinical interest in laboratory parameters. 
9.3.6 Other analyses 
9.3.6.1  Pharmacokinetic modelling 
Insulin icodec serum concentration data and semaglut ide plasma concentration data will be used for 
population PK analysis. The objective of the population PK analysis is to evaluate the effects of 
relevant covariates on insulin icodec and semaglutide exposure. 
The population PK analysis will be performed by Quantitative Clinical Pharmacology, Novo 
Nordisk. A more technical and detailed elaboration of the population PK analysis will be given in a 
modelling analysis plan, which will be prepared before database lock. In brief, previously 
developed PK models for insulin icodec and sema glutide will be applied. The absorption rate 
constants in the models will be fixed, and the apparent clearance and volume of distribution 
parameters will be re-estimated. The covariates of in terest will be incorporated into the PK models 
using criteria which will be specified in the modelling analysis plan. 
The population PK analysis will be reported in a separate modelling report, which will not be part 
of the clinical study report. The individual insulin icodec serum concentration data and the 
individual semaglutide plasma concentration data w ill be tabulated in the bioanalytical report. 
9.4 Interim analysis 
Not applicable for this study. 
9.5 Sample size determination 
The sample size is determined in order to ha ve at least 90% power for meeting the primary 
hypothesis. 
It is assumed that the amount of participants experi encing an intercurrent event will be similar to 
what was observed in the subcutaneous semaglutide for T2D development program, and that the 
intercurrent events will have the same impact on ef fect size and are equally distributed between 
treatment arms. The amount of participants experi encing an intercurrent event ranged from 14.1% 
to 25.7% in open-label studies with various durati ons except for semaglutide 0.5 mg in the Japan 
studies, see Table  9-1 . Based on this the percentage of partic ipants experiencing an intercurrent 
event is expected to be 17%. CONFIDENTIAL
VV-CLIN-219731 1 .0 .
Protocol 
CONFIDENTIAL Date: 23 March 2023 Novo Nordisk 
Study ID: NN1535-4592 Version: 8.0 
      Status: Final 
      Page: 59 of 113 
 
 Table  9-1 Participants exper iencing an intercurrent event ! open-label subcutaneous 
semaglutide for diabetes studies (NN9535) 
Study 
ID Description Study 
duration Participants experiencing 
intercurrent events (%) 
Semaglutide 
0.5 mg Semaglutide 
1.0 mg 
3624 SUSTAIN 3: Semaglutide 1.0 mg vs. Exenatide ER 2.0 mg 56 weeks  25.7 
3625 SUSTAIN 4: Semaglutide 1.0/0.5 mg vs. Insulin glargine 30 weeks 17.4 17.8 
4216 SUSTAIN 7: Semaglutide 1.0/0.5 mg vs. Dulaglutide 1.5/0.75 mg 40 weeks 16.6 16.6 
4339 SUSTAIN 10: Semaglutide 1.0 mg vs. Liraglutide 1.2 mg 30 weeks  15.5 
4092 SUSTAIN Japan: Semaglutide 1.0/0.5 mg vs. Sitagliptin 30 weeks 3.9 14.7 
4091 SUSTAIN Japan: Semaglutide 1.0/0.5 mg vs. One additional OAD 56 weeks 6.3 14.1 
Participants experiencing an intercurrent event is participants discontinuin g randomised treatment or initiating rescue 
medication. The definition of rescue medication differ across  the studies and is different from the current study. 
For the primary hypothesis that IcoSema is superior to semaglutide 1.0 mg in terms of change in 
HbA 1c from baseline to week 52 (V54) the sample  size considerations are based on studies 
comparing IDegLira (insulin degludec/liraglutide) to GLP-1 treatment, see Table 9-2 .  
Table 9-2 HbA 1c results ! IDegLira studies (NN9068)  
Study 
ID Description Study 
duration Change from baseline in 
HbA 1c (%-point) 
ETD [95% CI] SD 
3697 DUAL I: IDegLira vs. Lira 26 weeks -0.63 [-0.73; -0.52] 0.9 
3697 DUAL I extension: IDegLira vs. Lira 52 weeks -0.63 [-0.75; -0.51] 1.0 
4183 DUAL I Japan: IDegLira vs. Lira 52 weeks -0.49 [-0.60; -0.37] 0.7 
4148 DUAL I China: IDegLira vs. Lira 26 weeks -0.59 [-0.72; -0.46] 0.7 
3851 DUAL III: IDegLira vs. previous GLP-1 treatment 26 weeks -0.93 [-1.09; -0.76] 0.8 
CI: Confidence interval, ETD: Estimated treatment di fference, Lira: Liraglutide 1.8 mg, IDegLira: insulin 
degludec/liraglutide, SD: Standard deviation. Data from after participants discontinuing randomised treatment were not 
collected in the studies. Change from baseline in HbA 1c were analysed using a mixed-effect model for repeated 
measurements. 
However, the current study and the IDegLira studies in Table 9-2  are different in key study design 
asperts such as: in the IDegLira studies the dur ation was shorter in some of the studies, the 
population was different e.g. in the DUAL I studies previous anti-diabetic treatment was only 
OADs, in study 3851 participants in the GLP-1 co mparator arm were asked to continue as their 
prior treatment without adjustment and for participants discontinui ng randomised treatment data 
were not collected after disconti nuation and hence not included. In addition the statistical method to 
be used in the current study also differs. The differences across development programmes are 
expected to impact the expected treatment di fferences. Based on these considerations it is 
considered reasonable to be able to detect a trea tment difference of at least a -0.33%-point in 
change in HbA 1c between the treatment arms for participan ts not experiencing intercurrent events 
and no treatment difference for pa rticipants experiencing intercurrent events. Thus, with 17% of 
participants expected to experience any of the sp ecified intercurrent events before week 52 (V54) CONFIDENTIAL
VV-CLIN-219731 1 .0 .
Protocol 
CONFIDENTIAL Date: 23 March 2023 Novo Nordisk 
Study ID: NN1535-4592 Version: 8.0 
      Status: Final 
      Page: 60 of 113 
 
 this leads to a mean treatment difference of (1- 	K -0.33% = -0.274%-point for the specified 
primary estimand in the overall population. The standard deviation (SD) is assumed to be 1.1%-
point based on the IDegLira studies. 
To be able to detect a treatment difference of -0.274%-point with the above considerations it 
requires 680 participants to ensure 90% power. 
The sample size calculation above is sensitive to the assumptions made for the mean treatment 
difference and standard deviation for superior ity for change from baseline in HbA 1c, and in 
Table 9-3  the power is presented with different assumptions.  
Table 9-3 Power with different assumptions for superiority for change from baseline in 
HbA 1c  
Randomised 
participants Treatment difference 
(%-point) Adjusted treatment 
difference (%-point) Standard deviation 
(%-point)  Marginal power 
680 0.26 0.216 1.0 80.3% 
680 0.26 0.216 1.1 72.5% 
680 0.26 0.216 1.2 64.9% 
680 0.33 0.274 1.0 94.6% 
680 0.33 0.274 1.1 90.0% 
680 0.33 0.274 1.2 84.4% 
680 0.40 0.332 1.0 99.1% 
680 0.40 0.332 1.1 97.6% 
680 0.40 0.332 1.2 95.0% 
Adjusted treatment difference is adjusted for 17% of participants experiencing intercurrent events. 
From the above assumptions and requirements for th e primary analysis, 680 participants will be 
randomly assigned to treatment. This will ensure sufficient marginal power of at least 90% for 
confirming superiority for the primary endpoint. 
9.6 Partial database lock 
A partial database lock may be performed at the end of the treatment period for all participants, i.e. 
after the date of the last participant last treatment vi sit. The database will be updated after the partial 
database lock to include remaining safety information. The full database lock will be performed 
after the date of the last participant last visit. 
The analysis of the primary endpoint and all othe r efficacy endpoints will be performed based on 
the data from the partial database lock. Analysis of  safety data will be performed after the full 
database lock. This approach is implemented to allow earlier availability of IcoSema to a T2D 
patient population in need of treatment intensificati on expected to benefit from an insulin and 
GLP-1 combination product. A detailed plan for data handling and operational aspects of the partial 
database lock and the database update will be  finalised before the partial database lock.   
 CONFIDENTIAL
VV-CLIN-219731 1 .0 .
Protocol 
CONFIDENTIAL Date: 23 March 2023 Novo Nordisk 
Study ID: NN1535-4592 Version: 8.0 
      Status: Final 
      Page: 61 of 113 
 
 10 	

  
10.1 Appendix 1: Regulatory, ethical, a nd study oversight considerations 
10.1.1  Regulatory and ethical considerations 
This study will be conducted in accordance with the protocol and with the following: 
 Consensus ethical principles derived from international guidelines including the Declaration of 
Helsinki23 and applicable ICH Good Clinical Practice (GCP) Guideline24 
 Applicable laws and regulations 
&0-8:7<7+7416.7:5-,+76;-6<.7: 516>-;<1/)<7:J;*:7+0=:-) ;)88 licable) and other relevant 
documents (e.g., advertisements) must be submitted  to an IRB/IEC and reviewed and approved by 
the IRB/IEC before the study is initiated. 
Regulatory authorities will receive the clinical trial application, protocol amendments, reports on 
SAEs, and the CSR according to national requirements. 
Any amendments to the protocol will require IRB/IEC approval before implementation of changes 
made to the study design, except for changes nece ssary to eliminate an immediate safety hazard to 
study participants. 
Before a site is allowed to start screening participants, written notification from Novo Nordisk must 
be received. 
The investigator will be responsible for: 
 providing written summaries of the status of the study annually or more frequently in 
accordance with the requirements, policies, and procedures established by the IRB/IEC and/or 
regulatory authorities 
 notifying the IRB/IEC of SAEs or other significant safety findings as required by IRB/IEC 
procedures 
 providing oversight of the conduct of the study at the site and adherence to requirements of ICH 
guidelines, the IRB/IEC, and all other applicable local regulations 
 ensuring submission of the CSR synopsis to the IRB/IEC 
 reporting any potential serious breaches to the sponsor immediately after discovery 
10.1.2  Financial disclosure 
Investigators and sub-investigators will provide Novo Nordisk with sufficient, accurate financial 
information as requested to allow Novo Nordisk to submit complete and accurate financial 
certification or disclosure statements to the appropriate regulatory authorities. Investigators are 
responsible for providing information on financial in terests during the course of the study and one 
year after completion of the study. 
Verification under disclosures per Code of Fe deral Regulations (CFR) of Financial Conflict of 
Interest. CONFIDENTIAL
VV-CLIN-219731 1 .0 .
Protocol 
CONFIDENTIAL Date: 23 March 2023 Novo Nordisk 
Study ID: NN1535-4592 Version: 8.0 
      Status: Final 
      Page: 62 of 113 
 
 10.1.3  Informed consent process 
The investigator or his/her representative will explain the nature of the study, including the risks 
and benefits, to the participant and answer all quest ions regarding the study. This includes the use of 
an impartial witness where required according to local requirements. 
The investigator must ensure the participant ample time to come to a decision whether or not to 
participate in the study. 
Participants must be informed that their participat ion is voluntary. Participants will be required to 
sign and date a statement of informed consent that meets the requirements of local regulations, ICH 
GCP24 guidelines, Declaration of Helsinki,23 privacy and data protection requirements, where 
applicable, and the IRB/IEC or site. 
The medical record must include a statement that wr itten informed consent was obtained before any 
study-related activity and the date when the wr itten consent was obtained. The authorised person 
obtaining the informed consent must also sign and date the informed consent form before any 
study-related activity. 
The responsibility of seeking informed consent must remain with the investigator, but the 
investigator may delegate the task to a medically qualified person, in accordance with local requirements. 
Participants must be re-consented to the most current version of the informed consent form(s) 
during their participation in the study. 
A copy of the informed consent form(s) must be provided to the participant. 
10.1.4   Information to participants during the study 
The site will be offered a communication package for the participant during the conduct of the 
study. The package content is issued by Novo Nordisk. The communication package will contain 
written information intended for distribution to the participants. The written information will be 
translated and adjusted to local requirements and di stributed to the participant at the discretion of 
the investigator. The participant may re +-1>-)G<0)63A7=.7:A7=:8):<1+18)<1764-<<-:H).<-:
completion of the study. Further, the participant may receive other written information during the 
study. 
All written information to participants must be sent to IRB/IEC for approval/favourable opinion and 
to regulatory authorities for approval or notification according to local regulations. 
10.1.5  Data protection 
Participants will be assigned a 6-digit unique iden tifier, a subject ID. Any participant records or 
datasets that are transferred to Novo Nordisk will contain the identifier only. No direct identifiers 
from the participant are transferred to Novo Nordisk. 
The participant and any biological material obtaine d from the participant will be identified by 
subject ID, visit number and study ID. Appropriate measures such as encryption or leaving out CONFIDENTIAL
VV-CLIN-219731 1 .0 .
Protocol 
CONFIDENTIAL Date: 23 March 2023 Novo Nordisk 
Study ID: NN1535-4592 Version: 8.0 
      Status: Final 
      Page: 63 of 113 
 
 certain identifiers will be enforced to protect the identity of participants as required by local, 
regional and national requirements. 
The participant must be informed about his/her privacy rights, including that his/her personal study-
related data will be used by Novo Nordisk in accordance with local data protection law. The 
disclosure of the data must also be explained to the participant. 
The participant must be informed that his/her medica l records may be examined by auditors or other 
authorised personnel appointed by Novo Nordisk, by appropriate IRB/IEC members, and by 
inspectors from regulatory authorities. 
#-:;76)4,)<)5)A*-+744-+<- ,.:758):<1+18)6<;,=-<78:7+-;; :-9=1:-5-6<;.:75!7>7!7:,1;3J;
suppliers. This data is needed to ensure that the relevant data analysis for the study can be 
performed, but will not be part of the data transferred to Novo Nordisk, the assessment of the study 
endpoints or the clinical study report. A list of any such data values must be kept as part of the 
study documentation along with an explanation of why it was required. 
10.1.6  Committees structure 
10.1.6.1  Novo Nordisk safety committee 
Novo Nordisk will perform ongoing safety surveillance. If new safety signals are identified, these 
will be evaluated by an internal safety co mmittee. The safety committee may recommend 
unblinding of any data for further analysis, and in this case an internal study-independent ad hoc 
group may be established in order to maintain  the blinding of the study personnel. 
10.1.6.2  Event adjudication committee 
An independent external EAC is established to perform ongoing blinded adjudication of selected 
AEs and deaths (see Table 8-1  and Appendix 9 (Section 10.9)). 
The EAC will evaluate events sent for adjudicati on using pre-defined definitions and guidelines in 
accordance with the EAC charter. The evaluation is based on review of pre-defined clinical data 
collected by the sites. The EAC is composed of  permanent members coveri ng all required medical 
specialities. EAC members must disclose any potential conflicts of interest and must be independent 
of Novo Nordisk. The EAC will have no authority to impact study conduct, study protocol or 
amendments. The assessments made by both the event adjudication committee and the investigator 
will be evaluated and included in the CSR. 
10.1.7  Dissemination of clinical study data 
Study information will be disclosed at clinicaltrials.gov and novonordisk-trials.com and, if 
applicable, also on other national or regional study registries. It will be disclosed according to 
applicable requirements, relevant recommendation s or regulations, such as the Declaration of 
Helsinki,23 the International Committee of Medical Journal Editors (ICMJE),25 the Food and Drug 
Administration Amendment Act (FDAAA),26 European Commission Requirements1, 27, 28 and in 
accordance with Novo Nordisk commitment to clinical transparency. If a participant requests to be 
included in the study via the Novo Nordisk e-mail contact at these web sites, Novo Nordisk may 
,1;+47;-<0-16>-;<1/)<7:J s contact details to the participant. As a result of increasing requirements CONFIDENTIAL
VV-CLIN-219731 1 .0 .
Protocol 
CONFIDENTIAL Date: 23 March 2023 Novo Nordisk 
Study ID: NN1535-4592 Version: 8.0 
      Status: Final 
      Page: 64 of 113 
 
 for transparency, some countries require public  disclosure of investigator names and their 
affiliations. 
10.1.8  Data quality assurance 
10.1.8.1  Case report forms 
Novo Nordisk or designee is responsible for the data management of this study including quality 
checking of the data. 
To demonstrate his/her oversight of the collected data, the investigator should sign the eCRF on a 
regular basis during the conduct of the study as well as at the end of the study, as described in the 
eCRF completion guideline, and review the HCP web portal. 
All participant data relating to the study will be  recorded on CRFs and eDiary unless transmitted 
electronically to Novo Nordisk or designee (e.g., laboratory and eDiary data). The investigator is 
responsible for verifying that data entries are accura te and correct by physically or electronically 
signing the CRF. 
The following will be provided as paper CRFs: 
 Pregnancy forms 
 
The following will be provided as paper CRFs to be used when access to the CRF is revoked or the 
CRF is temporarily unavailable: 
 AE forms  
 Safety information forms  
 Technical complaint forms (also to be used to report complaints on study intervention not yet 
allocated to a participant)  
Corrections <7<0-$,)<)5)A*-5),-*A<0-16>-;<1/)<7:7:<0-16>-;<1/ )<7:J;,-4-/)<-,;<)..
An audit trail will be maintained in the CRF application containing as a minimum: the old and the 
new data, identification of the person entering the da ta, date and time of the entry and reason for the 
+7::-+<176.+7::-+<176;):-5),-*A<0-16>-;<1/)<7:J;,-4-/ )<-,;<)..).<-:<0-,)<-?0-6<0-
investigator signed the CRF, the CRF must be signed and dated again by the investigator. 
The investigator must ensure that data is recorded in the CRF as soon as possible, preferably within 
5 working days after the visit. Once data has been entered, it will be available to Novo Nordisk for 
data verification and validation purposes. 
10.1.8.2  Monitoring 
The investigator must permit study-related monitoring, audits, IRB/IEC review, and regulatory 
agency inspections and provide direct access to source data documents (original documents, data 
and records). Direct access includes permission to examine, analyse, verify and reproduce any 
record(s) and report(s) that are important to the evaluation of the study. If the electronic source data 
does not have a visible audit trail, the investigat or must provide the monitor with signed and dated CONFIDENTIAL
VV-CLIN-219731 1 .0 .
Protocol 
CONFIDENTIAL Date: 23 March 2023 Novo Nordisk 
Study ID: NN1535-4592 Version: 8.0 
      Status: Final 
      Page: 65 of 113 
 
 printouts. In addition, the relevant site staff should be available for discussions at monitoring visits 
and between monitoring visits (e.g., by telephone). 
Study monitors will perform ongoing source data ve rification of critical data points to confirm that 
data entered into the CRF by authorised site pe rsonnel are accurate, complete and verifiable from 
source documents. Study monitors will perform ongoing source data review to ensure that the study 
is being conducted in accordance with the current approved protocol and any other study 
agreements, ICH GCP24, and all applicable regulatory requirements, evaluating the adequacy of 
critical processes at site for the executi on of the protocol, collection of study data, to ensure that the 
safety and rights of participants are being protected. 
Monitoring will be conducted using a risk-based  approach including risk assessment, monitoring 
plans, centralised monitoring (remote assessment of data by Novo Nordisk) and visits to sites. 
Quality tolerance limits (QTLs) will be predefined in the relevant monitoring plan to identify 
systematic issues that can impact participant safe ty and/or reliability of study results. These 
predefined parameters will be monitored during the study, and important deviations from the QTLs 
and remedial actions taken will be summarised in the clinical study report. 
Monitors will review the participant J;5-,1+)4:-+7:,;)6,7<0-:;7=:+-,)<)<7-6;=:-+76;1;<-6+A
and/or identify omissions compared to the eCRF.  
10.1.8.3  Protocol compliance 
Deviations from the protocol should be avoided. If deviations do occur, the investigator must 
inform the monitor without delay and the implica tions of the deviation must be reviewed and 
discussed. 
Deviations must be documented and explained in a protocol deviation by stating the reason, date, 
and the action(s) taken. Some deviations, for which corrections are not possible, can be 
acknowledged and confirmed via edit checks in th e CRF or via listings from the study database. 
10.1.9  Source documents 
All data entered in the eCRF or paper CRF mu st be verifiable in source documentation. 
)<)16<0-;-:>1+-8:7>1,-:;J,)<)*);-1;+76;1,-:-,; ource data e.g. laboratory data. Data in eDiary 
database is considered source data, unless stated  otherwise in source documentation agreements. 
 
Source documents provide evidence for the exis tence of the participant and substantiate the 
integrity of the data collected. Source documents are filed at the site. Any source data generated by 
16>-;<1/)<7:J;;=*+76<:)+<7:;5=;<*-):+01>-,)6,)++-;;1*4-* A<0-;1<-  
Data that is transcribed into the eCRF or paper CRF from source documents must be consistent with 
the source documents, or the discrepancies must be explained. The investigator may need to request 
previous medical records or transfer records. Also , current medical records must be available. 
If source data is entered directly in a paper CRF, each data entry or clear series of data entries must 
be signed and dated separately by the study staff making the entry. CONFIDENTIAL
VV-CLIN-219731 1 .0 .
Protocol 
CONFIDENTIAL Date: 23 March 2023 Novo Nordisk 
Study ID: NN1535-4592 Version: 8.0 
      Status: Final 
      Page: 66 of 113 
 
 <5=;<*-87;;1*4-<7>-:1.A8):<1+18)6<J;5-,1+)401;<7:A16 ;7=:+-,7+=5-6<;;=+ 0);8):<1+18)6<J;
medical record.  
The investigator must document any attempt to obtain external medical information by noting the 
date(s) when information was requested, and who was contacted. 
Definition of what constitutes source data must be  found in a source document agreement at each 
site. There will only be one source document defined at any time for any data element. 
10.1.10  Retention of clinical study documentation 
Records and documents, including signed informed consent forms, pertaining to the conduct of this 
study must be retained by the investigator for 25 years after end of study unless local regulations or 
institutional policies require a longer retention period. No records may be destroyed during the 
retention period without the written approval of Novo Nordisk. No records may be transferred to 
another location or party without written notification to Novo Nordisk. 
The investigator must be able to access his/her st udy documents without involving Novo Nordisk in 
any way. If applicable, electronic CRF (eCRF) and other participant data will be provided in an 
electronic readable format to the investigator before access is revoked to the systems and/or 
electronic devices supplied by Novo Nordisk. Site-s pecific CRFs and other participant data (in an 
electronic readable format or as paper copies or prin ts) must be retained by the site. A copy of all 
data will be stored by Novo Nordisk. 
#):<1+18)6<J;5-,1+)4:-+7:,;5=;<*-3-8<.7:<0-5)@15=58-:1 7,8-:51<<-,*A<0-07;81<)4
institution or private practice. 
10.1.11  Study and site closure 
Novo Nordisk reserves the right to close the site or terminate the study at any time for any reason at 
the sole discretion of Novo Nordisk. If the study is suspended or terminated, the investigator must 
inform the participants promptly and ensure a ppropriate therapy and follow-up. The investigator 
and/or Novo Nordisk must also promptly inform the regulatory authorities and IRBs/IECs and 
provide a detailed written explanation. 
Sites will be closed upon study completion. A site is  considered closed when all required documents 
and study supplies have been collected and a site closure visit has been performed. 
The investigator may initiate site closure at any time, provided there is reasonable cause and 
sufficient notice is given in advance of the intended termination. 
Reasons for the early closure of a site by Novo Nordisk or investigator may include but are not 
limited to: 
 failure of the investigator to comply with the protocol, the requirements of the IRB/IEC or local 
health authorities, Novo Nordisk procedures or GCP guidelines 
 inadequate recruitment of participants by the investigator 
 discontinuation of further study intervention development. CONFIDENTIAL
VV-CLIN-219731 1 .0 .
Protocol 
CONFIDENTIAL Date: 23 March 2023 Novo Nordisk 
Study ID: NN1535-4592 Version: 8.0 
      Status: Final 
      Page: 67 of 113 
 
 10.1.12  Responsibilities 
The investigator is accountable for the conduct of the study at his/her site and must ensure adequate 
supervision of the conduct of the study at the site. If any tasks are delegated, the investigator must 
maintain a log of appropriately qualified persons to  whom he/she has delegated specified study-
related duties. The investigator must ensure that th ere is adequate and documented training for all 
;<)..8):<1+18)<16/16<0-+76,=+<7.<0-;<=,A<1;<0-16>- ;<1/)<7:J;:-;876;1*141<A<7;=8-:>1;-<0-
conduct of the study and to protect the rights, safety, and well-being of the participants. 
A qualified physician, who is an investigator or a sub investigator for the study, must be responsible 
for all study-related medical decisions. 
The investigator is responsible for filing essential documents (i.e., those documents which 
individually and collectively permit evaluation of th e conduct of a study and the quality of the data 
produced) in the investigator trial master file . The documents, including the participant 
identification code list must be kept in a secure locked facility so that no unauthorised persons can 
get access to the data. 
The investigator will take all necessary technical and organisational safety measures to prevent 
accidental or wrongful destruction, loss or deteriora tion of data. The investigator will prevent any 
unauthorised access to data or any other processing of data against applicable law. This also 
includes ensuring that no indirect sharing of user credentials for IT systems used in this study takes 
place (e.g., by not sharing IT equipment with others in a way where user credentials have the 
possibility of being shared). The investigator must be able to provide the necessary information or 
otherwise demonstrate to Novo Nordisk that such technical and organisational safety measures have 
been taken. 
During any period of unavailability, the investigat or must delegate responsibility for medical care of 
participants to a specific qualified physician who w ill be readily available to participants during that 
time. 
If the investigator is no longer able to fulfil the role as investigator (e.g., if he/she moves or retires), 
a new investigator will be appointed in consultation with Novo Nordisk. 
The investigator and other site personnel must have sufficient English skills according to their 
assigned task(s). 
10.1.13  Indemnity statement 
Novo Nordisk carries product liability for its pro ducts, and liability as assumed under the special 
laws, acts and/or guidelines for conducting clinical studies in any country, unless others have shown 
negligence. 
Novo Nordisk assumes no liability in the event of negligence or any other liability of the sites or 
investigators conducting the study or by persons for whom the said site or investigator are 
responsible. 
 
Novo Nordisk accepts liability in accordance with local laws/acts/guidelines, see Section 10.11  for 
more information.  CONFIDENTIAL
VV-CLIN-219731 1 .0 .
Protocol 
CONFIDENTIAL Date: 23 March 2023 Novo Nordisk 
Study ID: NN1535-4592 Version: 8.0 
      Status: Final 
      Page: 68 of 113 
 
 10.1.14  Publication policy 
The information obtained during the conduct of this st udy is considered confidential and may be 
used by or on behalf of Novo Nordisk for regulatory purposes as well as for the general 
development of the study intervention. All infor mation supplied by Novo Nordisk in connection 
with this study shall remain the sole property of N ovo Nordisk and is to be considered confidential 
information. 
No confidential information shall be disclosed to others without prior written consent from Novo 
Nordisk. Such information shall not be used except in the performance of this study. 
The information obtained during this study may be made available to other investigators who are 
conducting other clinical studies with the study intervention, if deemed necessary by Novo Nordisk. 
Provided that certain conditions are fulfilled, Novo Nordisk may grant access to information 
obtained during this study to researchers who require access for research projects studying the same 
or related diseases and/or study intervention studied in this study. 
Novo Nordisk may publish on its clinical studies website a redacted CSR for this study. 
One or two investigators will be appointed by Novo  Nordisk to review and sign the CSR (signatory 
investigators) on behalf of all participating investigators. 
10.1.14.1  Communication of results 
Novo Nordisk commits to communicate and disc lose results of studies regardless of outcome. 
Disclosure includes publication of a manuscript in  a peer-reviewed scientific journal, abstract 
submission with a poster or oral presentation at a scientific meeting or disclosure by other means.  
The results of this study will be subject to publ ic disclosure on external web sites according to 
international and national regulations. Novo Nordisk reserves the right to defer the release of data 
until specified milestones are reached, for example when the CSR is available. This includes the 
right not to release the results of interim analyses, because the release of such information may 
influence the results of the entire study. 
At the end of the study, one or more scientific pub lications may be prepared collaboratively by the 
investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or 
communication for up to 60 days to protect intellectual property. 
In all cases, the study results will be reported in an objective, accurate, balanced and complete 
manner, with a discussion of the strengths and limitations. In the event of any disagreement on the 
2+76<-6<7.)6A8=*41+)<176*7<0<0-16>-;<1/)<7:;J)6,!7>7!7 :,1;37816176;?144*-.)1:4A)6,
sufficiently represented in the publication. 
10.1.14.2  Authorship 
Novo Nordisk will work with one or more investig ator(s) and other experts who have contributed to 
the study concept or design, acquisition, analysis or interpretation of data to report the results in one 
or more publications. CONFIDENTIAL
VV-CLIN-219731 1 .0 .
Protocol 
CONFIDENTIAL Date: 23 March 2023 Novo Nordisk 
Study ID: NN1535-4592 Version: 8.0 
      Status: Final 
      Page: 69 of 113 
 
 Authorship of publications should be in acc ordance with the Recommendations for the Conduct, 
Reporting, Editing and Publication of Scholarly  Work in Medical Journals by the International 
Committee of Medical Journal Editors.29 
All authors will be provided with the relevant st atistical tables, figures, and reports needed to 
evaluate the planned publication. 
Where required by the journal, the investigator from each site will be named in an 
acknowledgement or in the supplementary mat erial, as specified by the journal.  
10.1.14.3  Site-specific publication (s) by investigator(s) 
For a multicentre clinical study, analyses based on single-site data usually have significant 
statistical limitations and frequently do not provide meaningful information for healthcare 
professionals or participants, and therefore may not be supported by Novo Nordisk. Thus, Novo 
Nordisk may deny a request or ask for deferment of the publication of indi vidual site results until 
the primary manuscript is accepted for publication. In line with Good Publication Practice, such 
individual reports should not precede the primary manuscript and should always reference the 
primary manuscript of the study. 
10.1.14.4  Investigator access to data and review of results 
As owner of the study database, Novo Nordisk has th e discretion to determine who will have access 
to the database. 
Individual investigators will have  their own research participa 6<;J,)<))6,?144*-8:7>1,-,?1<0
the randomisation code after results are available. CONFIDENTIAL
VV-CLIN-219731 1 .0 .
Protocol 
CONFIDENTIAL Date: 23 March 2023 Novo Nordisk 
Study ID: NN1535-4592 Version: 8.0 
      Status: Final 
      Page: 70 of 113 
 
 10.2 Appendix 2: Clinical laboratory tests  
The tests detailed in Table 10-1  and Table 10-2  will be performed by the central laboratory and by 
the special laboratories. 
Additional tests may be performed at any time during the study as determined necessary by the 
investigator or required by local regulations. Only laboratory samples specified in the protocol 
should be sent to the central laboratory for analys is; if additional laboratory sampling is needed, 
e.g., to follow-up on AEs, this must be done at a local laboratory. 
The central laboratory will communicate to the investigator abnormal values of parameters not 
requested in the protocol but identified by the laboratory equipment and/or their processes 
according to their laboratory Standard Operating Procedures. These data will not be transferred to 
the study database. The investigator should review such values for AEs and report these according 
to this protocol. 
The investigator must review all laboratory resu lts for concomitant illnesses and AEs,with the 
exception of the pharmacokinetics and antibodies (sections 8.4 and 8.7.1 ), as these results will not 
be available to the investigator until afte r finalisation of the clinical study report. 
The investigator must keep an overview, e.g. a log, of laboratory samples not handled according to 
the laboratory manual. In addition, the investigator must keep an overview, e.g. a log, of laboratory 
samples stored at site. 
Laboratory samples will be destroyed no later th an at the end of the study or no later than at 
finalisation of the CSR. 
Human bio samples will be stored as  described in Appendix 6 (Section 10.6). 
Table 10-1 Protocol-required efficacy laboratory assessments 
Laboratory 
assessments Parameters  
Glucose metabolism  
V2, V12, V20, V28, 
V38, V46, V54/V54A  Fasting plasma glucose (FPG)a 
 HbA 1c (also at V1) 
NOTES: 
aAn FPG result <3.9 mmol/L (70 mg/dL) in relation to planned fasting visits should not be reported as a 
hypoglycaemic episode but as an AE at the disc retion of the investigator (Appendix 3, Section 10.3). 
Table 10-2 Protocol-required safety laboratory assessments 
Laboratory 
assessments Parameters  
Haematology  
V1, V12, V28, V38, 
V54/V54A   Erythrocytes 
 Haematocrit 
 Haemoglobin 
 Leucocytes 
 Thrombocytes 
 Basophils 
 Eosinophils 
 Lymphocytes CONFIDENTIAL
VV-CLIN-219731 1 .0 .
Protocol 
CONFIDENTIAL Date: 23 March 2023 Novo Nordisk 
Study ID: NN1535-4592 Version: 8.0 
      Status: Final 
      Page: 71 of 113 
 
 Laboratory 
assessments Parameters  
 Monocytes 
 Neutrophils 
Biochemistrya 
V1, V12, V28, V38, 
V54/V54A    Alanine Aminotransferase (ALT) 
 Albumin 
 Alkaline phosphatase (ALP) 
 Aspartate Aminotransferase (AST) 
 Creatinine 
 Potassium 
 Sodium 
 Total bilirubin 
 Gamma-glutamyltransferase (GGT) (only at V1, V28 and 54/V54A) 
Lipids  
V2, V12,  V20, V28, 
V38, V46, V54/V54A    Cholesterol 
 High density lipoprotein (HDL) cholesterol 
 Low density lipoprotein (LDL) cholesterol 
 Very low density lipoprotein (VLDL) cholesterol 
 Triglycerides 
 Free fatty acids 
Pregnancy testingb 
V1, V2, V54/V54A, V56  Highly sensitive urine human chorionic gonadotropin (hCG) pregnancy test  
Anti-drug antibodies  
V2, V4, V8, V12, V20, 
V28, V38, V54/V54A, 
V56  Anti-insulin icodec binding antibodies (IcoSema arm) 
 
Pharmacokinetics  
(V4, V8, V12, V20, V28, 
V38, V54/V54A, V56)   Insulin-icodec serum concentration (IcoSema arm) 
 Semaglutide plasma concentratio n (IcoSema and semaglutide arms) 
 
Other tests 
 
Hypersensitivity samples 
should be collected as 
soon as possible after the systemic hypersensitivity 
reaction, and again
 2-4 
weeks following onset of 
the systemic 
hypersensitivity reaction  eGFR calculated by the central laboratory based on the creatinine value using the 
CKD-EPI equation (V1).  
 
 In case of systemic hypersensitivity rea ction in participants in the IcoSema arm 
(Section 8.7.2 ):  
 Tryptase (optimal 0.5-2 hours post the hypersensitivity reaction)c 
 Total immunoglobulin E (IgE) antibodiesc 
 Anti-human insulin IgE antibodiesd 
 Anti-insulin icodec IgE antibodiesd 
 Anti-insulin icodec binding antibodiese 
 Anti-semaglutide IgE antibodiesd 
 Anti-semaglutide binding antibodiese 
Hypersensitivity data will not be shared with investigators until after CSR 
finalisation. 
Notes: 
aDetails of required actions for increase d liver parameters are given in Appendix  3 (Section 10.3). 
bFor women of childbearing potential, as needed, local urine tes ting will be standard unless serum testing is required 
by local regulation or IRB/IEC, see Appendix  4 (Section 10.4). 
c Samples collected from Chinese participants will be analys ed by a central lab in China. Samples collected from 
participants  in the rest of the world will be analysed by Novo Nordisk MÃ¥lÃ¸v, Denmark  
d Samples will be analysed by Novo Nordisk MÃ¥lÃ¸v, Denmark for all countries except China , where these tests will 
not be done (see Appendix 11, Section 10.11 ). 
e Samples collected from Chinese participants will be anal ysed in a special lab in China. Samples collected from 
participants in the rest of the world will be analysed by a special lab designated by Novo Nordisk.  
 CONFIDENTIAL
VV-CLIN-219731 1 .0 .
Protocol 
CONFIDENTIAL Date: 23 March 2023 Novo Nordisk 
Study ID: NN1535-4592 Version: 8.0 
      Status: Final 
      Page: 72 of 113 
 
 10.3 Appendix 3: Adverse Events and Serious Adver se Events: Definitions and procedures 
for recording, evaluating, follow-up, and reporting 
10.3.1  Definition of adverse event 
An AE is any untoward medical occurrence in a clinical study participant that is temporally 
associated with the use of IMP, whether or not cons idered related to the IMP. An AE can therefore 
be any unfavourable and unintended sign (includi ng an abnormal laboratory finding), symptom or 
disease (new or exacerbated) temporally associated with the use of an IMP. 
Events to be reported as AEs: 
 Any abnormal laboratory test results or safety assessments considered clinically significant in 
the medical and scientific judgment of the investigator, including events that have worsened 
from prior to the time point from which AEs are collected 
 Conditions detected or diagnosed after IMP administration even though it may have been 
present prior to the time point from which AEs are collected 
 Exacerbation/worsening of a chronic or intermittent condition including either an increase in 
frequency and/or intensity of the condition 
 Signs, symptoms or the clinical sequelae of a suspected drug-drug interaction 
 Signs, symptoms or the clinical sequelae of a suspected overdose of IMP regardless of intent 
I4)+37.-..1+)+AJ7:I.)14=:-7.-@8-+<-,80):5)+747/1+)4)+ <176J8-:;-?14467<*-:-87:<-,);)6
AE or SAE. Such instances will be captured in the efficacy assessments. However, the signs, 
symptoms and/or clinical sequelae resulting from lack of efficacy will be reported as AE or SAE if 
they fulfil the definition. 
Events NOT to be reported as adverse events: 
 Conditions present prior to the time point from wh ich AEs are collected and anticipated day-to-
day fluctuations of these conditions. This includes those conditions identified during screening or identified during other study procedures performed before exposure to IMP.  
Note: Conditions present or occurring prior to the time point from which AEs are collected 
should be recorded as concomitant illness/medical history. 
 Medical or surgical procedures (e.g., endoscopy, appendectomy). The condition that leads to the 
procedure is the AE. 
 Medical or surgical procedures not preceded by an AE or worsening of a known condition. 
10.3.2  Definition of a serious adverse event 
An SAE is any untoward medical occurrence that fulfils at least one of the following criteria: 
 Results in death 
 CONFIDENTIAL
VV-CLIN-219731 1 .0 .
Protocol 
CONFIDENTIAL Date: 23 March 2023 Novo Nordisk 
Study ID: NN1535-4592 Version: 8.0 
      Status: Final 
      Page: 73 of 113 
 
  Is life-threatening 
 &0-<-:5I41.- -<0:-)<-616/J:-.-:;<7)6->-6<16?01+0<0-8):<1+18)6<?);)< :1;37.
death at the time of the event. It does not refer to an event which hypothetically might have caused death, if it were more severe. 
 
 Requires inpatient hospitalisation or pr olongation of existing hospitalisation 
 Hospitalisation signifies that the participant has been admitted at the hospital or 
emergency ward for observation and/or tr eatment that would not have been 
)88:78:1)<-16<0-80A;1+1)6J;7. .1+-7:7=<8)<1-6<;-<<16/7 5841+)<176;<0)<7++=:
during hospitalisation are AEs. If a complication prolongs hospitalisation or fulfils 
any other seriousness criteria, the event is serious. When in doubt as to whether 
I07;81<)41;)<176J7++=::-,7:?);6-+-;;):A<0-;07=4,*-+ 76;1,-:-,;-:17=;  
 Hospitalisation for elective treatment (e.g ., elective medical or surgical procedures) 
of a condition that was present prior to the time point from which AEs are collected, and that did not worsen, is not considered an AE. 
Note: Hospitalisations for administrative, stud y-related, social and convenience reasons do not 
constitute AEs and should therefore not be repor ted as AEs or SAEs. Hospital admissions for 
medical or surgical procedures, planned before study inclusion, are not considered AEs or SAEs 
 
 Results in persistent or significant disability/incapacity 
 &0-<-:5I,1;)*141<AJ5-)6;); =*;<)6<1)4,1;:=8<1767.)8-:;7 6J;)*141<A<7+76,=+<
normal life functions. This definition is not intended to include experience of 
relatively minor medical significance, such as uncomplicated headache, nausea, 
vomiting, diarrhoea, influenza, and accidental trauma (e.g., sprained ankle), that may 
interfere with or prevent everyday life functions but do not constitute a substantial 
disruption. 
 
 Is a congenital anomaly/birth defect 
 
 Important medical event: 
 Medical or scientific judgment should be exercised by the investigator in deciding 
whether SAE reporting is appropriate in other situations. This includes important 
medical events that may not be immediately life-threatening or result in death or 
hospitalisation but may jeopardise the participant or may require medical or surgical 
intervention to prevent one of the other outcomes listed in the above definition. 
These events should usually be considered serious and reported as SAEs using the 
important medical event criterion. 
 The following must be reported as an SAE using the important medical event 
criterion if no other seriousness criteria are applicable: 
Âƒ Suspicion of transmission of infectious agents via IMP 
Âƒ Risk of liver injury defined as alanine aminotransferase or aspartate 
aminotransferase >3x UNL and total bilirubin >2x UNL where no alternative 
)-<1747/A-@1;<;AJ;4)?  CONFIDENTIAL
VV-CLIN-219731 1 .0 .
Protocol 
CONFIDENTIAL Date: 23 March 2023 Novo Nordisk 
Study ID: NN1535-4592 Version: 8.0 
      Status: Final 
      Page: 74 of 113 
 
 10.3.3  Description of adverse events requiring a dditional data collection and other events 
requiring collection of additional information  
Adverse events requiring a dditional data collection 
An AE requiring additional data collection is an AE where Novo Nordisk has evaluated that 
additional data is needed in the evaluation of safe ty. A specific event form needs to be completed 
for these events.  
Medication error: 
 A medication error is an unintended failure in th e IMP treatment process that leads to, or has the 
potential to lead to, harm to the participant, such as: 
 administration of wrong drug 
Note: Use of wrong DUN is not considered a medication error unless it results in 
administration of wrong drug. 
 wrong route of administration, such as in tramuscular instead of subcutaneous 
 accidental administration of a lower or higher dose than intended. The administered dose 
must deviate from the intended dose to an extent where clinical consequences for the study 
participant were likely to happen as judged by the investigator, although they did not 
necessarily occur. 
Misuse and abuse: 
 Situations where the IMP is intentionally and inappropriately used not in accordance with the 
protocol (e.g., overdose to maximise effect) 
 Persistent or sporadic, intentional excessive us e of an IMP which is accompanied by harmful 
physical or psychological effects (e.g., overdose with the intention to cause harm) 
Note: Medication error, misuse and abuse must al ways be reported on an AE form and a specific 
event form must be completed. The AE diagnosis on the AE form must reflect what occurred (e.g., 
accidental overdose, intentional overdose or other). If the medication error and/or misuse and abuse 
resulted in a clinical consequence, this must be reported on an additional AE form. 
Hypersensitivity: 
Systemic hypersensitivity can be manifested as is olated symptoms such as urticaria, angioedema, 
conjunctivitis, rhinitis, bronchospasm, gastrointes tinal symptoms (nausea, vomiting, diarrhoea, 
abdominal pain), or as anaphylaxis or anaphylactic shock. 
Anaphylaxis is an acute, potentially lethal, multisystem syndrome resulting from the sudden release 
of mast cell- and basophil-derive d mediators into the circulation.30 It most often results from 
immunologic reactions to foods, medications, and in sect stings, although it can also be induced 
through nonimmunologic mechanisms by any agent capable of producing a sudden, systemic 
degranulation of mast cells or basophils31. Characteristic symptoms and signs, occurring minutes to 
a few hours after exposure to potential triggering agents or events may include: flushing, urticaria, angioedema, hoarseness, throat tightness, stridor, wheezing, coughing, shortness of breath, 
abdominal pain, vomiting, and/or hypotension, dizziness or collapse. CONFIDENTIAL
VV-CLIN-219731 1 .0 .
Protocol 
CONFIDENTIAL Date: 23 March 2023 Novo Nordisk 
Study ID: NN1535-4592 Version: 8.0 
      Status: Final 
      Page: 75 of 113 
 
 Local hypersensitivity reactions, including rash, redness, pruritus and oedema, may occur at the site 
of investigational drug injection. 
Drug hypersensitivity reactions are the adverse effects of pharmaceutical formulations (including 
active drugs and excipients) that clinically resemble allergy.32 They can be allergic and non-allergic. 
If a hypersensitivity event is suspected, the participants must contact the site staff as soon as possible for further guidance. All events must be reported, and in case of systemic hypersensitivity, 
additional information must be provided on a separate form.  
Injection site reactions: 
If an event of injection site reaction is observed, additional information must be obtained if 
available on a separate form. 
 
Acute gallbladder diseases: 
Events of symptomatic acute gallbladder disease (including gallstones and cholecystitis) 
Malignant neoplasms: 
Confirmed malignant neoplasm by histopathology or other substantial clinical evidence 
Other events requirin g collection of additional information 
Hypoglycaemic episodes  
All hypoglycaemic episodes must be recorded by the participant in the eDiary. Instructions on how 
to transfer SMPG values to the eDiary will be given to the participants. If the hypoglycaemic 
episode fulfils the criteria for an SAE the investig ator/site must report it as such. One AE form and 
safety information form can cover several hypoglycaemic episodes, if the participant has not 
recovered between the episodes. For more informa tion on hypoglycaemic episodes, please refer to 
Appendix 10.7. 
10.3.4  Recording and follow-up of adverse event and/or serious adverse event 
10.3.4.1  Adverse event and serious adverse event recording 
The investigator will record all relevant AE/SAE information in the CRF. 
The investigator will attempt to establish a diagnosis of the event based on signs, symptoms, and/or 
other clinical information. In such cases, the diagnosis (not the individual signs/symptoms) will be 
documented as the AE/SAE. 
When an AE/SAE occurs, it is the responsibilit y of the investigator to review all documentation 
(e.g., hospital progress notes, laboratory and diagnostics reports) related to the event. 
There may be instances when copies of source documents (e.g., medical records) for certain cases 
are requested by Novo Nordisk. In such cases, all participant identifiers, with the exception of the 
subject ID, must be redacted on the copies of the source documents before submission to Novo 
Nordisk. CONFIDENTIAL
VV-CLIN-219731 1 .0 .
Protocol 
CONFIDENTIAL Date: 23 March 2023 Novo Nordisk 
Study ID: NN1535-4592 Version: 8.0 
      Status: Final 
      Page: 76 of 113 
 
 For all non-serious AEs, the applicable forms should be signed when the event is resolved or at the 
end of the study at the latest. For sign-off of SAE- :-4)<-,.7:5;:-.-:<7G)6,%:-87:<16/>1)
8)8-:$H4)<-:16<01;;-+<176  
Novo Nordisk products used as concomitant medication or NIMP: if an AE is considered to have a 
causal relationship with a Novo Nordisk marketed product used as NIMP or concomitant 
medication in the study, it is important that the suspected relationship is reported to Novo Nordisk, 
e.g., in the alternative aetiology section on the safety information form. Novo Nordisk may need to 
report this AE to relevant regulatory authorities. 
10.3.4.2  Assessment of severity 
The investigator will assess severity for each event reported during the study and assign it to one of 
the following categories: 
 Mild : An event that is easily tolerated by the participant, causing minimal discomfort and not 
interfering with everyday activities. 
 Moderate : An event that causes sufficient discomfort and interferes with normal everyday 
activities. 
 Severe : An event that prevents normal everyday activities.  
Note: An AE that is assessed as severe should not be confused with an SAE. Both AEs and 
SAEs can be assessed as severe. 
10.3.4.3  Assessment of causality 
The investigator is obligated to assess the relationship between IMP and the occurrence of each 
AE/SAE. The investigator will use clinical judgment to determine the relationship.  
Relationship between an AE/SAE and the relevant IMP should be assessed as:  
 Probable  - Good reason and sufficient documentation to assume a causal relationship. 
 Possible  - A causal relationship is conceivable and cannot be dismissed. 
 Unlikely  - The event is most likely related to aetiology other than the IMP. 
Alternative aetiology, such as underlying disease(s), concomitant medication, and other risk factors, 
as well as the temporal relationship of the event to IMP administration, should be considered and 
investigated. 
&0-16>-;<1/)<7:;07=4,=;-<0-16>-;<1/)<7:J;*:7+0=:-)6,7: 8:7,=+<16.7:5)<176.7:5):3-<-,
products, for the assessment. For each AE/SAE, th e investigator must document in the medical 
records that he/she has reviewed the AE/SAE  and has provided an assessment of causality. 
There may be situations in which an SAE has occurred, and the investigator has minimal 
information to include in the initial report. However, it is important that the investigator always 
makes an assessment of causality for every ev ent before the initial transmission of the SAE 
data . 
The investigator may change his/her opinion of causality, in light of follow-up information, and 
update the causality assessment in the CRF. CONFIDENTIAL
VV-CLIN-219731 1 .0 .
Protocol 
CONFIDENTIAL Date: 23 March 2023 Novo Nordisk 
Study ID: NN1535-4592 Version: 8.0 
      Status: Final 
      Page: 77 of 113 
 
 The causality assessment is one of the criteria used when determining regulatory reporting 
requirements 
10.3.4.4  Final outcome 
The investigator will select the most appropriate outcome: 
 Recovered/resolved : The participant has fully recovered, or by medical or surgical treatment 
the condition has returned to the level observed when first documented 
 Recovering/resolving : The condition is improving, and the pa rticipant is expected to recover 
from the event.  This term may also be applicable for AEs ongoing at the time of death (where 
death was due to another AE). 
Note: For SAEs, this term is only applicable if  the participant has completed the follow-up 
period and is expected to recover. 
 Recovered/resolved with sequelae : The participant has recovered from the condition but with 
lasting effect due to a disease, injury, treatment or procedure. If a sequela meets an SAE 
criterion, the AE must be reported as an SAE. 
 Not recovered/not resolved : The condition of the particip ant has not improved, and the 
symptoms are unchanged, or the outcome is not known. This term may be applicable in cases of chronic conditions, cancer or AEs ongoing at time of death (where death is due to another AE). 
 Fatal : This term is only applicable if the participant died from a condition related to the 
reported AE. Outcomes of other reported AEs in  a participant before he/she died should be 
);;-;;-,);I:-+7>-:-,:-;74>-, JI:-+7>-:16/:-;74>16/JI:-+7 >-:-,:-;74>-,?1<0;-9=-4)-J7:
I67<:-+7>-:-,67<:-;74>-,J6?1<0).)<)47=<+75-5=;<* -:-87:<-,);)6%  
 Unknown : This term is only applicable if the participant is lost to follow-up 
10.3.4.5  Follow-up of adverse event and serious adverse event 
The investigator is obligated to perform or arrange for the conduct of supplemental measurements 
and/or evaluations as medically indicated or as requested by Novo Nordisk to elucidate the nature 
and/or causality of the AE or SAE as fully as possible (e.g., s ->-:-0A8-:;-6;1<1>1<A:-)+<176;AJ;
law). This may include additional laboratory tests or investigations, histopathological examinations, 
or consultation with other health care professionals. 
If a participant dies during participation in the study or during a recognised follow-up period, the 
investigator should, upon request, provide Novo Nordisk with a copy of the autopsy report 
including histopathology. 
New or updated information should be recorded in the CRF. 
10.3.5  Reporting of serious adverse events 
Adverse event and serious adv erse event reporting via CRF 
Relevant forms must be completed in the CRF. CONFIDENTIAL
VV-CLIN-219731 1 .0 .
Protocol 
CONFIDENTIAL Date: 23 March 2023 Novo Nordisk 
Study ID: NN1535-4592 Version: 8.0 
      Status: Final 
      Page: 78 of 113 
 
 For SAEs, initial notification via telephone is acce ptable, although it does not replace the need for 
the investigator to complete the AE and safety in formation forms within the designated reporting 
timelines (see Figure 10-1 ): 
 AE form within 24 hours 
 Safety information form within 5 calendar days 
 AE form and safety information form must be signed within 7 calendar days after first 
knowledge by the investigator. 
 Specific event form within 14 calendar days. 
 For timelines related to events for adjudication, refer also to Appendix 9 (Section 10.9) and 
Figure 10-1 . 
If the eCRF is unavailable for more than 24 hours, then the sites will use the paper AE form, and if 
the eCRF is unavailable for more than 5 calendar days, then the site will use the paper safety 
information form. The site should enter the SAE data in the eCRF as soon as it becomes available. 
The relevant CRF forms (AE and safety information forms) must be forwarded to Novo Nordisk in 
accordance with Section 10.1.5 . 
After the study is completed, the study databa se will be locked, and the CRF will be 
decommissioned to prevent the entry of new data or changes to existing data.  If a site receives a 
report of a new SAE from a participant or receives updated information on a previously reported 
SAE after CRF decommission, the site can report this information on a paper AE and safety 
information form (see below) or to Novo Nordisk by telephone.  CONFIDENTIAL
VV-CLIN-219731 1 .0 .
Protocol
CONFIDENTIALDate: 23 March 2023 Novo Nordisk
Study ID: NN1535-4592 Version: 8.0
     Status: Final
     Page: 79 of 113
Figure 10-1 Decision tree fo r determining the event type and the respective forms to 
complete with associated timelines
For further information on events for adjudication, refer to Appendix 9 (Section 10.9).
If the event adjudication system (EAS) is not available for docu ment upload, the investigator should ensure that the 
relevant source documents are collected and sa ved locally until the EAS is available again.
Contact details for SAE reporting can be found  in the investigator trial master file.
10.3.6 Reporting of adverse events for non-Novo Nordisk medical devices 
Reporting of adverse events for non-Novo Nord isk medical devices provided by Novo Nordisk 
for use in the study
All complaints should be reported directly to the manufacturer. Any AEs related to the complaint 
should be reported to both the manufacturer and Novo Nordisk.
AE identifiedAE formâ‰¤  24 hours
SIF â‰¤5 calendar days
Sign offâ‰¤ 7 calendar days
Is the AE serious , or
non-serious or an 
AESI ?
Does the AE require 
additional data 
collection?
Non-seriousSe rious
NoSpecific event form
(For SAEs: 
â‰¤14 calendar days)
Yes
 Timelines are from the awareness of an AE.
 All hypoglycaemic episodes must be recorded by the participant in the eDiary. If 
the hypoglycaemic episode fulfils the criteria for an SAE, the investigator/site 
must report it as such.
 Queri es a nd fol low-up re quests  to be resolved â‰¤14 calendar days.
 In general data must be recorded in the CRF as soon as possible, preferably within 
5 working days (see Appendix 1)
AE: Adverse Events, SAE: Serious Adverse Events, SIF: Safety Information FormAE Form
No additional 
action
Is the event to be 
adjudicated?Adjudication form
â‰¤14 calendar days
Source data â‰¤  4 weeks
Yes
No additional 
actionNoCONFIDENTIAL
VV-CLIN-219731 1 .0 .
Protocol 
CONFIDENTIAL Date: 23 March 2023 Novo Nordisk 
Study ID: NN1535-4592 Version: 8.0 
      Status: Final 
      Page: 80 of 113 
 
 10.4 Appendix 4: Contraceptive guidance and collection of pregnancy information 
10.4.1  Definitions 
Woman of childbearing potential (WOCBP)  
A woman is considered fertile following menarche and until becoming postmenopausal unless 
permanently sterile. 
If fertility is unclear (e.g., amenorrhea in adol escents or athletes), and a menstrual cycle cannot be 
confirmed before first dose of study intervention, additional evaluation should be considered. 
Females in the following categories are not considered WOCBP  
1. Premenarcheal 
2. Females with one or more of the following: 
 Documented total hysterectomy 
 Documented bilateral salpingectomy 
 Documented bilateral oophorectomy 
For females with permanent infertility due to an alternate medical cause other than the above (e.g., MÃ¼llerian agenesis, androgen insensitivity), investigator discretion should be applied in 
determining study enrolment. 
3. Postmenopausal female: 
 A postmenopausal state is defined as amenorr hoea for at least 12 months without an 
alternative medical cause in a female > 45 year s of age.  Alternative medical causes for 
amenorrhoea include, but are not limited to, hormonal contraception or hormonal 
replacement therapy.  
 -5)4-;EA-):;7.)/-+)6*-+76;1,-:-,87;<5-678)=;)4  
Females on hormone replacement therap y and whose menopausal status is in doubt are considered 
of childbearing potential and will be required to use one of the highly effective contraception 
methods.  
Note: Documentation regarding categories 1- +)6+75-.:75<0-;1<-;<)..J;:->1-?7.8):<1+18)6<J;
medical records, medical examination or medical history interview. 
10.4.2  Contraceptive guidance 
Male participants 
No contraception measures are required as the risk of teratogenicity/fetotoxicity caused by transfer 
of insulin icodec or semaglutide in seminal fluid is unlikely.
33   
Female participants  
Female participants of childbearing potential are eligible to participate if they agree to use methods 
of contraception consistently and correctly. Table 10-3  lists the highly effective methods of 
contraception allowed. Local regulations may apply, see Appendix 11 (Section 10.11 ). 
Highly effective contraception should be utilised until the end of treatment. CONFIDENTIAL
VV-CLIN-219731 1 .0 .
Protocol 
CONFIDENTIAL Date: 23 March 2023 Novo Nordisk 
Study ID: NN1535-4592 Version: 8.0 
      Status: Final 
      Page: 81 of 113 
 
 Highly effective contraception should be utilis ed for a least 35 days after last dose of IMP 
(corresponding to time during treatment and until the end of relevant systemic exposure). 
Table 10-3 Highly effective contraceptive methods allowed34 
Highly effective methodsa (Failure rate of <1% per year when  used consistently and correctly): 
 Combined (estrogen- and progestogen- containing) hormonal contraception associated with inhibition of ovulationb 
 oral 
 intravaginal 
 transdermal 
 Progestogen-only hormone contraception associated with inhibition of ovulation 
 oral 
 injectable 
 implantable  
 Intrauterine device (IUD) 
 Intrauterine hormone-releasing system (IUS) 
 Bilateral tubal occlusion 
 Vasectomized partner  
Vasectomized partner is a highly effective contr aceptive method provided that the partner is the sole sexual partner 
of the woman of childbearing potential, and the absence of sperm has been confirmed. If not, an additional highly 
effective method of contraception should be used. Spermatogenesis cycle is approximately 90 days.  
 Sexual abstinence 
Sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual 
intercourse during the entire period of risk associated with the study intervention. The reliability of sexual 
abstinence needs to be evaluated in relation to the duration of the study and the preferred and usual lifestyle of the 
participant. 
NOTES a. 
Contraceptive use by men or women should comply with local regulations regarding the use of contraceptive 
methods for those participating in clinical studies. 
b. If locally required, in accordance with Clinical Tr ial Facilitation Group guidelines, acceptable contraceptive 
methods are limited to those which inhibit ovulation as the primary mode of action. 
The following methods are not acceptable methods of contraception: Periodic abstinence (calendar, 
symptothermal, post-ovulation methods), withdrawal (coitus interruptus), spermicides only, and 
lactational amenorrhoea method (LAM). 
10.4.3  Collection of pregnancy information 
Female participants who become pregnant 
Investigator will collect pregnancy information on any female participant who becomes pregnant 
while participating in this study. 
Information will be recorded on the appropriate form and submitted to Novo Nordisk within 14 
+)4-6,):,)A;7.4-):616/7.)8):<1+18)6<J;8:-/6)6+A;-- Figure 10-2 ). 
The participant will be followed to determine the outcome of the pregnancy. The investigator will 
collect follow-up information on participant and ne onate which will be forwarded to Novo Nordisk 
within 14 calendar days. Generally, follow-up will not be required for longer than 1 month beyond 
the delivery date. 
Any termination of pregnancy will be reported, regardless of foetal status (presence or absence of 
anomalies) or indication for procedure. CONFIDENTIAL
VV-CLIN-219731 1 .0 .
Protocol 
CONFIDENTIAL Date: 23 March 2023 Novo Nordisk 
Study ID: NN1535-4592 Version: 8.0 
      Status: Final 
      Page: 82 of 113 
 
 While pregnancy itself is not considered to be an AE or SAE, any AE in connection with pregnancy 
or elective termination of a pregnancy for medical reasons will be reported as an AE or SAE. If 
:-4->)6<+76;1,-:),,16/I/-;<)<176)4JI8:-/6)6+A -relate,J7:);1514):<-:5?0-6:-87:<16/<0-
AE/SAE. 
#:-/6)6+A7=<+75-;07=4,*-,7+=5-6<-,16<0-8):<1+18)6<J;5-, 1+)4:-+7:,*67:5)48:-/6)6+A
outcome (e.g., spontaneous abortion, foetal death, stillbirth, congenital anomalies and ectopic 
pregnancy) is considered an SAE. In case of abnormal pregnancy outcome, paternal information 
should be recorded in the appropriate form after obtaining the necessary signed paternal informed 
consent. 
If the investigator learns of an SAE occurring as a result of a post-study pregnancy which is 
considered related to the IMP by the investigator, the SAE should be reported to Novo Nordisk as 
described in Appendix 3 (Section 10.3.) 
Figure 10-2 Decision tree for determining the forms to complete for collection of pregnancy 
information and timelines for reporting ! For female participants 
Maternal form 1b  
â‰¤ 14 calendar days after birthMaternal form 1a
â‰¤ 14 calendar daysAfter birth/
termination 
of pregnancy
No additional 
action Normal outcome Maternal form 2 â‰¤ 14 calendar days
Paternal form*1 â‰¤ 14 calendar days Abnormal outcome 
Pregnancy 
verified
*1 Further information collected on Paternal form for male partners of 
female participants requires signing of specific informed consent.
AE/SAEs in connection with the pregnancy and in the foetus/newborn 
should follow the timelines in Fi gure 10.1.Prior to 
birth or 
pregnancy 
termination For female participants
 
Any female participant who becomes pregnant while participating in the study will discontinue 
randomised treatment.  CONFIDENTIAL
VV-CLIN-219731 1 .0 .
Protocol 
CONFIDENTIAL Date: 23 March 2023 Novo Nordisk 
Study ID: NN1535-4592 Version: 8.0 
      Status: Final 
      Page: 83 of 113 
 
 10.5 Appendix 5: Technical complaints: Defini tion and procedures for recording, 
evaluation, follow-up and reporting 
10.5.1  Definition of technical complaint 
A technical complaint is any written, electronic or oral communication that alleges product 
(medicine or device) defects. The technical complaint may be associated with an AE but does not 
concern the AE itself.  
Examples of technical complaints: 
 Problems with the physical or chemical appe arance of IMPs or auxiliary supplies (e.g., 
discoloration, particles or contamination) 
 Problems with packaging material including labelling 
 Problems related to devices (e.g., to the inje ction mechanism, dose setting mechanism, push 
button or interface between the pen-injector and the needle) 
Time period for detecting technical complaints 
All technical complaints which occur from the time of receipt of the product at site until the time of 
the last usage of the product must be collected for products predefined on the technical complaint 
form. 
10.5.2  Recording and follow-up of technical complaints 
Reporting of technical complaints to Novo Nordisk 
For contact details for Customer Complaint Center, please refer to Attachment I . 
Technical complaints on products allocated to a par ticipant must be reported on a separate technical 
complaint form: 
1. For products with DUN: One technical complaint form must be completed for each affected 
DUN. 
2. For products without DUN: One technical complaint form must be completed for each batch, 
code or lot number. 
Timelines for reporting technical complaints to Novo Nordisk 
The investigator must complete the technical complaint form in the CRF within: 
 24 hours if related to an SAE 
 5 days calendar for all other technical complaints  
If the CRF is unavailable, or when reporting a technical complaint on a product that is not yet 
allocated to a participant, the information must be provided on a paper form to Customer Complaint 
Center, Novo Nordisk, within the same timelines as  stated above. When the CRF becomes available 
again, the investigator must enter the information on the technical complaint form in the CRF. CONFIDENTIAL
VV-CLIN-219731 1 .0 .
Protocol 
CONFIDENTIAL Date: 23 March 2023 Novo Nordisk 
Study ID: NN1535-4592 Version: 8.0 
      Status: Final 
      Page: 84 of 113 
 
 Follow-up of technical complaints 
The investigator is responsible for ensuring that ne w or updated information will be recorded on the 
originally completed form. 
Collection, storage and shipment of technical complaint samples  
The investigator must collect the technical complaint sample and all associated parts and notify the 
monitor within 5 calendar days of obtaining the samp le at site. The sample and all associated parts 
must be sent as soon as possible to Customer Complaint Center, Novo Nordisk, together with a 
copy of the completed technical complaint form. The technical complaint sample should contain the 
batch, code or lot number and, if available, th e DUN. If the technical complaint sample is 
unobtainable, the reason must be stated on the tec hnical complaint form. If several samples are 
shipped in one shipment, the sample and the corr esponding technical complaint form should be kept 
together. 
Storage of the technical complaint sample mu st be done in accordance with the conditions 
prescribed for the study intervention. 
10.5.3  Reporting of technical complaints for products not included in the technical 
complaint form 
Technical complaints on products not included in the technical complaint form should be reported 
to manufacturing holder. CONFIDENTIAL
VV-CLIN-219731 1 .0 .
Protocol 
CONFIDENTIAL Date: 23 March 2023 Novo Nordisk 
Study ID: NN1535-4592 Version: 8.0 
      Status: Final 
      Page: 85 of 113 
 
 10.6 Appendix 6: Retention of human biosamples 
Hypersensitivity reaction samples 
In case of a systemic hypersensitivity reaction, the additional blood samples taken in relation to the 
reaction (Section 8.7 and 10.2)  may be retained to follow-up on the hypersensitivity reaction. If 
deemed relevant by Novo Nordisk, relevant exploratory tests may be performed, e.g. histamine 
release (basophil activation). If measured, such data will be reported in a separate report. 
The samples will be stored at a central laboratory, at  a central storage facility, and/or at an analysing 
laboratory contracted by Novo Nordisk. The samples might be transferred to other countries, if not 
prohibited by local regulations. Only Novo Nordisk staff and bio-repository personnel will have 
access to the stored samples. The samples may be sh ipped to a contract research organisation for 
analysis. 
The samples will be anonymised (identified onl y by a unique sample ID, visit number, study 
identification number and sampling date). Confid entiality and personal data protection will be 
ensured during storage after the end of the study a nd no direct identification of the participant will 
be stored together with the samples.  
Potential further analyses of the samples will not have any consequences for the participant and 
their relatives. Participants can contact the investig ator if they wish to be informed about results 
derived from stored antibody samples obtained from their own body. 
The samples will be stored at Novo Nordisk or a Novo Nordisk designated referral central 
bio-repository after the end of the study and until marketing authorisation approval or until the 
research project terminates, but no longer than 15 years from the end of the study, after which they 
will be destroyed. 
Antibody samples  
Antibody samples may be retained for later analysis for further characterisation of antibody 
responses towards drug, if required by health authorities or for safety reasons. A fraction of the 
individual participant samples may be pooled and us ed for further development of antibody assays, 
or for generating reagents for in study vali dation and control of future assay performance. 
The antibody samples will be stored at Novo No rdisk or at a designated referral central 
bio-repository after the end of the study and until marketing authorisation approval or until the 
research project terminates, but no longer than 15 years from the end of the study after which they 
will be destroyed. 
Metabolism samples (PK samples) 
Samples for metabolism analysis may be retained for later analysis of metabolites if needed. The 
samples will be stored at Novo Nordisk or at a design ated referral central bio-repository after end of 
study and until marketing authorisation approval or until the research project terminates, but no 
longer than 15 years from end of study after which they will be destroyed. CONFIDENTIAL
VV-CLIN-219731 1 .0 .
Protocol 
CONFIDENTIAL Date: 23 March 2023 Novo Nordisk 
Study ID: NN1535-4592 Version: 8.0 
      Status: Final 
      Page: 86 of 113 
 
 10.7 Appendix 7: Hypoglycaemic episodes 
Table 10-4 Classification of hypoglycaemia 
Classification of hypoglycaemia 
Level Glycaemic criteria Description 
Hypoglycaemia alert value 
(level 1)  < 3.9 mmol/L (70 mg/dL) and  
E5574
5/,  Sufficiently low for treatment with fast-acting 
carbohydrate and dose adjustment of glucose -lowering 
therapy 
Clinically significant 
hypoglycaemia (level 2) < 3.0 mmol/L (54 mg/dL) Sufficiently low to indicate serious, clinically important 
hypoglycaemia 
Severe hypoglycaemia 
(level 3)1 No specific glucose threshold 1Hypoglycaemia associated with severe cognitive 
impairment requiring external assistance for recovery 
Notes: The Novo Nordisk terms are adapted fr om The International Hypoglycaemia Study Group,35 ADA,36 ISPAD,37 
type 1 diabetes outcomes program ,38 Advanced Technologies & Treatments for Diabetes.39 Severe hypoglycaemia as 
defined by Seaquist40 and ISPAD.37 
 
Severe hypoglycaemia 
1Severe hypoglycaemia is an event requiring assi stance of another person to actively administer 
carbohydrates, glucagon, or take other corrective acti ons. Plasma glucose concentrations may not be 
available during an event, but neurological recovery following the return of plasma glucose to 
normal is considered sufficient evidence that the event was induced by a low plasma glucose 
concentration.40 
Nocturnal hypoglycaemia 
Nocturnal hypoglycaemic episodes: episodes occurring between 00:01 and 05:59 both inclusive. 
Reporting of hypoglycaemic episodes 
 
Reporting of hypoglycaemic episodes by BG meters:  
Plasma glucose (PG) should always be recorded in the (e)diary when a hypoglycaemic episode is 
suspected. 
 
When a participant experiences a hypoglycaemic ep isode, the participant should record the general 
information in relation to the hypoglycaemia (timing, PG measurements, symptoms, etc.) as 
described in the e-diary. The investigator should ensure correct reporting of the hypoglycaemic 
episode. In case a participant is not able to fill in the e-diary (e.g., in case of hospitalisation), the 
investigator should still report the hypoglycaemi c episode on the hypoglycaemic episodes form. 
Upon onset of a hypoglycaemic episode the partic ipant is recommended to measure PG every 15 
516=<-;=6<14<0-#>)4=-1;E55745/,)6,7:;A5 8<75;0)>-*--6:-;74>-,16
accordance with current guidelines.40 
Repeated PG measurements and/or symptoms will by default be considered as one hypoglycaemic -81;7,-=6<14);=++--,16/#>)4=-1;E55745/, )6,7:;A58<75;0)>-*--6
resolved and should be reported as only one hypoglycaemic episode. In case of several low PG CONFIDENTIAL
VV-CLIN-219731 1 .0 .
Protocol 
CONFIDENTIAL Date: 23 March 2023 Novo Nordisk 
Study ID: NN1535-4592 Version: 8.0 
      Status: Final 
      Page: 87 of 113 
 
 values within the hypoglycaemic episode, the lowest value is the one that will be reported as the PG 
value for the hypoglycaemic episode, but the start ti me of the episode will remain as the time for the 
first low PG value and/or symptom. The remaining values will be kept as source data. 
If the severity of a hypoglycaemic episode changes, only one hypoglycaemic episode will be 
reported, reflecting the most severe degree of hypoglycaemia. 
$-/):,16/<0-9=-;<176G&7.--4*-<<-:,1,A7=6--,0-48<7/ -<);=/):A,:163.77,7:
5-,1+16-H<0-16>-;<1/)<7:5=;<16;<:=+<<0-8):<1+18)6<;<7) 6;?-:G(-;H1.<0--81;7,-?);)6
event that required assistance of another person to  actively administer carbohydrate, glucagon, or 
take other corrective actions. PG concentrations  may not be available during an event, but 
neurological recovery following the return of PG to normal is considered sufficient evidence that 
the event was induced by a low PG concentration.40 
Please refer to Section 10.3.3  for information regarding reporting of hypoglycaemia in the eDiary. 
Diary review 
At each contact the investigator must review the diary data for correct reporting of PG values and 
hypoglycaemic episodes. In case of incomplete or incorrect data in the diary, the participant must be 
questioned whether there have been any severe hy poglycaemic episodes since the last visit and 
report accordingly. 
Re-training of participants 
The participant must be re-trained in how to report hypoglycaemic episodes if the investigator 
identifies low PG values not reported as hypoglycaemic episodes. The training should be 
documented by the investigator in source documents.  CONFIDENTIAL
VV-CLIN-219731 1 .0 .
Protocol 
CONFIDENTIAL Date: 23 March 2023 Novo Nordisk 
Study ID: NN1535-4592 Version: 8.0 
      Status: Final 
      Page: 88 of 113 
 
 10.8 Appendix 8: Titration guideline 
Titration guidelines have been developed, providing  recommended dose adjustments at different PG 
levels to ensure that participants receive an optimal treatment. However, it is recognised that 
treatment with insulin and combination products containing insulin should be individualised, and 
the specific titration algorithms may not be applic able in certain clinical situations. Hence, it is 
important that other information, such as sympto ms of hypo/hyperglycaemia, previous response to 
dose adjustments, other glucose measurements and other indicators of the participant J;4->-47.
glycaemic control, is taken into consideration when decisions on dosing are made. In addition, since 
this is a superiority study, it is important that the semaglutide is dose optimised. The investigator is 
responsible for the treatment of the participants and can therefore overrule the guidelines to avoid 
safety hazards. 
Initiation of trial products 
At randomisation eligible participants will be randomised to receive IcoSema or semaglutide. 
IcoSema  should be taken once weekly at the same  day of the week. The starting dose at 
randomisation (V2) will be 40 dose steps, which is  equivalent to 40 units of insulin icodec and 
0.114 mg of semaglutide. 
Semaglutide  should be taken once weekly at the same day of the week. The starting dose should be 
0.25 mg.  
The first dose of IcoSema or semaglutide should be ad ministered at least 5 days after the last dose 
of pre-trial weekly GLP-1 receptor agonist. The first dose of IcoSema or semaglutide can be 
administered the following day after the last dose of pre-trial daily GLP-1 receptor agonist. 
IcoSema dose adjustment during the study 
After randomisation IcoSema should be adjusted once weekly by the investigator in connection 
with the visits/phone contacts. 
The dose adjustment will be based on the three pre-breakfast SMPG values measured on two days 
prior to the dose adjustment and on the day of the contact. 
If one or more pre-breakfast SMPG values are missing, the dose adjustment should be performed on 
the remaining SMPG value(s). 
Adjustment of IcoSema will be done in accordance with Table 10-5 . 
Table 10-5 IcoSema adjustment 
Pre-breakfast SMPG IcoSema adjustment 
Value to use mmol/L mg/dL dose steps 
Lowest of the SMPG 
values <4.4 <80 -10 
Mean of the SMPG 
values  4.4-7.2 80-130 0 
>7.2 >130 +10 CONFIDENTIAL
VV-CLIN-219731 1 .0 .
Protocol 
CONFIDENTIAL Date: 23 March 2023 Novo Nordisk 
Study ID: NN1535-4592 Version: 8.0 
      Status: Final 
      Page: 89 of 113 
 
 Semaglutide dose adjustment during the study 
After 4 weeks of treatment with 0.25 mg, the dos e should be increased to 0.5 mg once-weekly. 
After at least 4 more weeks the dose should be increased to 1 mg once-weekly.  
If adverse events occur, the escalation to 1 mg can be extended up to 26 weeks after randomisation.  
Dose reductions of semaglutide from 1 mg to 0.5 mg is allowed in case of safety concern or 
unacceptable intolerability. 
Novo Nordisk should follow up every four weeks (from V2) to ensure that the maximum tolerated 
dose is reached for the individual participant. 
Deviations from the algorithm 
It is recommended that the algorithm is followed. However, it is also important that the decision to 
adjust doses is based on all relevant information. A reason for deviating from the algorithm should 
be entered into the HCP portal by the investigator, as applicable. 
Missing IcoSema dose guidance 
.)6+7%-5),7;-1;51;;-,.7:D,)A;).<-:<0-84)66-,,7; 16/,)A<0-8):<1+18)6<;;07=4,
inject the planned dose. If the dose is missed for > 3 days, the participants should await the next 
planned day of injection. Please note that the visit window is +/- 3 days. 
Missing semaglutide dose guidance 
If a semaglutide dose is missed, it should be administered as soon as possible and within 5 days 
after the missed dose. If more than 5 days have  passed, the missed dose should be skipped, and the 
next dose should be administered on the regularly scheduled day. In each case, participant can then 
resume their regular once weekly dosing schedule. 
Dose recommendation from end of treatment and during follow-up 
IcoSema treated participants 
If it is decided that the participant should continue  basal insulin treatment after end of study it is 
recommended that the participant is switched from  IcoSema to any available basal insulin at the 
discretion of the investigator. Regarding switch from IcoSema to post-study basal insulin the 
following should be considered: 
 Calculate the new daily  basal insulin dose by dividing the latest IcoSema dose in dose step 
by 7. 
 Initiate the new daily basal insulin two weeks  after the last injection of IcoSema. 
 Continue to measure pre-breakfast SMPG daily in the follow-up period. If pre-breakfast 
SMPG exceeds 10.0 mmol/L (180 mg/dL), it should be  considered to initiate the daily basal 
insulin dose earlier than two weeks after the last dose of IcoSema. 
 Consider titrating the basal insulin once or twice weekly according to the pre-breakfast 
SMPG values and the local label of the chosen insulin. CONFIDENTIAL
VV-CLIN-219731 1 .0 .
Protocol 
CONFIDENTIAL Date: 23 March 2023 Novo Nordisk 
Study ID: NN1535-4592 Version: 8.0 
      Status: Final 
      Page: 90 of 113 
 
 If it is decided that the participant is switched to a GLP-1 receptor agonist, the start should also 
await two weeks  off IcoSema. Thereafter, the treatment can  be initiated in accordance with local 
label for the individual product. 
Semaglutide treated participants 
If it is decided to continue semaglutide treat ment, the participant can continue with the same 
semaglutide dose as during the study. If it is decided to continue with another GLP-1 analogue, the 
initiation should be in accordance with the local label of said GLP-1 analogue. 
Data collection  
The participant should be instructed to report the following: 
 Date, dose and time of IcoSema or semaglutide injections should be reported in the eDiary. 
 Injection site area of IcoSema and semaglutide.  The investigator must then register the 
injection site area in the eCRF 
 % #>)4=-;?1<0)616,1+)<1767.G8:- -*:-)3.);<H7:G7<0-:H;07=4,*-:-87:<-,*A
participants in the eDiary. 
 Hypoglycaemic episodes as described in Appendix  10.3 and 10.7 should be reported in the 
eDiary. 
While using the HCP web portal for titration the following will be entered by investigator: 
 IcoSema or semaglutide doses prescribed at this contact. 
 Reasons for deviation from the titr ation algorithm, if applicable. 
Data surveillance 
Surveillance of titration data will be performed centrally by Novo Nordisk in an unbiased manner. 
The data will be reviewed and significant deviatio ns from the titration algorithm will be followed 
up. 
Titration data for IcoSema will consist of: 
 Relevant SMPG values 
 Recommended IcoSema dose 
 Prescribed IcoSema dose 
 Actual IcoSema doses taken by the participant 
 Reasons for deviation from the titrati on guidelines. Deviations are divided into 
o G0A87/4A+)-51)H  
o G/);<:716<-;<16)4),>-:;-->-6<H  
o G7<0-:84-);-;8-+1.AH  
 Hypoglycaemia information 
 
Dosing data for semaglutide will consist of: 
 SMPG values 
 Prescribed semaglutide dose CONFIDENTIAL
VV-CLIN-219731 1 .0 .
Protocol 
CONFIDENTIAL Date: 23 March 2023 Novo Nordisk 
Study ID: NN1535-4592 Version: 8.0 
      Status: Final 
      Page: 91 of 113 
 
  Actual semaglutide dose taken by the participant 
 Reason for not increasing the semaglutide dose. Deviations are divided into 
o G0A87/4A+)-51)H  
o G/);<:716<-;<16)4),>-:;-->-6<H  
o G7<0-:84-);-;8-+1.AH  
 Hypoglycaemia information 
 
It is important that titration data are entered into the eDiary and into the eCRF in a timely manner, 
as the aim is to reduce the time in which the participant may receive inadequate treatment. 
The titration data should be reviewed by Novo Nordisk within 24 hours (on workdays). Novo 
Nordisk may contact the investigator by phone or via an online portal (CONNECT) after e-mail 
notification to clarify reasons for deviation or to request entry of missing data. When the 
investigator receives an inquiry, a response should be received at Novo Nordisk within 24 hours (on 
workdays). 
Novo Nordisk will also monitor changes in HbA 1c!7>7!7:,1;3J;5-,1+)4;<)..5)A>1:<=)44A
visit at regular intervals to discuss progress in glycaemic control and titration of individual 
participants. CONFIDENTIAL
VV-CLIN-219731 1 .0 .
Protocol 
CONFIDENTIAL Date: 23 March 2023 Novo Nordisk 
Study ID: NN1535-4592 Version: 8.0 
      Status: Final 
      Page: 92 of 113 
 
 10.9 Appendix 9:  Events requiring adjudication 
Event adjudication will be performed in randomised  participants. An event for adjudication is a 
selected AE or death evaluated by an independent external Event adjudication committee (EAC) in 
a blinded manner, please refer to Table 10-6  for event types in scope.  
For details on the EAC, refer to Appendix 1 (Section 10.1.6.2 ). 
Table 10-6 Adverse events requiring event adjudication 
Event type (AE category) 
(serious and non -serious AEs)  Description  
Death  All cause death  
Acute coronary syndrome (acute myocardial 
infarction and unstable angina pectoris requiring hospitalisation)  All types of acute myocardial infarction and unstable angina 
pectoris requiring hospitalisation 
Cerebrovascular event (stroke and transient 
ischemic attack)   Episode of focal or global neurological dysfunction that could be 
caused by brain, spinal cord, or retinal vascular injury as a result of haemorrhage or ischemia, with or without infarction 
Heart failure (requiring hospitalisation and 
urgent heart failure visits)   New episode or worsenin g of existing heart failure leading to an 
urgent, unscheduled hospital admission or 
clinic/office/emergency department visit 
 
There are four ways to identify events rele vant for adjudication as described below: 
1. Investigator-reported events for adjudication: investigator selects the appropriate AE category 
relevant for adjudication (see Table 10-6 ). 
2. AEs reported with fatal outcome 
3. AE search (standardised screening): All AEs not reported with an AE category relevant for 
adjudication will undergo screening to identify  potential events for adjudication. Investigators 
will be notified of these events in the CRF. 
4. EAC-identified events: Unreported events relevant for adjudication identified by the EAC 
during review of source documents provided for another event for adjudication. Investigators 
will be notified of these events in the CRF and has the option to report the EAC-identified 
event. 
For each event relevant for adjudication, an ev ent type specific adjudication form should be 
completed in the CRF within 14 days ( Figure 10-1 ). 
Copies of source documents should be uploaded to the EAS as soon as possible and preferably 
within 4 weeks ( Figure 10-1 ). In cases where the EAS is not accessible for document upload, the 
investigator should ensure that the relevant source documents are collected and saved locally until 
the EAS is available. If no, or insufficient so urce documents are provided to the adjudication 
supplier, the investigator can be asked to complete a clinical narrative to be uploaded to the EAS. 
If new information becomes available for an event sent for adjudication, it is the responsibility of 
the investigator to ensure the new information is uploaded to the EAS. CONFIDENTIAL
VV-CLIN-219731 1 .0 .
Protocol 
CONFIDENTIAL Date: 23 March 2023 Novo Nordisk 
Study ID: NN1535-4592 Version: 8.0 
      Status: Final 
      Page: 93 of 113 
 
 An Event Adjudication Site Manual will be provided to each site detailing which source documents 
are relevant and how these should be provided to the adjudication supplier. The anonymization and 
labelling requirements are also described in the event adjudication site manual. CONFIDENTIAL
VV-CLIN-219731 1 .0 .
Protocol 
CONFIDENTIAL Date: 23 March 2023 Novo Nordisk 
Study ID: NN1535-4592 Version: 8.0 
      Status: Final 
      Page: 94 of 113 
 
 10.10  Appendix 10: Mitigations to ensure participan t safety and data integrity during an 
emergency situation 
10.10.1  Definition and scope of appendix 
A major emergency is defined as a situation that ca uses substantial restrictions to study site access 
for participants and/or sponsor representatives. 
In case local restrictions due to a major emergency, e.g. due to a COVID-19 outbreak, lead to lock-
down of a site, the site must contact Novo No rdisk to allow for implementation of mitigations 
mentioned in this appendix based on mutual agreement. 
According to local regulation, health authorities and independent ethics committees should be 
notified in case elements of the emergency appendix are activated. 
Table 10-7  indicates the minimum requirements for asse ssments that should be performed during a 
lock-down, but sites should always try to follow the assessments outlined in the original flowchart 
(Section 1.2) to the extent possible. Implementation of specific mitigations should be based on 
assessment of feasibility at the individual site.  
Alternative visit formats are examples of th e mitigations that can be implemented: 
 Home visits: visits to be performed at the participantÂ´s home  
 Off-site visits: visits to be performed at a pl ace other than the site or the participantÂ´s home  
Alternative visit formats and all other mitigations  mentioned in this appendix can be implemented 
only if allowed and deemed feasible according to  local regulations, requirements and/or guidelines 
at the sites and countries and shoul d be performed by the site-staff. As a pre-requisite, sites need to 
ensure that the study site staff is covered by workers' compensation insurance, also when performing home and off-site visits. 
Sites should comply with local regulations, requirements and/or guidelines if they are issued. 10.10.2  Visits 
Screening (V1) and randomisation/baseline (V2) should always be performed as on-site visits. If a 
site is unable to perform these visits on-site, scre ening and randomisation of new participants at that 
site should be on hold until on-site visits are possible. 
Visits 4 and 8 should always be performed as on-s ite visits to ensure co llection of, at least, 
antibodies and PK samples.  
The visit at week 52 (V54) should always be perform ed as on-site visit. The visit window can be 
extended for up to 28 days. Participants should continue randomised treatment until the visit at 
week 52 (V54) takes place.  
The last follow-up visit (V56) should always be perf ormed as on-site visit to ensure, at least, 
collection of antibodies and PK samples. CONFIDENTIAL
VV-CLIN-219731 1 .0 .
Protocol 
CONFIDENTIAL Date: 23 March 2023 Novo Nordisk 
Study ID: NN1535-4592 Version: 8.0 
      Status: Final 
      Page: 95 of 113 
 
 On-site visits (visits V3, V5, V6, V10, V 12, V16, V20, V24, V28, V30, V34, V38, V42, V46, V50, 
V55) can be converted to remote visits (video, phone or similar) or home or off-site visits.  
At each visit, the investigator must indicate in the CRF how the visit was performed and specify the 
reason for the preferred assessment method. 
10.10.3  Assessments 
Assessments used for safety or the confirmatory endpoi nts (i.e., HbA1c) should be prioritised, as 
well as antibodies and PK. The preferred order for the method of assessment is shown in 
Table 10-7 ): 
HbA 1c should be prioritised and be performed on-site at least at V1, V2 and V54. 
Antibodies and PK should be prioritised and be perf ormed on-site at least at  V2 (antibodies only), 
V4, V8, V54 and V56.  
Specifications regarding how to perform these as sessments using remote visits (phone visits or 
video contact) or as home visits or off-site visits  will be provided by Novo Nordisk or the vendor.  
All laboratory samples should be analysed at the ce ntral and special laboratories.  In case of lock 
down of the site, samples of V1, V2, V4, V8, V54 and V56 should be  prioritised, and the Lack of 
Efficacy Criteria 5, Section 7.1.1  would be evaluated based on the SMPG only (instead of 
evaluating based on SMPG and FPG).  
Home measurements of pregnancy tests and vital signs (other than the ones to be collected at V1, 
V2 and V54) can be performed if on-site visits are not possible and if deemed feasible for the 
participant. Only findings meeting the definition for an AE (refer to Appendix 3 [Section 10.3]) 
should be reported in the CRF. Pregnancy tests and equipment to perform vital signs can be 
delivered to the participants if on-site visits are not possible. The site is responsible for contracting a 
suitable courier and costs will be reimbursed by Novo Nordisk. ParticipantsÂ´ own home scales 
cannot be used for measuring body weight.  
If the assessments indicated in Table 10-7  cannot be performed as on-s ite visits, home-visits or 
remote visits (video, phone or similar), they shoul d be performed at the first possible timepoint 
following the originally scheduled visit in agreement with Novo Nordisk. 
10.10.4  Study intervention 
Alternative dispensing methods of study interven tion may be implemented, and details will be 
communicated and documented. The dispensing options will be provided by Novo Nordisk A/S and 
will be based on options and requirements at coun try level and if permitted by local regulations. CONFIDENTIAL
VV-CLIN-219731 1 .0 .
Protocol       Date: 23 March 2023 Status:  Final  Novo Nordisk 
Study ID: NN1535-4592       Version: 8.0 Page: 96 of 113 
 
 Table 10-7 Minimum assessments following randomisation 
Please refer to Section 1.2 for the full flowchart. 
Procedures marked with a X should be prioritised and be performed on-site.  
Procedures marked with an X can be performed at the participantÂ´ s home, off-site, via the phone or video call if deemed necessa ry because of the lockdown. 
Procedures marked with a red X can subsequently be cancelled. 
 Protocol Sections Screening  Randomisation 
Treatment period Follow up Discontinuation 
 Visit (preferred 
visit format) 
V: On site Visit  V1 V2 V3 V
4 V5 V6 V
8 V10 V12 V16 V20 V24 V28 V30 V34 V38 V42 V46 V50 V54 V55 V5
6 V54
A 
Alternative visit 
format  
    H/O/R
/P  H/O/R
/P H/O/R
/P  H/O/R
/P H/O/R
/P H/O/R
/P H/O/R
/P H/O/R
/P H/O/R
/P H/O/R
/P H/O/R
/P H/O/R
/P H/O/R
/P H/O/R
/P H/O/R
/P  H/O/R
/P   
 Weekly Phone 
Contact number 
(P)       P7 P9 P11 P13 
P14 
P15 P17 
P18 
P19 P21 
P22 
P23 P25 
P26 
P27 P29 P31 
P32 
P33 P35 
P36 
P37 P39 
P40 
P41 P43 
P44 
P45 P47 
P48 
P49 P51 
P52 
P53     
 Timing of Visit 
(Weeks)   <-
2W 0W 1W 2
W 3W 4W 6
W 8W 10W 14W 18W 22W 26W 28W 32W 36W 40W 44W 48W 52
W 54W 57
W  
 Visit Window 
(Days)     Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 -
3/+2
8 +3 +3  
    Informed 
Consent and 
Demography 10.1.
3  
(App 
1)  X                       
VV-CLIN-219731 1.0 .
Protocol       Date: 23 March 2023 Status:  Final  Novo Nordisk 
Study ID: NN1535-4592       Version: 8.0 Page: 97 of 113 
 
  Protocol Sections Screening  Randomisation 
Treatment period Follow up Discontinuation 
 Visit (preferred 
visit format) 
V: On site Visit  V1 V2 V3 V
4 V5 V6 V
8 V10 V12 V16 V20 V24 V28 V30 V34 V38 V42 V46 V50 V54 V55 V5
6 V54
A 
Alternative visit 
format  
    H/O/R
/P  H/O/R
/P H/O/R
/P  H/O/R
/P H/O/R
/P H/O/R
/P H/O/R
/P H/O/R
/P H/O/R
/P H/O/R
/P H/O/R
/P H/O/R
/P H/O/R
/P H/O/R
/P H/O/R
/P  H/O/R
/P   
 Weekly Phone 
Contact number 
(P)       P7 P9 P11 P13 
P14 
P15 P17 
P18 
P19 P21 
P22 
P23 P25 
P26 
P27 P29 P31 
P32 
P33 P35 
P36 
P37 P39 
P40 
P41 P43 
P44 
P45 P47 
P48 
P49 P51 
P52 
P53     
 Timing of Visit 
(Weeks)   <-
2W 0W 1W 2
W 3W 4W 6
W 8W 10W 14W 18W 22W 26W 28W 32W 36W 40W 44W 48W 52
W 54W 57
W  
 Visit Window 
(Days)     Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 -
3/+2
8 +3 +3  
    Eligibility 
Criteria  5.1, 
5.2 X X                      
    Concomitant 
Medication  6.8 X X X X X X X X X X X X X X X X X X X X X X X 
    Medical 
History/Concomi
tant Illness  8.2 X X                      
    Tobacco Use 5.3.2 X                       
    Childbearing 
Potential  10.4 
(App 
4) X                       
VV-CLIN-219731 1.0 .
Protocol       Date: 23 March 2023 Status:  Final  Novo Nordisk 
Study ID: NN1535-4592       Version: 8.0 Page: 98 of 113 
 
  Protocol Sections Screening  Randomisation 
Treatment period Follow up Discontinuation 
 Visit (preferred 
visit format) 
V: On site Visit  V1 V2 V3 V
4 V5 V6 V
8 V10 V12 V16 V20 V24 V28 V30 V34 V38 V42 V46 V50 V54 V55 V5
6 V54
A 
Alternative visit 
format  
    H/O/R
/P  H/O/R
/P H/O/R
/P  H/O/R
/P H/O/R
/P H/O/R
/P H/O/R
/P H/O/R
/P H/O/R
/P H/O/R
/P H/O/R
/P H/O/R
/P H/O/R
/P H/O/R
/P H/O/R
/P  H/O/R
/P   
 Weekly Phone 
Contact number 
(P)       P7 P9 P11 P13 
P14 
P15 P17 
P18 
P19 P21 
P22 
P23 P25 
P26 
P27 P29 P31 
P32 
P33 P35 
P36 
P37 P39 
P40 
P41 P43 
P44 
P45 P47 
P48 
P49 P51 
P52 
P53     
 Timing of Visit 
(Weeks)   <-
2W 0W 1W 2
W 3W 4W 6
W 8W 10W 14W 18W 22W 26W 28W 32W 36W 40W 44W 48W 52
W 54W 57
W  
 Visit Window 
(Days)     Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 -
3/+2
8 +3 +3  
    Pregnancy 
Test 8.3.5
, 
10.4 
(App 
4) X  X                  X  X X 
    Body 
Measurements 8.2.2 X X       X  X  X   X  X  X   X 
Body Weight 8.2.2 X X       X  X  X   X  X  X   X 
    Vital Signs 8.2.3 X X       X  X  X   X  X  X   X 
    Physical 
Examination 8.2.2 X                   X   X 
    ECG 8.2.5 X                   X   X 
    Eye 
Examination 8.2.4 X                   X   X 
VV-CLIN-219731 1.0 .
Protocol       Date: 23 March 2023 Status:  Final  Novo Nordisk 
Study ID: NN1535-4592       Version: 8.0 Page: 99 of 113 
 
  Protocol Sections Screening  Randomisation 
Treatment period Follow up Discontinuation 
 Visit (preferred 
visit format) 
V: On site Visit  V1 V2 V3 V
4 V5 V6 V
8 V10 V12 V16 V20 V24 V28 V30 V34 V38 V42 V46 V50 V54 V55 V5
6 V54
A 
Alternative visit 
format  
    H/O/R
/P  H/O/R
/P H/O/R
/P  H/O/R
/P H/O/R
/P H/O/R
/P H/O/R
/P H/O/R
/P H/O/R
/P H/O/R
/P H/O/R
/P H/O/R
/P H/O/R
/P H/O/R
/P H/O/R
/P  H/O/R
/P   
 Weekly Phone 
Contact number 
(P)       P7 P9 P11 P13 
P14 
P15 P17 
P18 
P19 P21 
P22 
P23 P25 
P26 
P27 P29 P31 
P32 
P33 P35 
P36 
P37 P39 
P40 
P41 P43 
P44 
P45 P47 
P48 
P49 P51 
P52 
P53     
 Timing of Visit 
(Weeks)   <-
2W 0W 1W 2
W 3W 4W 6
W 8W 10W 14W 18W 22W 26W 28W 32W 36W 40W 44W 48W 52
W 54W 57
W  
 Visit Window 
(Days)     Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 -
3/+2
8 +3 +3  
    Self Measured 
Plasma Glucose 8.1.1  X X X X X X X X X X X X X X X X X X X X X X 
    Adverse 
Eventa 8.3, 
10.3 
(App 
3)   Xa X X X X X X X X X X X X X X X X X X X X 
    Laboratory 
Assessmentsb 10.2 
(App 
2) X X       X  X  X   X  X  X   X 
    HbA 1cb  X X       X  X  X   X  X  X   X 
    Antibodiesb 8.7  X  X   X  X  X  X   X    X  X X 
    Pop-PKb 8.4    X   X  X  X  X   X    X  X X 
    Drug 
Dispensing  6  X       X  X  X   X  X      
VV-CLIN-219731 1.0 .
Protocol       Date: 23 March 2023 Status:  Final  Novo Nordisk 
Study ID: NN1535-4592       Version: 8.0 Page: 100 of 113 
 
  Protocol Sections Screening  Randomisation 
Treatment period Follow up Discontinuation 
 Visit (preferred 
visit format) 
V: On site Visit  V1 V2 V3 V
4 V5 V6 V
8 V10 V12 V16 V20 V24 V28 V30 V34 V38 V42 V46 V50 V54 V55 V5
6 V54
A 
Alternative visit 
format  
    H/O/R
/P  H/O/R
/P H/O/R
/P  H/O/R
/P H/O/R
/P H/O/R
/P H/O/R
/P H/O/R
/P H/O/R
/P H/O/R
/P H/O/R
/P H/O/R
/P H/O/R
/P H/O/R
/P H/O/R
/P  H/O/R
/P   
 Weekly Phone 
Contact number 
(P)       P7 P9 P11 P13 
P14 
P15 P17 
P18 
P19 P21 
P22 
P23 P25 
P26 
P27 P29 P31 
P32 
P33 P35 
P36 
P37 P39 
P40 
P41 P43 
P44 
P45 P47 
P48 
P49 P51 
P52 
P53     
 Timing of Visit 
(Weeks)   <-
2W 0W 1W 2
W 3W 4W 6
W 8W 10W 14W 18W 22W 26W 28W 32W 36W 40W 44W 48W 52
W 54W 57
W  
 Visit Window 
(Days)     Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 -
3/+2
8 +3 +3  
    Training in 
Trial Product, 
Pen-handling  6.1  X X   X  X X  X  X   X  X      
    Hand Out and 
Instruct in 
Devices  6  X                      
    Attend Visit 
Fasting  5.3.1  X       X  X  X   X  X  X   X 
Notes: 
a All AEs and SAEs must be collected from first administration of randomised treatment  
b Laboratory assessments, including HbA1c, PK and antibodies, should be collected at the site and sent to the central laborator y. All efforts should be made to collect the samples on-site at 
the original frequency, but if on-site visits are not possible du e to lock-down, then the samp le collection can be cancelled.  
Abbreviations for visit formats: V, on-site visit; H, home visit; O, off-site visit; R, remote video call; P, phone visit 
VV-CLIN-219731 1.0 .
Protocol 
CONFIDENTIAL Date: 23 March 2023 Novo Nordisk 
Study ID: NN1535-4592 Version: 8.0 
      Status: Final 
      Page: 101 of 113 
 
 10.11  Appendix 11: Country/Region-specific requirements 
Brazil 
 Exclusion criteria: Participation in other studies within one year prior to screening visit 
unless there is a direct benefit to the participant )<<0-16>-;<1/)<7:J;,1;+:-<176  
 Treatment after the end of the study: At the end of the trial, all participants should be 
assured the access to the best proved prophylactic, diagnostic and therapeutic methods 
identified during the study.  
 Clinical laboratory results: All laboratory results will be communicated to the 
investigators. 
 Contraceptive guidance: For women who expressively declare themselves free of the risk 
of pregnancy, either by not engaging in sexual activity or by having sexual activity with no 
birth potential risk (e.g. sex with a same sex partner), use of contraceptive method will not 
be mandatory.  
 Retention of human biosamples:  Biological samples from Brazil will not be stored but 
destroyed after completion of the study.  
 Indemnity statement: Novo Nordisk takes responsibility for their products and the 
responsibilities set out in legislation, laws a nd/or special rules for the conduct of research 
trials in Brazil. If the trial pa rticipant has questions or believes to have suffered any medical 
harm as a result of their participation in this  research,  the trial team should be contacted 
immediately. If the trial participant suffers an y harm directly or indirectly, now or later 
caused by the trial procedures (which the trial part icipant  would not have been exposed to if 
not participating in the trial) or the admini stration of trial medication, Novo Nordisk will 
ensure that the trial participant will receive full care for such harm at no cost for as long as 
necessary. If any harm occurs as described above , the trial participant is entitled to receive 
compensation in accordance with applicable Brazilian law. 
Canada 
Retention of clinical study documentation: Part C, Division 5 of the Food and Drug Regulations 
[C.05.012] requires a 25-year retention period.   
China: 
 Study Population: pre-screening activities are not applicable in China.  
 Regulatory and ethical considerations: 
o Regulatory authorities will receive th e clinical trial application, protocol 
amendments, reports on SAEs, and the CSR according to national requirements. 
o 7:016))616<-:6)<176)4+778-:)<1>-:-4->)6<:-87:<7.:-4) <-,016)J;=5)6
Genetic Resources will be subm itted based on local regulation. CONFIDENTIAL
VV-CLIN-219731 1 .0 .
Protocol 
CONFIDENTIAL Date: 23 March 2023 Novo Nordisk 
Study ID: NN1535-4592 Version: 8.0 
      Status: Final 
      Page: 102 of 113 
 
  Clinical laboratory tests : All laboratory assessments will be analysed in a central 
laboratory or special laboratory located in China. There will be no exploratory 
tests/exploratory endpoints/investigations for Chinese participants. In case of systemic 
hypersensitivity reaction, the samples required in Section 8.7.2  and 10.2 should be taken and 
stored at the central laboratory before further analysis in the special laboratory.  
The following hypersensitivity analytes are not possible to be tested in China, see 
Appendix 2 (Section 10.2), and will not be included in the hypersensitivity case assessment: 
o Anti-human insulin IgE 
o Anti-insulin icodec IgE 
o Anti-semaglutide IgE 
The following hypersensitivity analytes will be tested by the Central lab in China: 
o Tryptase 
o Total IgE antibodies 
o The following hypersensitivity analytes will be tested by special lab in China: 
o Anti-insulin icodec binding antibodies 
o Anti-semaglutide binding antibodies 
 Retention of human biosamples:  
o Laboratory samples for Chinese participants including samples for antibody analysis 
will be destroyed according to local regu latory requirement. No sample will be 
stored after the latest date of local regulatory approval. 
o For China, remaining samples after test at si te local laboratory, will be immediately 
destroyed according to local bio-waste procedure. 
o Remaining samples after test at the central la boratory will be destroyed according to 
bio-waste procedure after the protocol required test. 
o If required by health authorities, Antibody samples, Biomarker samples, Gene test 
samples and other special test samples will  be retained for further analysis and/or 
characterisation of responses towards drug . These samples (include their backup) 
will be stored at a central bio-reposit ory after end of trial and until marketing 
authorisation approval or until the research project terminates, after which they will 
be destroyed. 
o All samples' collection, shipment, analysis, temporary storage and destruction will be 
clearly recorded. 
o The participantJ;1,-6<1<A?144:-5)16+76.1,-6< 1)4)6,<0-;)584-;?144*-1, -6<1.1-,
only by subject ID, visit number and tr ial identification number. No direct 
identification of the participant will be  stored together with the samples.  
o Only Novo Nordisk staff and laboratory personnel involved in the analyses will have 
access to the stored antibody samples.  CONFIDENTIAL
VV-CLIN-219731 1 .0 .
Protocol 
CONFIDENTIAL Date: 23 March 2023 Novo Nordisk 
Study ID: NN1535-4592 Version: 8.0 
      Status: Final 
      Page: 103 of 113 
 
 o Participants can contact the investigator if  they wish to be informed about results 
derived from stored antibody samples obtained from their own body. 
 Dissemination of clinical study data: Information of the study will be disclosed at 
clinicaltrials.gov, chinadrugtrials.org.cn and novonordisk-trials.com. 
 Inclusion and Exclusion criteria: The inclusion/exclusion criteria will be assessed at the 
investigator's discretion unless otherwise stated. 
 Inclusion criteria 7:  Allow recruitment of patients treated with GLP-1 RA with or without 
any of the anti-diabetic drugs listed in Inclusion Criteria No.7, at the discretion of the 
investigator. 
 Exclusion criteria 4:   the n7<-G%15=4<)6-7=;8):<1+18)<1 7616);<=,A?1<0<0-8:15):A
objective of evaluating an approved or non-a pproved investigational medicinal product for 
prevention or treatment of COVID-19 disease or postinfectious conditions is allowed if the 
last dose of the investigational medicinal produc t has been received more than 30 days 
before screening in the current study and if si multaneous participation is allowed by local 
)=<07:1<1-;H is not applicable for China.  
 Discontinuation criteria 4:  the note GSimultaneous participation in a study with the 
primary objective of evaluating an approved or non-approved investigational medicinal 
product for prevention or treatment of COVID-19 disease or post-infectious conditions is 
allowed at the investig )<7:J;,1;+:-<176?1<07=<,1;+76<16=)<1767.  randomised treatment if 
simultaneous participation is allowed by local authorities , is not applicable for China.  
 Retention of clinical trial documentation:  About site specific data storage, sites have the 
-9=)4:1/0<?1<0;876;7:76/<-:58:-;-:>)<1767.016-;-#)< 1-6<;J&:1)4)<)1;
Prohibited in any other entities. 
France 
 Indemnity statement: French Public Health Code article L 1121-10 (law nÂ° 2004-806 of 9 
August 2004 art. 88 I, '7=:6)4"..1+1)47.		=/=;<
G&0-;876;7:1;:-;876; 1*4-
for identification of the harmful consequences  of the biomedical research for the person 
lending himself thereto and for indemnification of his beneficiaries, except in case of proof, 
incumbent on it, that the prejudice is not attributable to his fault of or the fault of any 
16<-:>-616/8):<A?1<07=<<0-;876;7:J;*-16/-6<1<4-,<7+)44 76)+<;*A)<01:,8):<A7:<0-
voluntary withdrawal of the person who had initially consented to cooperating in the 
:-;-):+0H  
 Demography: ParticipantJ;.=44)<-7.1:<01;67<)447?-,<7*-+744-+<-,)6,5=;<* -
shortened to Year of Birth in CRF. Race and et hnic origin will not be collected in the eCRF. 
Race will only be recorded in the central laboratory requisition form for the eGFR 
calculation.  
 Appendix 2: Collection of age is needed for the calculation of eGFR per CDK-EPI CONFIDENTIAL
VV-CLIN-219731 1 .0 .
Protocol 
CONFIDENTIAL Date: 23 March 2023 Novo Nordisk 
Study ID: NN1535-4592 Version: 8.0 
      Status: Final 
      Page: 104 of 113 
 
  Regulatory and Ethical Considerations: The inclusion of people at risk is not allowed 
(persons under guardianship or Curatorship). Affili ation to a "sÃ©curitÃ© sociale" regime is 
mandatory. 
Japan 
 Inclusion criteria 3: )/-E
A-):;)<<0-<15-7.;1/616/16.7:5-,+76;-6<  
 Preparation/Handling/Storage/Accountability: The head of the study site or the study 
product storage manager assigned by the head of the study site (a pharmacist in principle) is 
responsible for control and accountability of the trial products. 
 Trial governance consideration: A name and seal is accepted as signature. 
 Exclusion criteria 4:   the n7<-G%15=4<)6-7=;8):<1+18)<1 7616);<=,A?1<0<0-8:15):A
objective of evaluating an approved or non-a pproved investigational medicinal product for 
prevention or treatment of COVID-19 disease or postinfectious conditions is allowed if the 
last dose of the investigational medicinal product has been received more than 30 days 
before screening in the current study and if si multaneous participation is allowed by local 
)=<07:1<1-;H is not applicable for Japan.  
 Discontinuation criteria 4:  <0-67<-G%15= ltaneous participation in a study with the 
primary objective of evaluating an approved or non-approved investigational medicinal 
product for prevention or treatment of COVID-19 disease or post-infectious conditions is 
)447?-,)<<0-16>-;<1/)<7:J;,1;+:-<1 on without discontinuation of randomised treatment if 
simultaneous participation is allowed by local authorities , is not applicable for Japan.  
 Table 10-3:  Following contraceptive methods are not approved in Japan. 
o Combined (estrogen- and progestogen- containing) hormonal contraception 
associated with inhibition of ovulation: 
Âƒ intravaginal 
Âƒ transdermal 
 
o Progestogen-only hormone contraception a ssociated with inhibition of ovulation 
Âƒ injectable 
Âƒ implantable 
Hungary 
Demography: #):<1+18)6<J;.=44)<-7.1:<01;67<)447?-,<7*-+744-+<-, )6,5=;<*-;07:<-6-,
to Year of Birth in CRF.  
Slovakia 
Regulatory and ethical considerations: 
The investigator  will be responsible for: CONFIDENTIAL
VV-CLIN-219731 1 .0 .
Protocol 
CONFIDENTIAL Date: 23 March 2023 Novo Nordisk 
Study ID: NN1535-4592 Version: 8.0 
      Status: Final 
      Page: 105 of 113 
 
  notifying the IRB/IEC of SAEs F only death, as required by IRB/IEC procedures and local 
regulations 
 providing oversight of the conduct of the study at the site and adherence to requirements of ICH 
guidelines, the IRB/IEC, and all other applicable local regulations 
 reporting any potential serious breaches to the sponsor immediately after discovery 
The sponsor  will be responsible for: 
 providing written summaries of the status of the study annually or more frequently in 
accordance with the requirements, policies, and procedures established by the IRB/IEC and/or regulatory authorities  
 notifying the IRB/IEC of SAEs or other significant safety findings according to local 
regulations and procedures established by the IRB/IEC and/or regulatory authorities ensuring 
submission of protocol, protocol amendments, ICF, investigator brochure, CSR synopsis and 
other relevant documents to the IRB/IEC and/or regulatory authorities 
Switzerland 
Demography: participantÂ´s full Date of Birth is not al lowed to be collected and must be shortened to 
Year of Birth in the CRF. 
Indemnity statement: The study will be conducted in compliance with the Therapeutic Products Act 
(HMG/TPA) of 15 December 2000, the Human Rese arch Act (HFG/HRA) of 30 September 2011 
and the Clinical Trials Ordinance (KlinV/ClinO) of 20 September 2013. 
Taiwan 
Inclusion criteria: Legal age in Taiwan is 20 years per lo cal law. Thus, age limitation for adult 
studies shall be above or equal to 20 years in the entry criteria . 
For USA: 
 Haematology samples:  For haematology samples (differential count) where the test result is 
not normal, then a part of the sample may be ke pt for up to two years or according to local 
regulations. 
 FDA Form 1572:  All US investigators will sign FDA Form 1572 
For USA sites: Intended for US sites . Conducted under the IND  
All US investigators, as described above, will sign FDA Form 1572 
For sites outside the USA: Intended for participating sites outside of the USA. Not conducted 
under the IND 
All investigators outside of the USA will not sign FDA form 1572 
Novo Nordisk will analyse and report data from all site s together if more than one site is involved in 
the trial. CONFIDENTIAL
VV-CLIN-219731 1 .0 .
Protocol 
CONFIDENTIAL Date: 23 March 2023 Novo Nordisk 
Study ID: NN1535-4592 Version: 8.0 
      Status: Final 
      Page: 106 of 113 
 
 10.12  Appendix 12: Abbreviations 
 
ADA American Diabetes Association 
AE adverse event 
BG blood glucose 
CI confidence interval 
CRF case report form 
CSR clinical study report 
CTFG Clinical Trial Facilitation Group 
DPP-4 dipeptidyl peptidase-4 
DRE disease related event 
DUN dispensing unit number 
EAC Event Adjudication Committee 
EASD European Association for the Study of Diabetes 
EAS event adjudication system 
ECG electrocardiogram 
EMA  European Medical Agency 
eCRF electronic case report form 
ETD estimated treatment difference 
FAS full analysis set 
FDA U.S. Food and Drug Administration 
FDAAA FDA Amendments Act 
FPG fasting plasma glucose 
GLP-1 glucagon-like peptide 1 
GCP Good Clinical Practice 
HbA1 c glycated haemoglobin 
HCP healthcare professional  
ICE intercurrent event 
ICH International Council for Harmonisation 
IEC independent ethics committee 
IHSG The International Hypoglycaemia Study Group 
IMP investigational medicinal product 
IND investigational new drug 
IRB institutional review board 
ISO International Organization for Harmonization 
ISPAD International Society for Pediatric and Adolescent Diabetes 
RTSM  Randomisation and Trial Supply Management CONFIDENTIAL
VV-CLIN-219731 1 .0 .
Protocol 
CONFIDENTIAL Date: 23 March 2023 Novo Nordisk 
Study ID: NN1535-4592 Version: 8.0 
      Status: Final 
      Page: 107 of 113 
 
 NIMP non-investigational medicinal product 
OAD oral anti-diabetic drug 
PG plasma glucose 
PK pharmacokinetics 
SAE serious adverse event 
SAP Statistical Analysis Plan 
s.c. subcutaneous  
SD standard deviation 
SmPC summary of product characteristics  
SMPG self-measured plasma glucose 
T2D type 2 diabetes mellitus 
SUSAR suspected unexpected se rious adverse reaction 
V visit 
WOCBP woman of childbearing potential 
 CONFIDENTIAL
VV-CLIN-219731 1 .0 .
Protocol 
CONFIDENTIAL Date: 23 March 2023 Novo Nordisk 
Study ID: NN1535-4592 Version: 8.0 
      Status: Final 
      Page: 108 of 113 
 
 10.13  Appendix 13: Protocol amendment history 
The Protocol amendment summary of changes table for the current protocol version is located 
directly before the table of contents. 
Overall rationale for preparing protocol, version 6.0: 
The protocol has been amended to implement the below changes which are required by the State 
Institute for Drug Control of Slovakia:  
Section # and name Description of change Brief rationale 
Appendix 11: Country/Region-
specific requirements -Slovakia Clarification of the investigatorÂ´s 
responsibilities and the sponsor 
responsibilities in relation to the Regulatory and ethical considerations mentioned in section 10.1.1.
 To align with SlovakiaÂ´s national 
legislation:  
a) According to Act 362/2011 Z. z. Â§43 
point b) sponsor takes responsibility for submissions of protocol,
 protocol 
amendments, ICF, investigator 
brochure, CSR synopsis and other 
relevant documents.  
b) According to Act 362/2011 Z. z. Â§ 
43 point n) number 5 and 6 sponsor 
takes responsibility for notifying of 
SAE. 
 
Protocol version 5, including version(s) 1, 2, 3, and 4 :  22 November 2021 
The protocol has been amended to implement th e below changes which are required by PMDA:  
Section # and name Description of change Brief rationale 
Introduction Sentence added to describe that 
Insulin icodec is a recombinant protein produced using yeast. PMDA requirement 
Appendix 11: Country/Region-
specific requirements  - Japan Text added to describe which 
contraceptive methods included in the 
protocol (Table 10 -3) have not been 
approved in Japan.  PMDA requirement 
Protocol version 4, including versio n(s) 1, 2 and 3: 10-Aug-2021 global 
The protocol has been updated to correct the below errors detected:  
Section # and name Description of change Brief rationale 
Protocol amendment summary of 
changes table Date format changed from DD-MM-
YYYY to DD-MMM-YYYY DD-MMM-YYYY is the standard 
Novo Nordisk date format. 
1.1 Synopsis, Key Exclusion Criteria, 
5.2 Ex clusion criteria 
 Anticipated initiation or change in 
concomitant medication (for more 
than 14 consecutive days) known to affect weight or glucose metabolism 
(e.g. treatment with orlistat, thyroid, 
hormones, or systemic 
corticosteroids).  &A87<;07=4,;)AG<0A:71,
hormon-;H67<G<0A:71,07:576-;H  CONFIDENTIAL
VV-CLIN-219731 1 .0 .
Protocol 
CONFIDENTIAL Date: 23 March 2023 Novo Nordisk 
Study ID: NN1535-4592 Version: 8.0 
      Status: Final 
      Page: 109 of 113 
 
 Section # and name Description of change Brief rationale 
Table 6-2, Auxiliary supplies NovoFineÂ® Plus 32G, 4 mm needles 
and NovoFineÂ® Plus 32G, 6 mm needles
 were renamed to NovoFineÂ® 
needles or similar according to local requirements
 Typo in the name NovoFineÂ® Plus 
32G, 6mm (it should not contain 
G#4=;H!7>716-C6--,4-;1;57:-
general and it covers all sizes needed. G7:;1514):)++7:,16/<747+)4
:-9=1:-5-6<;H)447?;<0-=;-7.
similar needles if NovoFineÂ® is not approved in a specific country. 
10.2 Appendix 2 Clinical laboratory 
tests Addition of tryptase to systemic 
hypersensitivity samples (IcoSema arm) Tryptase should be collected in case 
of systemic hypersensitivty  in the 
IcoSema arm. 
 
Protocol version 7, including versio n(s) 5 and 6: 10-May-2022 global 
The protocol has been updated to correct below errors detected, in addition to further changes 
shown below:  
Section # and name Description of change Brief rationale 
Introduction Sentence added to describe that insulin 
icodec is a recombinant protein produced 
using yeast. PMDA requirement 
Section 1.3 F Flowchart F Phone 
contacts Addition of a Flowchart for phone 
contacts To clarify the procedures to be 
performed during phone contacts 
Section 5.3.1 F Meals and 
dietary restrictions  Text in italic s was added as follows: 
Randomised treatment and other glucose 
lowering agents  should be withheld on the 
day of the fasting visit until blood  
sampling has been performed.  To clarify that participants should not 
take glucose lowering agents on the day of fasting
 visits until blood sampling 
has been performed  
Sections 5.4, 6.2, 6.3, 7.1.1, 7.2 
and 8 Replacement of IWRS by RTSM To reflect the change in systems used 
in the study 
Section 8.2.2 F Physical 
Examinations  Text in italics  was added, and text crossed 
out was deleted as follows:    
From the body weight and height  
measured at V1 , the body mass index 
(BMI) should be calculated at V2 to 
evaluate inclusion criteria no. 8   To clarify that the BMI should be 
calculated using the weight measured at 
visit 1.  
Section 8.3 Adverse events and 
other safety reporting  ,,1<1767.<0-+4):1.A16/67<-G All 
cerebrovascular events are to be reported 
and sent for adjudication, however the 
?144764A+76.1:5;<:73-;H  To clarify that the EAC will only 
confirm strokes  
Section 9.3.1. - General 
considerations Addition of Hungary and removal of 
Ukraine in the definition of regions. To reflect the new country allocation 
for the study 
Appendix 11: Country/Region-
specific requirements - China Country specific requirement added for 
China in relation to inclusion criteria no. 7. 
 Broadening of allowed OAD 
combinations to reflect clinical practice 
in China and in accordance with 
international guidelines CONFIDENTIAL
VV-CLIN-219731 1 .0 .
Protocol 
CONFIDENTIAL Date: 23 March 2023 Novo Nordisk 
Study ID: NN1535-4592 Version: 8.0 
      Status: Final 
      Page: 110 of 113 
 
 Section # and name Description of change Brief rationale 
Appendix 11: Country/Region-
specific requir ements - Japan Text added to describe which 
contraceptive methods included in the protocol (Table 10
-3) have not been 
approved in Japan.  PMDA requirement 
Appendix 11: Country/Region-
specific requirements - Hungary Country specific requirement added for 
Hungary in relation to demography 
  HungaryÂ´s HA requirement  
Appendix 11: Country/Region-
specific requirements -Slovakia Clarification of the investigatorÂ´s 
responsibilities and the sponsor responsibilities in relation to the Regulatory and ethical considerations 
mentioned in section 10.1.1.
 To align with SlovakiaÂ´s national 
legislation:  
a) According to Act 362/2011 Z. z. Â§43 
point b) sponsor takes responsibility for 
submissions of protocol, protocol amendments, ICF, investigator brochure, CSR synopsis and other relevant documents. 
 
b) According to Act 362/2011 Z. z. Â§ 
43 point n) number 5  and 6 sponsor 
takes responsibility for notifying of SAE. 
Section 11 References Update of references Addition of new reference 1 CONFIDENTIAL
VV-CLIN-219731 1 .0 .
Protocol 
CONFIDENTIAL Date: 23 March 2023 Novo Nordisk 
Study ID: NN1535-4592 Version: 8.0 
      Status: Final 
      Page: 111 of 113 
 
 11 
  
1. The European Parliament and the Council of the European Council. Directive 2001/20/EC 
of the European Parliament and of the Council  of 4 April 2001 on the approximation of the 
laws, regulations and administrative provisions  of the member states relating to the 
implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use. 2001. 
2. American Diabetes Association. 2. Classificati on and Diagnosis of Diabetes:. Diabetes Care. 
2019;42(Suppl 1):S13-S28. 
3. International Diabetes Federation. IDF Diabetes Atlas, 9th Edition. 2019. 4. Kapitza C, Nosek L, Jensen L, Hartvig H, Jensen CB, Flint A. Semaglutide, a once-weekly 
human GLP-1 analog, does not reduce the bioavailability of the combined oral 
contraceptive, ethinylestradiol/levonorge strel. J Clin Pharmacol. 2015;55(5):497-504. 
5. Novo Nordisk A/S. Ozempic Â® (semaglutide), EU Summary of product characteristics 
(SmPC). 27 Mar 2020. 
6. Novo Nordisk A/S. OzempicÂ® (semaglutide), US prescribing Information (PI). Jan 2020. 7. European Medicines Agency, CHMP. Guideline on clinical development of fixed 
combination medicinal products. 2017. 
8. Leahy JL. Pathogenesis of type 2 diabetes  mellitus. Arch Med Res. 2005;36(3):197-209. 
9. DeFronzo RA. Pathogenesis of type 2 diabetes mellitus. Med Clin North Am. 
2004;88(4):787-835, ix. 
10. )>1-; J4-;;17 , Fradkin J, Kernan W, Mathieu C, Mingrone G, et al. Management 
of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). 
Diabetes Care. 2018;41(12):2669-701. 
11. Alatorre C, FernÃ¡ndez LandÃ³ L, Yu M, Brown K,  Montejano L, Juneau P, et al. Treatment 
patterns in patients with type 2 diabetes mellitus treated with glucagon-like peptide-1 
receptor agonists: Higher adherence and persistence with dulaglutide compared with once-weekly exenatide and liraglutide. Diabetes Obes Metab. 2017;19(7):953-61. 
12. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. 
Management of hyperglycaemia in type 2 d iabetes, 2015: a patient-centred approach. 
Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia. 2015;58(3):429-42. 
13. Novo Nordisk A/S. Xultophy
Â® (Insulin Degludec/Liraglutide), EU Summary of Product 
Characteristics (SmPC). 2015. 
14. Boye KS, Matza LS, Walter KN, Van Brunt K, Palsgrove AC, Tynan A. Utilities and 
disutilities for attributes of injectable treatm ents for type 2 diabetes. Eur J Health Econ. 
2011;12(3):219-30. 
15. Evans M, Jensen HH, BÃ¸gelund M, Gundgaard J, Chubb B, Khunti K. Flexible insulin 
dosing improves health-related quality-of-life (HRQoL): a time trade-off survey. J Med Econ. 2013;16(11):1357-65. 
16. Novo Nordisk A/S. Investigator's Brochure, IcoSema, NN1535, (edition 4). 17 March 2023. 
17. !7>7!7:,1;3%**:->1)<-,6>-;<1/)<7:J;:7+0=:-;-5)/4=< 1,-;+"B-581+C
NN9535, (edition 19). 27 July 2022. 
18. American Diabetes Association. 9. Pharmacolo gic Approaches to Glycemic Treatment:. 
Diabetes Care. 2021;44(Suppl 1):S111-S24. 
19. American Diabetes Association. American Diabetes Association standards of medical care 
in diabetes 2019. Diabetes Care2019. p. S1 FS187. 
20. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic 
Kidney Disease. http://www.kidney-international.org. 2013 2013. CONFIDENTIAL
VV-CLIN-219731 1 .0 .
Protocol 
CONFIDENTIAL Date: 23 March 2023 Novo Nordisk 
Study ID: NN1535-4592 Version: 8.0 
      Status: Final 
      Page: 112 of 113 
 
 21. McEvoy BW. Missing data in clinical trials for weight management. J Biopharm Stat. 
2016;26(1):30-6. 
22. Little R, Rubin D. Statistical analysis with missing data. Sons. JW, editor. New York.: John 
Wiley & Sons. 1987. 
23. World Medical Association. WMA Declaration of Helsinki - Ethical Principles for Medical 
Research Involving Human Subjects. Last amended by the 64th WMA General Assembly, Fortaleza, Brazil. October 2013. 
24. ICH Harmonised Tripartite Guideline. Guideline for Good Clinical Practice E6(R2), Current 
step 4 version. 09 Nov 2016. 
25. De Angelis C, Drazen JM, Frizelle FA, Haug C, Hoey J, Horton R, et al. Clinical trial 
registration: a statement from the International Committee of Medical Journal Editors. N 
Engl J Med. 2004;351(12):1250-1. 
26. U.S. Department of Health and Human Services, Food and Drug Administration. Food and 
Drug Administration Amendments Act of 2007 as amended by the Final Rule "Clinical Trials Registration and Results Informat ion Submission". 21 September 2016. 
27. The European Parliament and the Council of the European Council. Regulation (EC) No 
726/2004 of the European Parliament and of th e Council of 31 March 2004 laying down 
Community procedures for the authorisation and supervision of medicinal products for 
human and veterinary use and establishing a European Medicines Agency, article 57. 30 April 2004. 
28. The European Parliament and the Council of the European Council. Regulation (EC) No 
1901/2006 of the European Parliament and of the Council of 12 December 2006 on 
medicinal products for paediatric use a nd amending Regulation (EEC) No 1768/92, 
Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004, article 41. 
Official Journal of the European Communities. 27 Dec 2006. 
29. International Committee of Medical Journal Editors. Recommendations for the Conduct, 
Reporting, Editing and Publication of Scholar ly Work in Medical Journals; current version 
available at www.icmje.org. 
30. Sampson HA, Munoz-Furlong A, Campbell RL, Adkinson NF, Bock SA, Branum A, et al. 
Second Symposium on the Definition and Mana gement of Anaphylaxis: Summary report - 
Second National Institute of Allergy and Infect ious Disease/Food Allergy and Anaphylaxis 
Network Symposium. Annals of Emergency Medicine. 2006;47(4):373-80. 
31. Kemp SF, Lockey RF. Anaphylaxis: a review of causes and mechanisms. J Allergy Clin 
Immunol. 2002;110(3):341-8. 
32. Johansson SG, Bieber T, Dahl R, Friedma nn PS, Lanier BQ, Lockey RF, et al. Revised 
nomenclature for allergy for global use: Report  of the Nomenclature Review Committee of 
the World Allergy Organization, October 2003. J Allergy Clin Immunol. 2004;113(5):832-6. 
33. Scialli AR, Bailey G, Beyer BK, BÃ¸gh IB, Breslin WJ, Chen CL, et al. Potential seminal 
transport of pharmaceuticals to the conceptus. Reprod Toxicol. 2015;58:213-21. 
34. Clinical Trial Facilitation Group (CTFG), He ads of Medicines Agency. Recommendations 
related to contraception and pregnancy te sting in clinical trials. 21 Sep 2020. 
35. International Hypoglycaemia Study Group. Glucose Concentrations of Less Than 3.0 
mmol/L (54 mg/dL) Should Be Reported in Clin ical Trials: A Joint Position Statement of 
the American Diabetes Association and the E uropean Association for the Study of Diabetes. 
Diabetes Care. 2017;40(1):155-7. 
36. American Diabetes Association. 6. Glycemic Targets: Standards of Medical Care in 
Diabetes-2018. Diabetes Care. 2018;41(Suppl 1):S55-S64. 
37. Abraham MB, Jones TW, Naranjo D, Karges B, Oduwole A, Tauschmann M, et al. ISPAD 
Clinical Practice Consensus Guidelines 2018: Assessment and management of CONFIDENTIAL
VV-CLIN-219731 1 .0 .
Protocol 
CONFIDENTIAL Date: 23 March 2023 Novo Nordisk 
Study ID: NN1535-4592 Version: 8.0 
      Status: Final 
      Page: 113 of 113 
 
 hypoglycemia in children and adolescents wi th diabetes. Pediatr Diabetes. 2018;19 Suppl 
27:178-92. 
38. Agiostratidou G, Anhalt H, Ball D, Blonde L, Gourgari E, Harriman KN, et al. 
Standardizing Clinically Meaningful Outcome Measures Beyond HbA1c for Type 1 Diabetes: A Consensus Report of the American  Association of Clinical Endocrinologists, 
the American Association of Diabetes Educators , the American Diabetes Association, the 
Endocrine Society, JDRF International, The Leona M. and Harry B. Helmsley Charitable 
Trust, the Pediatric Endocrine Society, and the T1D Exchange. Diabetes Care. 2017;40(12):1622-30. 
39. Danne T, Nimri R, Battelino T, Bergenstal RM, Close KL, DeVries JH, et al. International 
Consensus on Use of Continuous Glucose Monitoring. Diabetes Care. 2017;40(12):1631-40. 
40. Seaquist ER, Anderson J, Childs B, Cryer P, Dagogo-Jack S, Fish L, et al. Hypoglycemia 
and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. Diabe tes Care. 2013;36(5):1384-95. 
 CONFIDENTIAL
VV-CLIN-219731 1 .0 .